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The use of psychoactive substance like ketamine, 3,4-methylenedioxy-
methamphetamine (MDMA/ 'ecstasy'), methamphetamine (METH/ 'ice') and 
marijuana among adolescents has become more popular in Hong Kong these past few 
years especially with a dramatic increase in ketamine use. To date, rave parties and 
discos are events where people usually take these recreational drugs. 
It has been shown that there is a higher risk for substance abuse in people who have 
been characterized to have personality traits like novelty seeking and harm avoidance 
behaviours. These behaviours have also been shown to have an association with 
certain gene variants. These gene variants include catechol-0-methytransferase 
(COMT), monoamine oxidase-A (MAO-A), human mu-opioid receptor (hMOR), 
human delta opioid receptor (hDOR), D2 dopamine receptor (DRD2), D4 dopamine 
receptor (DRD4), serotonin receptor IB (5HT1B), and serotonin transporter linked 
polymorphism region (5HTTLPR) which may cause an imbalanced release of 
neurotransmitters in the brain, eventually resulting in the development of impulsive 
and addictive behaviours like drug abuse, smoking, gambling and drinking. 
In the present study, a structured-interview using a questionnaire together with two 
personality trait assessments (Chinese version) were obtained for each club drug user 
to ascertain the growing trend of club drug use in the Hong Kong Chinese population 
as well as to determine the association of sensation seeking and harm avoidance 
personality traits with club drug use respectively. The questionnaire examined the 
demographics, pattern of drug use, experiences of first time drug use, current drug use, 
effects of drug use, potential dependence/withdrawal and knowledge about drugs of 
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abuse. The two personality trait assessments were the sensation seeking scale form V 
(SSS-V; M. Zuckerman, 1994) which is composed of four subscales, namely, ‘thrill 
and adventure seeking', 'experience seeking', 'disinhibition' and 'boredom 
susceptibility', each of which has 10 forced-choice items. The other personality trait 
scale, the behavioural inhibition system and behavioural activation system scale 
(BIS/BAS; Carver and White, 1994) which is also composed of four subscales namely 
‘BAS fun seeking,, ‘BAS drive', ‘BAS reward responsiveness' and 'BIS' (anxiety 
trait). 
In addition, DNA samples were obtained from the club drug users to investigate 
whether an association exists between club drug use and personality traits with certain 
gene variants including the COMT G1947A Met polymorphism, MAO-A 
T941G polymorphism, hDOR T921C polymorphism, hMOR A118G polymorphism, 
DRD2TaqI A polymorphism, DRD4 VNTR 48 bp repeat and -C521T polymorphism, 
5-HTlB G861C polymorphism, and the 5-HTTLPR 44 bp insertion/deletion 
polymorphism. 
Results showed that ketamine (88.5%) followed by marijuana (83.6%), 'ecstasy' 
(79.8%) and ‘ice, (30.1%) were the most commonly lifetime use drugs in Hong Kong. 
Ketamine, marijuana, and 'ecstasy' were usually used in combination, with the 
occasional use of marijuana together with other stimulants or hallucinogenic drugs. 
Near to 90% and 60% of the club drug users have ever tried drugs during rave parties 
or discos in Hong Kong and in Shenzhen respectively (across the border). 
Club drug users showed a significantly higher score in 'boredom susceptibility' 
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(pO.OOOl), ‘disinhibition, (p<0.0001), 'experience seeking' (pO.OOOl) and ‘thrill 
and adventure seeking' (p<0.001) in the sensation seeking SSS-V scale; and the 'BAS 
fun seeking' (pO.OOOl) and 'BAS drive' (p<0.0001) of the BIS/BAS scales. A 
significantly lower score in ‘BIS，of the BIS/BAS scale was also shown in the club 
drug users when compared to the controls. There is a significant difference between 
male and female controls in 'boredom susceptibility' and 'disinhibition' in which 
males have higher scores. Females however have a higher BIS (harm avoidance) score. 
A similar trend was also observed between male and female club drug users with the 
addition of 'thrill and adventure seeking. The higher score for the 'thrill and adventure 
seeking' subscale in club drug users was merely contributed by male users. In general, 
male club drug users scored higher for ‘boredom susceptibility', ‘disinhibition，，and 
lower for ‘BIS，than female club drug users. The higher scores observed between the 
controls and the club drug users may be attributable to their chronic drug use. 
Statistical significance was found between the club drug users and controls in the 
COMT Vali08"58Met polymorphism in both the genotype (p=0.003) and the allelic 
frequency with higher G allele (p=0.013). For the MAO-A T941G polymorphism, a 
significant difference (p=0.012) in allelic frequency with higher T alelle in the female 
subjects was found. For the hDOR T921C polymorphism, significant differences were 
found in both the genotype (p=0.027) and allelic frequency with higher C allele 
(p=0.004). Genotype frequencies of the DRD27a^/ A polymorphism (p=0.011) and 
the 5-HTlB G861C polymorphism (p=0.015) were also found to be significantly 
different between subjects and controls. However, no statistical significance was 
found in the polymorphisms of the hMOR, DRD4, and 5-HTTLPR genes. 
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When the interaction between personality traits and gene variants were investigated, it 
has been shown that club drug users with two copies of the G allele of COMT gene 
scored significantly lower than individuals with at least one of the A allele on the 
subscale 'boredom susceptiMlity, (p=0.02) and 'BAS drive' (p=0.01) while the 
control individual with at least one of the A allele of COMT gene scored significantly 
lower than individuals with two copies of the G allele on the subscale ‘BAS fun 
seeking' (p=0.02). In the MAO-A T941G polymorphism in female club drug users, 
individuals with two copies of the T allele scored significantly lower than individuals 
with at least one of the G allele on 'BIS' (p=0.008) and individuals carried 
homozygous G allele scored significantly higher than individuals with at least one of 
the T allele on BAS reward responsiveness (p=0.024). In the hDOR T921C 
polymorphism, the control individuals with two copies of T allele scored significantly 
higher than individuals with at least one of the C allele on the subscales ‘BAS reward 
responsiveness' (p=0.02) and 'BAS flin seeking' (p=0.004). In the TaqI A 
polymorphism of the DRD2 gene, club drug users with two copies of A1 allele scored 
significantly lower than individuals with at least one of the A2 allele on the subscales 
‘BIS, (p=0.01|). However, no interaction between personality traits and the G861C 
polymorphism in the 5-HTlB gene was found. 
A significantly higher G allele frequency of COMT polymorphism and a 
higher C allele frequency of the hDOR T921C polymorphism were found in club drug 
users, and both these allelic variants were also associated with 'BAS fon seeking' in 
controls, it suggests that individuals who carry at least one of the G allele of COMT 
Vaii08/i58Met polymorphism or at least one of the C allele of the hDOR T921C 
polymorphism may be more susceptible to club drug use because of having high level 
V 
of 'BAS flin seeking' personality trait. However, the different association of 
personality traits and the same gene variant found between club drug users and 
controls might be the effect of chronic club drug use. A longitudinal study involving 
re-testing this same group of club drug users will further elucidate this. Moreover, it 
seems that multi-gene effects contribute to the effects of club drug use, in the present 
study, COMT, MAO-A, hDOR, DRD2, and 5HT1B gene variants were all found to be 
associated with club drug use of which both COMT and hDOR gene variants were 
also associated with 'BAS fun seeking' in the control group while both MAO-A and 
DRD2 gene variants were associated with ‘BIS, in club drug users. It is therefore 
concluded from the present study that both gene variants and personality traits were 
associated with club drug use. In the fliture other gene variants in linkage 
disequilibrium with the current candidate genes studied should be examined to further 
establish a clearer role of the genetic contribution to personality traits and their link to 
substance abuse. 
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方法： 3 6 6名溢用精神興奮劑者會在訪問員接見下完成一份問卷（包括：個人基本資料，濫用藥 
物趨勢，第一次濫用藥物之經驗’服用藥物的原因，癥狀及潛在耐忍性或依賴性’對濫用藥物之 
認識及心理狀况）及兩份測量性格問卷（一份是由 C a r v e r 與 W h i t e ( 1 9 9 4 ) 的行為抑制與行為激 
發系統敏感度測量表 ( B I S / B A S S c a l e )，此量表包含四個因素，分別為「行為抑制」（B I S )，而「行 
為激發」包含其餘三個因素，「酬賞反應」（ R e w a r d R e s p o n s i v e n e s s ) ’ 「趨力 � （ D r i v e ) 及「尋求 
樂趣」（Fun S e e k i n g ) ；而另一份則是由 Z u c k e r m a n ( 1 9 9 4 ) 的刺激尋求量表五 ( S S S - V S c a l e ) ，此 
量表亦包含四個因素，名為「驚險及冒險活動尋求」（ T h r i l l and Adventure S e e k i n g )，「厭煩 
易感性」（ B o r e d o m S u s c 印 t i b i l i t y ) ，「反抑制性」（ D i s i n h i b t i o n ) 及「經驗尋求」（ E x p e r i e n c e 
S e e k i n g ) , 從而找出以上各種人格特質與濫用精神興奮劑的關係。另外’ 6毫升的血液會被抽取 
用作基因分析，在這實驗主要是研究以下幾個基因：兒茶紛 - 0 -甲基轉移酵 ( C O M T )基因 1 5 8 / 1 0 8 
位密碼子、抑制單胺氧化雖 A受體 ( M A O - A )基因 T 9 4 1 G多態型性、 ^ 1阿片受體基因（M O R )的 A 1 1 8 G 
多型性及卵可片受體基因（D O R )的T 9 2 1 C多型性、多巴胺乙型（D R D 2 )基因的T a q l A型性、多巴胺第 
四型（ D R D 4 ) 基因的 - 5 2 1 C / T 及第三外顯子 4 8 b p V N T R多型性、 5 -經色胺一乙型（ 5 H T 1 B )基因的 
G 8 6 1 C多型性及 5 - H T T基因啟動區缺失/插入多態性，從而找出這群基因多型性會否與濫用精神 
興奮劑及人格特質有直接關係° 
實驗結果：在 3 6 6 名濫用精神興奮劑青少年中’報稱濫用 � K 仔」佔 8 8 . 5 % ’其他較常濫用的藥 







顯著高分是直接受到男性濫藥者的分數反映。從基因多型分析結果中 ’ COMT�MAO-A�DOR�DRD2 
及 5 H T 1 B的基因多型與濫用精神興奮劑有關。而在濫藥者中 ’ C O M T的基因多型與「厭煩易感性」 
和「趨力」有關 ’ D R D 2及M A O - A的基因多型與「行為抑制」有關，但在對照組中 ’ C O M T基因多 
型卻被發現與「尋求樂趣」有關，D O R的基因多型與「酬賞反應」及「尋求樂趣」有關。 
總結：人格特質及遺傳基因與濫用精神興奮劑有關，多種基因多型性同時亦與濫用精神興奮劑及 
人格特質有密切關係。「尋求樂趣」主要是導致濫用精神興奮劑的人格特質，而長期濫用這些藥 
物亦會改變服用者的性格 °所以，與濫用藥物相關基因有連鎖不平衡（ l i n k a g e d i s e q u i l i b r i u m ) 
關係之其他基因，是值得繼續研究’有助於深入了解基因及性格對濫用精神奮劑的關係° 
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CHAPTER ONE INTRODUCTION 
1.1 Club drugs 
Club drugs are chemical substances usually used recreationally to enhance social 
experiences. They first gained popularity in Europe in the 80s with the advent of the 
raves. Raves are all night dance parties with fast-paced and repetitive electronic music 
played by celebrated disc jockeys (DJs) and often accompanied by elaborate light 
displays. It embraced a party etiquette of "Peace", “Love”，"Unity" and “Respect”， 
which is captured in the rave logo "PLUR" (Weber, 1999). Raves centre around 
mobile sound system, musical blend of psychedelic hippiedom with combination of 
vigorous dancing and the liberal use of drugs such as 3, 
4-methylenedioxyamphetamine (MDMA, 'ecstasy'), gamma-hydroxybutyrate (GHB), 
ketamine hydrochloride (ketamine), lysergic acid diethylamide (LSD), 
methamphetamine (‘ice,; METH) and marijuana (Weir, 2000; 2004). 
Over the years, the global trend of drug abuse has increased substantially and has 
become a problematic situation all over the world. According to the epidemiologic 
trends in drug abuse advance report generated by the Community Epidemiology Work 
Group (CEWG) in June 2002, 'ecstasy' is the most frequently used "club drug" in 20 
states in the United States of America. The 2000 National Household Survey on Drug 
Abuse showed that 6.4 million American had ever tried ‘ecstasy’ at least once in their 
lifetime of which people in 12-17 increased 1.3 times to 615,000 people and those in 
18-25 increased 3.18 times to 4,014,000 people. The US national school survey 
showed that high school and college-aged youngsters tended to use 'ecstasy' with an 
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increasing trend (Johnston et a l , 2001; Strote et aL, 2002). From the annual report on 
the state of drug problems in the European Union (EU) and Norway, 2002, cannabis 
continued to be the illegal substance most commonly used in all EU countries. 
Lifetime use of cannabis was reported to range from 10% (Finland) to 30% (the 
United Kingdom) of the whole adult population; amphetamines have been tried by 1% 
to 6% of the population, cocaine and ‘ecstasy，have been tried each by about 0.5% to 
4.5% of the population. Especially in the United Kingdom, ‘ecstasy, and 
amphetamine are often taken in combination by drug users (Riley et al., 2001). From 
the statistics on drug use in Australia 2002 reported by the Australian Institute of 
Health and Welfare, it showed that recent illicit drug use was most prevalent among 
persons aged 20-29 years old followed by 14-19 years old. Around 35% people aged 
20-29 years used at least one illicit drug and 30% used cannabis in the previous 12 
months; about 10% used amphetamines and 'ecstasy'. Moreover, population-based 
studies showed that cannabis is consistently the most common illicit drug used 
(Lenton et al., 1997; Lynskey et al., 1999; Turner et al., 2003). In China, drugs 
including heroin, ‘ecstasy，，ketamine, and solvent use among teenage students had 
also been reported recently (Liu et al., 2001). Another study in China also showed that 
illicit drug use including heroin, ketamine and ‘ecstasy, has continued to escalate 
across the six high-prevalence areas, namely, Guangzhou, Wenshan, Xi'an, Anshun, 
Lanzhou and Chongqing (Hao et al. 2002). 
1.1.1 Pattern of "club drug" use in Hong Kong 
Following the craze in western countries, attending rave parties have become a 
popular culture amongst young people in Hong Kong in recent years. "Club drug" use 
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in rave parties has also become popular amongst adolescents and young adults. In 
Hong Kong, of all the newly reported cases in 2002, 48%, 23%, 19.7% and 5.6% were 
known to abuse ketamine, ‘ecstasy，，marijuana and ‘ice，respectively. For those under 
the age of 21, ketamine and 'ecstasy' are the most commonly used drugs. Their use 
increased dramatically from 1.1% in 1999 to 73.0% in 2002 and from 19.1% in 1999 
to 35.8% in 2002 respectively (51'^ Central Registry of Drug Abuse, Security Bureau, 
Hong Kong SAR). 
In line with the rapid economic growth in many cities and provinces in mainland 
China and the close connection between mainland China and Hong Kong, 
cross-border "club drug" use has become a new pattern among the young drug users 
in Hong Kong. Therefore, crossing the border to the border-town, Shenzhen, has 
become the main stream of cross-border drugs use among Hong Kong "club drug" 
users nowadays. This link of drug use pattern between Hong Kong and mainland 
China may probably be due to Hong Kong and Shenzhen having a common drug 
source. 
International drug smuggling was mainly through the “China Channels" (places where 
there is a high prevalence of illicit drug use) from the "Golden Triangle" (where Thai, 
Burmese and Lao borders meet). The 'Golden Triangle, is notorious as a major 
production area of opium; it has now expanded its output to include large supplies of 
methamphetamine and manufacture of illegal stimulants including ‘ecstasy’ and 
cocaine. There is no physical barrier for Wenshan in Yunnan Province to the "Golden 
Triangle”. The main route of drug smuggling starts from the "Golden Triangle" to 
Yunnan Province, then to Sichuan, Guizhou, Gansu, Shanxi Provinces, then from 
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these provinces to Guangzhou city, near to Hong Kong. Hong Kong or Guangzhou 
was the first place in China which is opened to the world and become one of the main 
drug trafficking centres (Hao et al. 2002). Therefore, "club drugs" in Hong Kong are 
mainly smuggled from mainland China. From the Security Bureau statistics in Hong 
Kong, it showed that “club drugs" smuggling has an increasing trend from 1999 to 
2002, cannabis increased from 19.3kg in 1999 to 382.59kg in 2002, 'ecstasy' from 
15,635 tabs in 1999 to 29,174 tabs in 2002, ‘ice, from 21.92kg in 1999 to 26.01kg in 
2002 but with a decrease in ketamine (from 45.09 kg in 2001 to 29.52 kg in 2002). 
1.1.2. Popular "club drugs" used in Hong Kong and their effects. 
1.1.2.1. MDMA ('ecstasy') 
MDMA was first synthesized in Germany in 1914 and used as an appetite suppressant 
(Nichols et al., 1989; Green et al., 1995) but never produced commercially. MDMA 
had been used as an adjunct to psychotherapy in the late 70s and become popular at 
raves in the 80s. It has been a Schedule I drug since 1985 in the United States. 
Street names for MDMA include ‘ecstasy，，X, ADAM, XTC, roll, M, lover's speed. It 
is available as a tablet, a capsule and a powder (Bethesda et al, 2000). The tablets 
usually contain 50 to 150 mg of MDMA (Graeme et al, 2000) and are formulated in 
different colours and imprinted with a popular icon like Nike swoosh, the Motorola 
logo and a butterfly. Other additives are usually found in the tablets including aspirin, 
caffeine, dextromethorphan, pseudoephedrine, ketamine and LSD (Baggott et al., 
2000). In Hong Kong, 'ecstasy' usually appears in round tablets (30 to 40mg MDMA 
per tablet of various colours and logos with additives in different combinations like 
4 
MDMA, MDA, ‘ice,, ketamine, diazepam, paracetamol, caffeine and theophylline. 
(Hong Kong Government Laboratory, 2002 Annual Report). 
MDMA is structurally similar to ‘ice，，hence it shares both stimulant and 
hallucinogenic properties (Schwartz and Miller, 1997a). Its effects on mood are 
mediated primarily by its activity on dopaminergic and serotonergic pathways (Milroy, 
1999). MDMA increases the release of serotonin (5-HT), dopamine (DA), and 
norepinephrine from presynaptic neurons and prevents their metabolism by inhibiting 
monoamine oxidase (Nichols and Oberlender, 1989). It targets the serotonin 
transporter, stimulating 5-HT efflux and inhibits serotonin uptake (Rudnick et al , 
1999). It results in an excessive amount of neurotransmitters available at the synapse; 
the excess 5-HT and DA are found to be responsible for the hallucinogenic effects 
(Nichols and Oberlender, 1989). 
The effects of MDMA typically begin 30-60 minutes (min) after oral administration 
with the peak action at 60-90 min and typically last for eight hours (hrs) (Shulgin, 
1986;Schwartz and Miller, 1997b). Metabolism of MDMA may be nonlinear 
particularly in higher-than-typical doses (de la Torre et al , 2000). MDMA is 
metabolized by N-demethylation to MDA, an active metabolite, but approximately 
two thirds of MDMA may also be excreted unchanged in the urine (Schwartz and 
Miller, 1997c), while MDMA is partially metabolized in the liver by the CYP2D6 
isoenzyme of cytochrome P-450 (Tucker et al., 1994). Several genetic variants can 
affect an individual's ability to metabolize MDMA and may be the result of variable 
short or long term effects of MDMA (Solowij et al., 1992). 
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MDMA does appear to cause distortion and illusion, euphoria, feeling of intimacy, 
and increased energy; other effects are a distorted sense of time and diminished 
hunger and thirst (Schwartz and Miller, 1997d). It can elevate body temperature 
(Graeme, 2000) hence hyperthermia and dehydration may easily occur during hours 
of dancing. The combination of high environmental temperature, elevated body 
temperature, and increased muscular exertion associated with prolong dancing may 
lead to rhabdomyolysis and subsequent renal failure (Steele et al , 1994). Other side 
effects include trismus (tightening of jaw muscles) and bruxism (jaw-clenching), 
which prompt many MDMA users to suck pacifiers or lollipops to help relieve this 
sensation (Shannon, 2000). MDMA also caused rebound effects like generalized 
fatigue, muscle aches, difficulty in concentrating, anxiety, insomnia and depression 
lasting 1 to 2 days after ingestion (Parrott and Lasky, 1998). 
Chronic MDMA use appears to have long-term neurotoxicity. Studies in animal 
models have shown that MDMA use decreases serotonin transporters resulting in 
relatively lower level of 5-HT in spinal fluid (Ricaurte et al., 1988) and causes the 
loss of 5-HT nerve endings (Bolla et al., 1998). In primates, this permanent neuronal 
damage was noticed seven years after exposure (Hatzidimitriou et al., 1999) while 
animals that showed signs of recovery often have abnormal patters of innervation 
(Fischer et al., 1995). Although the mechanism of neurotoxicity is not clear, it was 
hypothesized that MDMA cause 5-HT release from target neurons, causing the 
depletion of intraneuronal 5-HT. DA synthesis and release are in the mean time 
stimulated by MDMA, and excessive DA enters the nerve terminals once 5-HT is 
metabolized (Sprague et al., 1998). DA is then deaminated by monoamine oxidase, 
resulting in free radical formation and selective oxidative damage to the neurons 
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(Bolla et al., 1998). It was also found that there is impairment of long-term memory 
and learning in the offspring of rats exposed to MDMA, and that this consequence 
continued into adulthood (Broening et al , 2001). Studies in human have shown that 
MDMA induces serotonergic hypoactivity in users as evidenced by a significant 
reduction in the concentration of 5-hydroxyindoleacetic acid (5-HIAA) in 
cerebrospinal fluid and a decrease in striatal (caudate, putamen, nucleus accumbens) 
levels of 5-HT as measured by positron emission tomography (PET) (Kish et al., 
2000). The amount of cortical 5-HT transporter and 5-HT uptake sites was also shown 
to be reduced (Obrocki et al., 1999; Semple et al., 1999). The patterns of glucose 
metabolism and blood flow in certain parts of the brain have been changed (McCann 
et al., 1998c) and the number of glial cells had increased (Chang et al., 1999). It 
clearly shows that MDMA can cause neuronal damage in humans even though the 
threshold dose for neurotoxicity has not been established. The serotonergic system 
modulates mood, impulse control, memory and some cognitive behaviour and it was 
shown that MDMA caused the decrease in 5-HT metabolites in the spinal fluid was 
correlated with a decrease in memory function (McCann et al., 1999) of users. A 
decrease in short-term memory (Zakzanis et al., 2001), visual (Steele et al., 1994), 
verbal (Krystal et al , 1992), working (Rodgers, 2000) and memory (Bolla et al., 1998) 
have also been reported. 
1.1.2.2. Ketamine 
Ketamine, a derivative of phencyclidine hydrochloride (PCP), was developed in the 
United States in 1962 and later patented by Parke-Davis in 1966 with trade names 
such as Ketaset and Ketajectm. Ketamine was promoted as a fast-acting general 
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anesthetic. It became widely used as an anesthetic during the Vietnam War (Siegel, 
1978), and was approved by the Food and Drug Administration (FDA) for use among 
children and elderly in 1970. Currently, veterinarians use ketamine to induce sedation 
in animals for surgery, travel, and euthanasia with the maintenance of respiration and 
blood pressure (Curran and Morgan, 2000b). In pediatric patients, emergency 
reactions are less common and tend to be mild (Green and Johnson, 1990), while in 
adults, most adverse reactions can be controlled with the administration of 
benzodiazepines (Reich and Silvay, 1989). Its recreational use has become 
increasingly popular in the United States and Europe in the last decades and has been 
classified as a Schedule III controlled substance in 1999 in the United States. 
Street names for ketamine include special K, K, kit-kat, super K and jet (Dillon et al., 
2003). It is available as a powder that is usually ingested orally or nasally, or as a 
liquid that may be smoked after application to cigarettes or may be administered 
intravenously or intramuscularly (Weiner et al , 2000). In Hong Kong, it is sold as in 
powder form usually packaged in coloured paper packets (250mg per packet). The 
purity is ranged from 32% to 80% with additives including paracetamol, caffeine, 
aspirin and antipyrine (Hong Kong Government Laboratory, 2002 Annual Report). 
Like PCP, ketamine interacts with the ion channel associated with the glutamate 
N-methyl-D-aspartate (NMD A) receptor (Krystal et al., 1994c) and binds 
non-competitively to the PCP receptor and inhibits glutamate activation of the channel. 
It affects opioid, DA (activates DA systems), 5-HT, noradrenaline (NE), nitric oxide, 
gamma amino-butyric acid (GABA, an inhibitory messenger), acetylcholine and 
endocrine system. It has also been found to inhibit the neuronal uptake of 
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norepinephrine, DA and 5-HT (Kohrs et al , 1998). A PET study showed that ketamine 
stimulates the release of DA from nerve terminals (Smith et al , 1998). 
Ketamine is fast acting with the redistribution half-life of less than 5 min and last 
approximately 30-45 min (Jansen, 2000). At 10-25% of an anaesthetic dose, effects 
begin about 30 seconds after an intravenous injection, 2-4 min after an intramuscular 
injection and 10-20 min after taking the drug orally (Jansen, 2000c). It is metabolized 
by the hepatic cytochrome P-450 system to the metabolite norketamine and excreted 
in urine (Bolze et al., 1998). With long-term use of ketamine, both tolerance and 
hepatic enzyme induction have been shown (Lim, 2003). 
Dissociative effects of ketamine have been shown at lower doses while amnesia 
occurred at higher doses (Jansen, 2000b). Its dissociative effects include 
hallucinations, perceived out-of-body experiences, slowed time perception and 
changes in the sensibility of environmental stimuli (Krystal et al., 1994b). Ketamine 
induces the cardiovascular toxicity from reflex sympathetic activation by inhibiting 
the reuptake of catecholamines resulting in mild to moderate increase in heart rate, 
blood pressure and overall cardiac output (Reich and Silvay，1989). Other common 
effects like anxiety, hallucinations, nystagmus and vomiting are also developed 
(Krystal et al., 1994a). Some users may describe visit to the "K-hole", a place 
referring to where users are under the influence of ketamine (Tori, 1996). It can 
sometimes generate the features of a "near to death experience", including 
buzzing/whistling sounds at the beginning, travelling through a dark tunnel into light 
at a high speed, communication with God, intense visions and out-of-body 
experiences (Jansen, 2000a). 
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A report showing that ketamine could cause toxic changes in the rat brain (Olney et al., 
1991b) and a high single dose or daily dose for 4 days can destroy neurons in the 
posterior cingulate and retrosplenial cortices and other corticolimbic brain regions 
(Olney et al., 1991a). In humans, ketamine has been shown to affect cognitive 
functions like, prose recall, speed of comprehension, letter fluency and digit 
cancellation indicating impaired episodic, semantic and working memory; with some 
of these impairments persisting even three days after drug use (Curran and Morgan, 
2000a). Cases of chronic abuse leading to impaired memory or attention have also 
been reported (Jansen, 1990). One study illustrated ketamine-induced dependence, 
since it was shown knockout mice of NMD A receptor epsilonl subunit gene markedly 
reduced the effect of ketamine, and eliminated the time-dependent sensitivity to 
ketamine (Sato et al., 2004). 
1.1.2.3. Cannabis 
Cannabis is the flowering tops and leaves of the plant Cannabis sativa, subspecies 
indica. It secretes a resin containing psychoactive compounds named cannabinoids 
which has the highest concentration in the flowering tops, followed by the leaves. The 
plant usually is cut, dried and incorporated into cigarettes with or without tobacco. 
Three types of plant preparations are used with the Indian names bhang, ganja and 
charas (Grinspoon and Bakalar, 1993). Bhang and ganja are referred as marijuana and 
charas is prepared from the resin itself that is 5 to 10 times stronger than marijuana. It 
has been used for both medicinal and non-medicinal purposes for thousands of years. 
The use of cannabis spread from China and the Middle East to Europe and then to 
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America in the middle of century. It was made illegal in the United States in 1937 
and has been continuously used as a recreational substance worldwide since that time. 
The street names for marijuana include Pot, Reefer, Grass, Weed, Dope, Ganja, Mary 
Jane, or Sinsemilla. Most users smoke marijuana in hand-rolled cigarettes named 
joints, pipes or water pipes called bongs and marijuana cigars called blunts. The 
active chemical in marijuana is delta-9-tetrahydrocannabinol (THC), which is thought 
to cause the psychoactive effects of marijuana intoxication. Once smoked, the effects 
of marijuana begin immediately and last from 1 to 3 hrs and it deposits several times 
more THC into the blood than if ingested orally (Adam and Martin, 1996). THC 
attaches to cannabinoid receptors on nerve cells in several brain regions, affecting the 
way those cell functions by inhibiting the activity of adenylate cyclase and hence the 
formation of cAMP, a second messenger of the cells. THC also activates the reward 
system by stimulating brain cells to release the chemical DA and disrupts coordination 
and balance by binding to receptors in the cerebellum and basal ganglia which 
regulate balance, posture, reaction time and coordination of movement (Adams and 
Martin, 1996). 
The primary effects of using marijuana recreationally are pleasant sensations, changes 
in perception, and time appears to pass very slowly. Since effects vary depending on 
dosage, users may become suddenly very hungry and thirsty; mouth feels dry, 
trembling hands and growing cold. Sleepiness or depression may also develop after 
the euphoria. Long-term effects include lung and throat problems such as coughing 
and increased frequency of throat and lung infections. 
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Cannabinoids have been shown to increase the release of NE, DA and 5-HT, 
especially the release of DA from rat corpus striatum, nucleus accumbens and medial 
prefrontal cortex. GAB A turnover is enhanced by cannabinoids (Pertwee, 1992}. 
Some animal studies indicate the chronic cannabis use producing morphological 
changes in synapses as well as hippocampal neuronal loss (Eldridge and Landfield, 
1990). Tolerance develops resulting from the pharmacological effects of cannabinoids 
in a variety of animal species, including pigeons, rodents, dogs, monkeys and rabbits 
(Rodriguez de Fonseca et al, 1994; Romero et al., 1995). Jones et al. (1983) showed 
that tolerance to the subjective effects of THC developed after oral administration of 
10 mg for several days and greater tolerance developed with increased amount of the 
drug (Jones, 1983). They also showed that if the dose of THC is small and infrequent, 
little behavioral tolerance develops. 
1.1.2.4. Methamphetamine ('Ice') 
‘Ice’ is a potent, dependence-forming, central nervous system (CNS) stimulant. Street 
names for ‘ice’ include speed, chalk, ice, crystal, or glass. It is a white, odourless, 
crystalline powder that easily dissolves in water or alcohol. It can be smoked, snorted, 
orally ingested, or injected. The crystals may also be round shaped and made into 
tablets, and sold under the guise of ‘ecstasy’. ‘Ice’ is usually carried in plastic bags or 
aluminium foil packets; a Ig plastic bag ‘ice’ is named a ‘stroke’. It is usually taken 
by heating the crystal on a strip of foil and sucking the smoke through a liquid-filled 
hookah device to cool it off before it enters the body (Leung, 2002). Since it has a 
high potential for abuse, ‘ice’ is a Schedule II stimulant. 
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‘Ice, is a powerful stimulant, even in a small dose can increase physical activity and 
wakefulness but decrease appetite. High dose can increase body temperature and 
respiration resulting in hyperthermia. Users can experience an intense rush and 
extreme pleasure, which lasts only a few minutes. The onset duration is 3 to 5 min by 
snorting and 15 to 20 min by oral ingestion. The mechanism of action is mainly due to 
the excessive release of DA (Jacobs and Fehr, 1987). 
Long-term use of 'ice' can result in memory loss, aggression, violence, psychotic 
behaviour, and potential cardiac and neurological damage. Early findings revealed 
that high and repeated doses of 'ice' in monkey and rat caused long-lasting depletion 
of DA and decreased the activity of tyrosine hydroxylase in brain (Seiden et al , 1976). 
Other animal studies also showed that the same dose of 'ice' reduced DA levels and 
TH activity in brain with prolonged reductions of 5-HT levels. It was suggested that 
‘ice’ produces neurotoxicity to these systems associated with motor and cognitive 
systems (Robinson and Becker, 1986; Volkow et al., 2001). 
1.2 Neurobiology of drug addiction 
1.2.1 Introduction to reward pathways and animal models of addiction 
Addiction is the result of the adaptation in specific brain neurons caused by repeated 
exposure to drugs of abuse. Addiction can be characterized by three major elements: 
(1) seeking and taking drugs compulsively; (2) loss self control in limiting dose; (3) 
emergence of a negative emotional state when drug access is inhibited (Koob and 
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Nestler, 1997). Drug addiction can be regarded as the disease of the brain reward 
system. The reward system is composed of pleasure and punishment systems that help 
in the seeking and craving of life's essentials such as food, water, and social contact. 
Such natural rewards allow the subject to feel pleasure and these pleasurable feelings 
can reinforce the same behaviour to be repeated. Electrical self-stimulation, an animal 
model study, are widely used to determine the brain regions that appear to mediate 
reward, animals with electrode implanted in these areas in such a way that electrical 
impulses produce a pleasurable sensation will repeatedly do any required task to 
receive further electrical stimulation (Koob et al., 1989). Another animal model of 
addiction, namely the operant intravenous drug self-administration (IVSA) model, in 
which drugs of abuse are readily self-administered intravenously by animals, and in 
general, drugs that are self-administered correspond to those having high abuse 
potential (Niesink et al., 1999). These studies have shown that particular limbic 
structures are associated with the reward pathway including the dopaminergic neurons 
of the ventral tegmental area (VTA) that project to the nucleus accumbens (NAc; a 
nucleus in the limbic system that controls emotion and behaviour, specifically 
perception, motivation, gratification and memory), amygdala helps to assess whether 
an experience is pleasurable or aversive and helps to forge connections between an 
experience an other cues, prefrontal cortex where and other forebrain structures (Koob 
et al, 1989). 
The conditioned place preference (CPP) animal study is used to show the learning 
association between environment stimuli and drug effect (Green and Brown, 2002). 
This experimental procedure provides an animal model of the subjective effects of 
drugs. A drug is injected and the subject is placed in a test chamber with distinctive 
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environmental cues. This procedure is repeated for several days. During these 
conditioning trials the animal develops an association between the subjective state 
produced by the drug (e.g., reward comparable to mood elevation and euphoria in 
humans) and the environmental cues present during the drug state. When the subject 
is tested in an apparatus that contains the drug-related environmental cues in one 
compartment and neutral cues in another, it voluntarily moves toward the 
compartment containing the drug-related cues. It was already suggested that brain 
regions other than that in reward take part in providing input to the mesocorticolimbic 
pathway (see 1.2.2.) concerning emotional and motivational variables. The 
association in "learning" of the drug and drug-related cues combined with complex 
interaction of psychological effect of drugs on brain areas associated with emotion 
and motivation may result in drug dependence. These learning processes mainly 
depend on the same motivational and emotional system in the brain once it was 
activated by the psychoactive substance (Schultz, 1998; Kelley and Mittleman, 1999; 
Schultz et al., 2000). 
1.2.2 Mesocorticolimbic dopamine pathway 
An essential part of this drug reward pathway appears to be the mesocorticolimbic 
pathway in Figure i (the proposed sites of action of the various drugs of abuse also 
shown in the pathway). This pathway is made up of axons of neuronal cell bodies in 
the VTA proj ecting to the NAc. 
It also connects the VTA to prefrontal cortex. Ventral tegmental neurons release DA 
to activate the cells in NAc and regulate the activity in prefrontal cortex. Thereby, 
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stimulation of DA transmission in the mesocorticolimbic system is crucial mechanism 
of drug addiction. 
The importance of DA in the reward pathway can be shown by several studies, for 
example, synaptic dopaminergic transmission in the NAc increases during natural 
rewarding action, like feeding or drinking as well as the administration of substances 
inducing addiction (Di Chiara and Imperato, 1988; Pontieri et al , 1995). The NAc is 
the key region that mediates the rewarding effects of drugs such as amphetamine and 
cocaine, which act directly by increasing the levels of DA at this site. Rats will 
self-administer tiny injections of amphetamine to the NAc by pressing a lever. More 
of the amphetamine was injected when their DA receptors were blocked 
pharmacologically, driving them to self-regulate the level of DA activity (Hoebel, et 
al. 1983). Many “knockout” studies have shown that mice lacking the DA D2 (DRD2) 
receptor consume less alcohol than intact controls (Phillips et al., 1998). 
Thus, in the absence of DA receptors, the reinforcing properties of amphetamine 
disappeared. It was shown that when the neurotoxin 6-hydroxydopamine (a 
neurotransmitter analogue that depletes noradrenergic stores in nerve endings and 
induces a reduction of dopamine levels in the brain) was administered to cause a 
massive depletion of DA, rats no longer self-administer amphetamine and cocaine 
(Wise, 1987). Animal studies showed that similar reinforcing effects were also 
demonstrated when rats self-administer morphine to the NAc (Bozarth and Wise, 
1984). It was further shown that there is a decrease in DA in the NAc during 
withdrawal from several drugs like morphine and amphetamine (Rossetti et al., 1992). 
Instead of looking at the tonic (minute-to-minute) level of extracellular DA in drug 
16 
addiction, one study illustrated the role of phasic (subsecond) DA signalling, DA was 
measured every 100 ms in the NAc using electrochemical technology. Rapid changes 
in extracellular DA concentration were observed at key aspects of drug-taking 
behaviour in rats. Before lever presses for cocaine, there was an increase in DA that 
coincided with the initiation of drug-seeking behaviours. Notably, these behaviours 
could be reproduced by electrically evoking DA release on this timescale. After lever 
presses, there were further increases in DA concentration at the concurrent 
presentation of cocaine-related cues. These cues alone also elicited similar, rapid DA 
signalling, but only in animals where they had previously been paired to cocaine 
delivery. These findings reveal an unprecedented role for DA in the regulation of drug 
taking in real time (Phillips et al., 2003). With the change in synaptic DA 
concentration, DA receptors undoubtedly play a crucial role in rewarding behaviours. 
Almost all psychoactive substances with reinforcing properties activate mesolimbic 
DA, either directly or indirectly. Therefore, it showed the crucial role of DA in the 
development of dependence for all classes of drugs because of its important role in 
response to reinforcement learning. 
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As shown in the rat brain, mesocorticolimbic dopamine (DA) systems originating in the ventral 
tegmental area (VTA) include projections from cell bodies of the VTA to the nucleus accumbens (NAc), 
amygdala, and prefrontal cortex (PFC); glutamatergic (GLU) projections from the PFC to the NAc to 
and the VTA; and projections from the y-aminobutyric acid (GABA) neurons of the NAc to PFC. 
Opioid intemeurons modulate the GABA-inhibitory action on the VTA and influence the firing of 
norepinephrine (NE) neurons in the locus ceruleus. Serotonergic (5-HT) projections from the raphe 
nucleus extend to the VTA and NAc. Source: Cami and Farre, 2003 
1.2.3 Behavioural processes of addiction 
Dependence-producing substances share the ability to produce persistent changes in 
brain regions that involved in the process of incentive, motivation and reward, and 
such changes make these regions hypersensitive (sensitized), resulting eventually in 
the complex behaviours like dependence, tolerance, sensitization and craving 
characterized in addiction. This main motivation circuitry takes part in the 
cortical-striatal-thalamic-cortical loops: a loop of the projection of axon from 
prefrontal cortex to NAc, ventral globus pallidus, then to the thalamus and finally 
back to the cortex (Fig. ii) (Chambers et al., 2003). NAc allows various motivations to 
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take place by changing the neuroplasticity of different neurotransmitters on their own 
path in this motivation circuitry. 
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Fig.ii Part A shows the Cortical-striatal-thalamic-cortical loops within primary motivation 
circuitry involved in the representation of motivated drives and the neurocomputational events of 
motivational decision making and behavioural instigation. 
Part B shows that DA discharge, in the NAc (thickened arrows) is implicated in the identification of 
environmental novelty, the actions of addictive drugs, and the gating of motivated drives into 
behavioural actions by changing responses of NAc neurons to cortical and limbic glutamatergic 
afferents. These events are proposed to lead to relative extremes in firing patterns among NAc neuronal 
ensembles, depicted as increases in local peak amplitudes that code for behaviourally activating events 
in downstream motor systems. These events may also facilitate mechanisms of neuroplasticity among 
NAc neurons and their afferents, determining the future repertoire of motivational drive representations 
and/or thresholds for behavioural instigation. 
Source: Chambers et al., 2003 
Exposure of the brain to psychoactive substances can activate the mesolimbic DA 
system with the primary role in guiding motivated behaviour. Repeat exposure of drug 
can lead to strong association mediated by DA and the brain becomes more sensitive 
or "sensitized" to the motivational and rewarding effects of psychoactive substances. 
Thereby, drug induced adaptations that enhance drug responsiveness with repeated 
drug exposure, more compulsive patterns of drug seeking and taking behaviour are 
found. This sensitization has been shown for various drugs including amphetamine, 
cocaine, morphine, PCP, ‘ecstasy,, nicotine and ethanol (Robinson and Berridge, 
1993). Increasing the presynaptic DA release and changing the postsynaptic receptor 
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sensitivity in the mesolimbic DA system result in sensitization. The idea of the 
transition from substance use to substance dependence may be closely related to the 
phenomenon of sensitization (Deroche et al., 1999). 
Tolerance refers to drug induced adaptations that lead to diminishing effects of a 
constant drug dose (Chao et al., 2002c). Some drug effects are increased upon 
repeated drug use. Rapid tolerance develops to the lethal effects of amphetamine and 
cocaine (Hoffman and Goldfrank, 1990). Tolerance can be developed by the changes 
in receptor number or sensitivity together with the presence of sensitization and an 
increase with repeated drug administration (Berke and Hyman, 2000). 
In short, possible relationships occur between neuronal plasticity of the related 
pathways in the brain as well as in the behavioural changes that result in addiction. 
Drug related behaviours may be contributed by several aspects of neural plasticity that 
are associated with repeated drug use in addicts: increasing the incentive motivational 
effects of drugs and enhancing craving for drugs are mediated by the change in 
neurotransmission between VTA and NAc in sensitization. Further increases in the 
tendency of drug related cues to drive drug-seeking behaviours by the enhancement 
from stimulus reward learning occur through the changes in neurotransmission 
between basolateral amygdala and NAc. Impairment of inhibitory control in 
governing reward-seeking behaviour may be caused by the changes in 
neurotransmission between PFC and NAc. Substance dependence can eventually 
induce the long lasting and nearly permanent behavioural changes, thereby the 
neuronal changes take a crucial role in this induction by changing (1) the synaptic 
plasticity in signalling; (2) the synaptic structure, and (3) the number of 
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neurotransmitter receptors. 
1.2.4 Other neurotransmitter systems in addiction 
Other neuronal pathways including neurotransmitters like 5-HT and glutamate also 
take part in regulating the activity of the mesolimbocortical DA pathway and 
mediating the rewarding properties of drugs of abuse. 
Studies showed that the dopamine transporter (DAT) also took part in reward. Excess 
DA in synaptic gap is recycled by the transporter, which facilitates re-uptake by the 
presynaptic neuron. However, cocaine, amphetamine and methylphenidate block the 
re-uptake of DA by binding to the DAT and result in the increase of DA in the 
synapse, therefore the reinforcing effects of cocaine and methylphenidate have been 
linked to their ability to block DAT (Volkow et al., 1998). PET imaging using 
[iiC]cocaine as a DAT ligand showed that DAT occupancies were significantly 
correlated with the "high" of the effect of cocaine use (Volkow et al., 1999). 
However, in some other human brain-imaging studies, many subjective responses to 
cocaine do not correlate with its action at the DAT level implying that other system 
besides the dopaminergic system may also be involved in reward. 
DA is one of the three catecholamines which are removed by reuptake into terminals, 
or into surrounding glial cells by Na+-dependent transporters and enzymes responsible 
for its catabolism may also play a role in reward. The two major enzymes involved in 
the catabolism of DA are monoamine oxidase (MAO) and 
catechol-0-methyltransferase (COMT), both of which are present within the 
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dopaminergic nerve terminals and are the targets of numerous psychoactive 
substances. Both COMT and MAO are the enzymes that catalyse the catecholamine 
neurotransmitters. Glutamatergic synapses located in the motivation circuitry play a 
role in memory and motivation by its projection to the NAc (Fig. 2) (Chambers et al., 
2003). The glutamate receptors, which are coupled to sodium channels or the 
potassium channels through a G protein, therefore are important for learning and play 
an essential role in the hippocampus. Hallucinogens, such as PCP act at the NMD A 
subtype of glutamate receptor. It is thought that glutamate pathways play a very 
important role in modulating neural responses to many other psychoactive substances 
by the direct effect of NAc DA discharge pattern. By this interaction between 
glutamatergic and dopaminergic system, DA can reinforce an association between a 
particular set of stimuli and a particular behaviour response. The associative learning 
mechanism is developed in association with addictive drugs. It could similarly 
promote a tendency to respond to drug related cues and context (Berke and Hyman, 
2000). Many studies showed that glutamatergic transmission takes part in drug 
addiction.. Chronic co-administration of glutamate receptor antagonists, like NMDA 
receptor antagonists, can attenuate the development of tolerance to the analgesic 
effects of opiates and the development of locomotor sensitization to several drugs of 
abuse (Robinson and Berridge, 1993; Tmjillo and Akil, 1994). NMDA antagonists 
including PCP and MK-801 have strong stimulant and reinforcing actions of their 
own and potentially activate the reinforcing action of drug of abuse (Carlezon et al, 
1996). 
5-HT neurotransmitter system has recently been highlighted since there is a mutual 
inhibitory interaction between the 5-HT and DA system. 5-HT suppresses intracranial 
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self-stimulation (ICSS) thresholds while serotonergic antagonists facilitate this 
behaviour (Niesink, 1999). Mice without the 5-HT IB serotonin receptor are more 
likely to self-administer cocaine (Rocha et al., 1998b). PET study showed that 
abstinent 'ecstasy' users had decreased global and regional brain 5-HT transporter 
(5-HTT) binding compared with never used ‘ecstasy’ controls. Decreases in 5-HTT 
binding positively correlated with the extent of previous MDMA use (McCann et al., 
1998b). Anti-depressant drugs shared with cocaine a high affinity for the 5-HTT 
molecule. Commonalities and co-morbidity between many forms of drug dependence 
and depression strengthen this link (McCann et al., 1998a). 5HT projects from the 
midbrain raphae nuclei to motivational circuit including VTA, NAc, PFC, amygdala, 
and hippocampus (Chambers, et al., 2003). Serotonergic deficit like a decrease in 
serotonin synaptic activity as well as lower level of platelet monoamine oxidase B 
(MAO-B) activity was found to be associated with pathological gambling (Ibanez et 
al., 2003). 
1.2.5 Molecular plasticity in addiction: signaling and gene expression 
Chronic administration of drugs of abuse induces changes in transcription factors, 
which are nuclear proteins that bind to the regulatory regions of certain genes, thereby 
regulating their transcription. Drug-induced changes at the level of gene expression 
could explain the longevity of the behavioural abnormalities associated with addiction. 
Different level of adaptive response at molecular level can be resulted in differences 
in vulnerability to dependence to different drugs (Nestler and Aghajanian, 1997). 
Chronic exposure to opiates, cocaine, and alcohol up-regulates the cAMP pathway in 
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the NAc (Terwilliger et al., 1991; Unterwald et al., 1993; Nestler and Aghajanian, 
1997). Drugs inhibit the re-uptake of DA in the VTA neurons (Volkow et al., 1999), 
where DA is initially produced from the amino acid tyrosine. DA is shown acting at 
the two main families of DA receptors (Dl and D2). These receptors are coupled to 
guanine-nucleotide-binding proteins (Gs and Gi), components of the intracellular 
cyclic AMP (cAMP) system, which also includes adenylyl cyclase and 
cAMP -dependent protein kinase (PKA). Possible substrates for this kinase include 
ion channels and the nuclear transcription factors CREB (cAMP response 
element-binding protein), c-Fos and c-Jun. 
CREB is a transcription factor, a protein that regulates the expression, or activity, of 
genes that code for proteins and these proteins are then used to carry out the functions 
of the cell and thus the overall behaviour of nerve cells. When drugs of abuse are 
administered, DA concentrations in the NAc rise, inducing DA-responsive cells to 
increase production of a small signalling molecule, cAMP, which in turn activates 
CREB. After CREB is activated, it binds to a specific set of genes, triggering 
production of the protein those genes encode. Hence, activation of CREB is 
downstream of the cAMP-signalling pathway, whose up-regulation has been 
extensively characterized as an adaptation to chronic exposure to drugs of abuse 
(Guitart et al., 1992). The up-regulation of CREB was also discovered in the culture 
of neuroblastoma and gliomacells (Sharma et al, 1977) and in neurons in response to 
repeated opiate administration (Sharma et al, 1977). Short-term administration of 
opioid activates the mu-opioid G protein Ga i/o-coupled receptor, which inhibited 
adenylyl cyclase, lowered cAMP level, decreases cAMP-dependent PKA activity, and 
reduces phosphorylation of the transcription factor, CREB. Activation of mu-opioid 
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receptors can also cause the phosphorylation of CREB and other transcription factors. 
Decrease in the number of opioid receptors had been related in some reports to the 
development of opioid tolerance. Continuous stimulation desensitizes opioid receptors, 
which become phosphorylated by G-protein-coupled receptor kinases, beta-arrestins 
then bind to the receptors, causing them to be internalized by the neuron (Nestler, 
2001; Berrendero et aL, 2002; Watts et al , 2002). 
Chronic drug use also causes sustained activation of CREB. For example, the chronic 
use of cocaine or amphetamine associated with activation of Dl-like dopamine 
receptors (D1 and D2 DA receptors) stimulates a cascade of events. This includes the 
activation of Gs proteins, an increase in the formation of intracellular cAMP which 
lead to phosphorylation of transcription factors including CREB and to the induction 
of immediate-early genes such as c-fos and c-jun, whose expression is induced within 
minutes of exposure to a stimulus (Nestler et al., 1995; Hyman et al., 1996). 
Chronic activation of opioid receptors produces effects opposed to those of acute 
activation. It up-regulates cAMP signalling pathways by increasing the activity of 
adenylyl cyclases, cAMP-dependent protein kinase A, and tyrosine hydroxylase (TH). 
Among the gene involved are adenylyl cyclase type VIII and TH whose expression is 
up-regulated by chronic morphine administration via the CREB-dependent 
mechanism. As a result, the phosphorylation of CREB and AFosB, factors regulating 
gene transcription is increased by activation of the cAMP cascade causing the influx 
of sodium, these changes correlate with the manifestations of the withdrawal 
syndrome (Lane-Ladd et aL, 1997; Chao et al., 2002b; Chao et al., 2002a). 
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Fos family proteins respond to drugs of abuse with a characteristic sharp 
up-regulation followed by a quick decline to basal levels within hours (Young et al, 
1991) but the isoforms of AFosB are very stable and demonstrate in vivo half-life of 
several weeks (Chen et al., 1997). It was shown that the presence of AFosB protein 
persisted for weeks even after the drug is withdrawn (Andresson et al., 2003). AFosB 
therefore plays a significant long-term role in subsequent regulation of gene 
expression. Transgenic mice over expressing AFosB showed that the NAc and dorsal 
striatum exhibit increased responsiveness to the rewarding and locomotors activating 
effects in response to chronic exposure to several drugs of abuse, including cocaine, 
amphetamine, opiates, nicotine, ethanol and PCP (Nye et al, 1995; Nye et al, 1996; 
Ryabinin et al, 1998; Kelz and Nestler, 2000) and enhanced drug-seeking behaviours 
(Chen et al., 1997; Nestler, 2002). So, AFosB becomes a unique target of chronic 
exposure to drug of abuse, it is deemed the 'molecular switch' that gradually converts 
acute drug response into relatively stable adaptations that contribute to the long-term 
neural and behavioural plasticity that underlies addiction (Nestler, 2001). By affecting 
the expression of many other genes within the same neurons with the accumulation of 
AFosB, the synaptic transmission as well as the neuronal functions in brain can be 
continuously affected, the long-lasting changes in neuronal composition will be 
resulted. 
1.3 Association of Personality Traits and Drug Abuse 
Substance use, like smoking, drinking, marijuana, heroin and cocaine, had been found 
to be associated to personality disorders. O'Malley et al. (1990) showed that 
substance abusers have a higher rate of DSM Axis II personality disorders than those 
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in the general population. To date, a number of studies have shown that there is an 
association between personality disorders and substance-use disorders. Gelemter et al. 
(1997) showed that both personality disorders and mood/anxiety disorders are 
consistently found to be highly prevalent among substance abusers. It was estimated 
that the prevalence of mood/ anxiety disorder among substance abusers to be in the 
range of 15-30% (Gelemter et al., 1997) and the prevalence of personality disorder to 
be as high as 30%-75% (Verheul et al., 2001). More specifically, there is a higher 
prevalence of smokers amongst the psychiatric population and the early onset of 
smoking was shown to be linked to depression and alcohol use disorder (Hanna, 
1999). Major depression among alcoholics, with a rate of 36%, was two to three times 
more prevalent than non-alcoholics (Robins and Regier, 1991). Furthermore, at least 
two thirds of alcohol-dependent individuals showed evidence of anxiety, sadness, and 
antisocial behaviours (Schuckit et al., 1997). Anxiety symptoms are also common 
with marijuana use. Patients of substance abuse disorder (SAD) with the majority 
involved in marijuana and stimulant use showed that 60% of them had mood disorder, 
63% with anxiety disorder and 80% with schizophrenia spectrum disorder (Swadi et 
al. 2003). Brooner et al. (1997) used the DSM-III-R criteria for antisocial personality 
disorder (APD) showed that APD is the most frequent personality disorder among the 
opioid abusers, (15% in females and 35% in males) (Brooner et al., 1997). When 
cocaine and heroin abusers were compared, heroin abusers (45%) showed a higher 
proportion of APD than in cocaine abusers (25%) (Fieldman et al., 1995). 
With the increase in comorbidity of substance dependence and mental illness, more 
studies emerged illustrating the personality traits of the substance abusers (Francis et 
al., 1997; Cooper et al., 2000; LoCastro et al., 2000; Sher et al., 2000; Soloff et al., 
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2000). Biologically, the personality traits are based either having a shared 
neurobiological basis or having an interaction of effects at some levels. Three 
personality traits are biologically conceptualized by Eysenck namely extraversion, 
neuroticism, and psychoticism (Eysenck et al , 1985). Extraversion is characterized by 
being outgoing, talkative, high on positive affect, and in need of external stimulation, 
according to Eysenck's theory, there is an optimal level of cortical arousal, and 
performance deteriorates as one becomes more or less aroused to this optimal level. 
Neuroticism is characterized by high levels of negative affects including depression 
and anxiety. Neuroticism, according to Eysenck's theory, is based on activation 
thresholds in the sympathetic nervous system or visceral brain (Eysenck et al., 1985). 
This is the part of the brain that is responsible for the fight or flight response in the 
face of danger. Psychoticism is characterized by nonconformity, hostility, and 
impulsivity (Eysenck et al., 1985). The physiological basis revealed by Eysenck for 
psychoticism is testosterone, with higher levels of psychoticism associated with 
higher levels of testosterone. Eysenck's model is useful because it specifies some of 
the biological mechanisms believed to underlie personality traits which may be risk 
factors for substance use. Other biologically based models, such as Zuckerman 
(Zuckerman et al., 1984), Gray (Gray, 1987), Cloninger (Cloninger, 1987a) and 
NEO PI-R (Costa and McCrae, 1991) gave rise to their own models related to 
Eysenck's model. 
Certain personality traits share the same biological determinants, namely, 
neurotransmitters, which takes part in the reward pathway of the brain. For example, 
higher DA and lower MAO levels in the cerebrospinal fluid (CSF) were found in high 
sensation seeking personalities (Zuckerman, 1985). Sensation seeking is similar to 
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dimensions related to impulsivity in Eysenck's and Cloninger's models (Zuckerman 
and Cloninger 1996; Zuckerman et al., 1993). 
Sensation seeking has been related to various high-risk behaviours including sports, 
criminal activities, sexual behavior, smoking, heavy drinking, drug use and abuse 
(Zuckerman and Kuhlman, 2000). Zuckerman's Sensation Seeking Scale form V 
(SSS-V) is one of the commonly used scales to measure sensation seeking traits 
(Zuckerman, 1994). The SSS-V is composed of four subscales, each of which has 10 
forced-choice items: (1) thrill and adventure seeking (TAS), with items expressing a 
desire to engage in sports or other activities involving speed or danger; (2) experience 
seeking (ES), which represents the seeking of experience through the mind and senses, 
travel and non-conforming lifestyle; (3) disinhibition (DI) which represents the desire 
for social and sexual disinhibition; and (4) boredom susceptibility (BS) representing 
an aversion to repetition, routine and restlessness when things are not changing. In the 
focus on the importance of sensation seeking as related to substance use, sometimes 
different names are used for sensation seeking, such as impulsivity (personality trait 
characterized by acting on impulse, non-planning, liveliness, and risk-taking) 
(Eysenck et al, 1985); behavioural approach (tendency to seek out pleasant stimuli) 
(Gray, 1987); novelty seeking (tendency to seek out-of-the-ordinary experiences) and 
reward dependence (approach motivation) (Cloninger, 1987a). 
Higher scores had been found on the subscales including impulsiveness, anxiety, 
sensation seeking, somatic complaints, obsessive-compulsive behaviour and 
psychoticism in 'ecstasy' users and even higher scores was found in heavier 'ecstasy' 
users (Daumann et al., 2004). A cross-sectional study showed that temperamental 
29 
characteristics were associated with an increased risk of substance use disorder in 
subjects with psychotic or mood disorder; subjects with higher SSS- subscales ES and 
DI scores were more likely to present with a lifetime history of alcohol 
abuse/dependence. Greater DI scores were also been shown to be associated with a 
lifetime use of cannabis (Liraud and Verdoux, 2000). Zuckerman (1999) has 
consistently found higher DI and ES scores related to drug use (Zuckerman, 1999). It 
had been shown that among young adult drug abusers, high sensation seekers tend to 
abuse all types of drugs, including marijuana, cocaine, amphetamines and barbiturates. 
The highest sensation seekers were polydmg abusers who abuse a variety of drug uses 
concurrently or over their lifetime (Ball et al, 1986). 
Gray illustrated that there are two main behavioural systems, namely, the behavioural 
inhibition system (BIS) and behavioural activation system (BAS), in which they are 
mediated by the serotonergic system originating in the median raphe and the 
dopaminergic activity in the mesolimbic system respectively (Gray, 1994). BAS in 
Gray's model is closely related to extraversion in Eysenck's model, whereas BIS in 
Gray's model is closely related to neuroticism in Eysenck's model (Gray, 1987). 
Craver and White (1994), based on the two main behavioural systems proposed by 
Gray (1987), had devised subscales to the BAS (brain system posited to underlay the 
tendency to seek out pleasant stimuli) and BIS (brain system posited to underlay the 
tendency to avoid unpleasant stimuli) systems. In this BIS/ BAS scales, BAS was 
divided into three subscales: reward responsiveness, drive and fun seeking. BIS was 
shown to reflect a greater tendency for anxiety and harm avoidance (capacity to leam 
and change behaviour as a result of punishment) (Carver and White, 1994). Using the 
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BIS/BAS system, it was shown that in individuals with a lifetime history of alcohol 
use, high BAS-fun seeking scores were found only among those without comorbid 
anxiety (Conrod et al., 2000; Johnson et al., 2003). Subjects with high BAS-drive 
scores experienced significantly stronger desires and intentions to drink alcohol and 
have negative reinforcement cravings (behaviors that terminate aversive effects are 
negatively reinforced, like the negative symptoms of withdrawal can be terminated by 
taking the drug again) during exposure to alcohol related cues than subjects with low 
BAS-drive scores (Franken, 2002). 
As defined by Cloninger (1987b), type 1 alcoholics drink to reduce anxiety and 
distress while type 2 alcoholics drink for enjoyment and for the disinhibition produced 
by alcohol and are more likely to be engaged in fighting and other antisocial 
behaviours. Early onset of alcohol abuse and criminality has also been shown to be 
associated with higher novelty seeking behaviour (Howard et al., 1997). It is therefore 
evident that the association of personality traits and substance use is complex, that 
different personality traits may be associated with different patterns of drug use and 
that the different dimensions of personality traits can be characterized even within the 
one type of drug use. 
1.4. Association between genetics and drug abuse 
Drug use is a complex behaviour in which both genetic and environmental factors 
exert a major influence on an individual's vulnerability to drug abuse (Anokhin et al., 
1999). Base on family, twin, adoption, case-control and linkage studies, there is a 
strong genetic factor that contributes to drug dependency; however, there is no single 
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gene that was shown to cause drug dependence. In other words, several distinct genes 
may combine to contribute to drug abuse susceptibility thus increasing the 
individual's risk of developing drug abuse. 
1.4.1 Family, twin and adoption studies 
Family, twin and adoption studies have revealed contribution of genetic factors to 
psychoactive substance use and dependence. It is supposed that if the proportion of 
monozygotic twins concordant for a given trait is greater than the proportion of 
dizygotic twins, it is likely that genetic factors are influencing the trait. If there is no 
significant difference in concordance rates between monozygotic and dizygotic twins, 
then the trait is likely to be influenced by environmental factors. The patterns of 
inheritance and relative risk of drug abuse can be examined from family studies by the 
inheritance of traits through a family. It was shown that there was an 8-fold increased 
risk of drug disorders among the first-degree relatives of 231 probands with drug 
disorders across a wide range of specific substances, including opioids, cocaine, 
cannabis, and alcohol (Merikangas et al , 1998). In a review of more than 17,500 
reared-together monozygotic and dizygotic twins from 14 different studies, it was 
estimated that genetic, familial-environmental and individual-specific environmental 
risk factors accounted for 56%, 24% and 20% of the variance in regular tobacco use 
respectively and genetic factors contribute to near to 60% of the variance in smoking 
(Sullivan et al., 1999). A twin study on alcoholism in males showed a concordance 
rate of 63.4% for monozygotic and 43.8% for dizygotic twin pairs (Pickens et al, 
1991). Another study on substance dependence with the twin pairs from the Vietnam 
Era Twin Registry showed that the genetic variance of heroin abuse was 38% but only 
32 
16% for marijuana and amphetamines abuse (Tsuang et al., 1998). 
1.4.2 Transgenic and knock out animal models 
Transgenic mice are genetically engineered by introducing a segment of DNA from a 
different organism into the germline of the mice that allow researchers to examine 
specific receptors that may mediate the addictive properties of drug abuse. For 
example, cultured cells (Hiremagalur et al., 1993) or transgenic mice with 
over-expressed TH, the rate-limiting enzyme controlling DA synthesis, was shown to 
be less sensitive to physiologic effects of nicotine (Nabeshima et al., 1994). In 
knock-out animals, the specific gene of interest will be replaced by an inactive or 
changed one, thereby a deficiency in protein expression corresponding to the gene can 
be observed and these transgenic mice is called knock-out mice. A knock-out mice 
lacking the DAT gene, the crucial binding site of cocaine, can retain the capability to 
self-administer cocaine intravenously (Rocha et al., 1998a). Psychostimulants and 
serotonin uptake inhibitors attenuated the hyperactivity of DAT knock-out mice 
(Powell et al., 2004). There was a suppression of rewarding behavior with morphine 
in DRD2 knock-out mice but these knockout mice displayed normal response when 
food was used as a reward (Maldonado et al., 1997). 
1.4.3 Candidate genes for drug abuse 
Receptor gene variant in the serotonergic, dopaminergic, GABAergic, opioid systems 
in the CNS which are shown to be associated with addictive behaviours like 
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alcoholism, cocaine, smoking, heroin dependence (Comings et al., 1997; Lappalainen 
et al , 1998; LaForge et al , 2000; Noble, 2000). 
1.4.3.1 Dopamine receptor genes 
The mesolimbic dopaminergic system has been shown to be involved in the 
reinforcing effects of many substance of abuse. Variants of the DA D2 receptor 
(DRD2) gene had been shown to be associated with alcohol, nicotine, cocaine and 
opioid dependence (Noble, 2000). The gene variant DRD2 TaqI Al allele has been 
shown to be associated with reduced D2 DA receptor binding affinity (Noble et al, 
1991). In alcoholic patients with the DRD2 Al allele, a greater severity of alcohol 
dependence was shown (Connor et al., 2002). 
A 48 base pair variable number of tandem repeats (VNTR) polymorphism in exon 3 
of the DRD4 gene has been identified and is thought to play a role in novelty seeking 
behaviours, attention deficit hyperactivity disorder (ADHD), Tourette syndrome (TS), 
pathological gambling, and substance abuse (Comings et al., 1999). Further 
association between the L allele of DRD4 gene and alcohol dependence was also 
shown. Participants were asked to consume 3 alcoholic drinks or 3 control drinks and 
measures of craving were completed on them after each drink. It was shown that those 
with the L allele demonstrated significantly higher craving after consumption of 
alcohol as compared to those who drank the control beverage (Hutchison et al., 2002). 
A polymorphism of the DAT has been identified which is associated with altered 
levels of the DAT protein in the brain (Heinz and Goldman, 2000), suggesting that the 
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polymorphism results in a functional difference. However, no association with 
substance dependence has been found. 
1.4.3.2 Monoamine Oxidase (MAO) gene 
MAO is encoded in X chromosome and the MAO-A locus is an attractive candidate 
for exploring genetic contribution to the variation in the risk for substance use 
disorders (SUD) (Vanyukov et al , 2003) because of its important role in the 
metabolism of neurotransmitters, including DA and 5-HT. The occurrence of a G at 
position 941 creates a restriction site for Fnu4Hl within the coding region of the 
MAO-A gene, one of the major enzymes responsible for the degradation of 
neurotransmitter such as 5-HT, NE and DA. The G allele was found in individuals 
with a higher MAO-A activity (Hotamisligil and Breakefield, 1991). Cigarette 
smokers have reduced brain levels of MAO-A (Fowler et al., 1996) and levels of 
MAO in peripheral tissues (Berlin et al.，1995). This may be due tobacco smoke 
contains MAO-A inhibitors which may contribute to the lower levels observed in 
smokers. 
Significant associations of alcohol dependence with MAO-A alleles were found 
among the Han Chinese people, but not in Taiwanese (Hsu et al., 1996). 
1.4.3.3 Catechol-O-methyltransferase (COMT) gene 
COMT is the enzyme that catalyses the first step in one of the major degradative 
pathways of the catecholamine neurotransmitters, DA, epinephrine, and NE (Cooper 
et al., 1996). In particular, the frontal cortex is the area where COMT is responsible 
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for more than 60% of DA degradation instead of MAO (Karoum et al , 1994). A 
single base pair change (G— A) in exon 4 of the COMT gene results in the creation of 
an Nla III site in the DNA and an amino acid change (Val, 108 COMT— Met, 158 
COMT). This single amino acid change from Val (H) to Met (L) results in a decrease 
of 3 to 4 fold COMT enzyme activity (Lotta et al., 1995; Lachman et al., 1996); the 
alleles are co-dominant, as heterozygous individuals have enzyme activity that is 
midway between homozygote individuals (Weinshilboum et al., 1999). In other words, 
individuals with L alleles presumably have relatively more baseline dopaminergic 
signalling at synapses while H alleles lead to increase DA catabolism resulting in 
relatively less DA in the prefrontal synapses. Thus, variations in COMT activity might 
affect prefrontal cortical activity. 
A functional high COMT activity homozygous val allele has been shown to be 
associated with alcohol dependence and polysubstance use (Vandenbergh et al., 1997; 
Horowitz et aL, 2000). Type I (with late-onset but without prominent antisocial 
behavior) alcoholism is more common among subjects with low activity COMT 
(met/met), compared to those with high activity val/val or heterozygotic (val/met) 
genotypes (Tiihnen et al., 1999). 896 middle-aged Finnish men with low COMT 
activity met/met genotype (30% of all subjects) were reported to have 27% higher 
weekly alcohol consumption when compared with the two other genotype groups, 
val/val and val/met (Kauhanen et al., 2000). However, the high COMT activity val/val 
genotype were reported in 18% of controls and 31% of the high lifetime substance 
user, hence the high activity COMT variant may have greater genetic vulnerability to 
drug abuse (Vandenbergh et al., 1997). 
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1.4.3.4 Serotonergic genes 
5-HT is an important neurotransmitter that regulates various essential brain functions 
via many 5-HT receptor subtypes. There are seven main classes of 5-HT receptors 
among which the 5-HTl receptor is divided into subclasses (A, D, E and F) on the 
basis of their pharmacologic and biochemical properties (Humphrey et al., 1993; 
Hoyer and Martin., 1996). In the CNS, 5-HT IB receptors are widely distributed in the 
basal ganglia, hippocampus and other regions of the cortex, and function as both 
5-HT autoreceptors and heteroreceptors, mediating respectively, the release of 
serotonin and non-serotonin neurotransmitters (Barnes and Sharp, 1999; Moret and 
Briley, 2000). 5 HTIB knockout mice has been found to exhibit greater aggression 
and impulsivity (Saudou et al., 1994) and to have an increase in alcohol intake and 
cocaine consumption (Crabbe et al., 1994; Rocha et al., 1998b). It was therefore 
suggested that 5HT-1B is important in the development of alcoholism and other 
psychiatric disorders (Scearce-Levi et al., 1999). This was confirmed by a Finnish 
study in which Finnish antisocial alcoholics were found to have a higher frequency of 
the 86IC allele in the 5-HT IB polymorphism G861C than Finnish controls 
(Lappalainen et al., 1998). 
Variation in the serotonergic system is related to mood regulation, impulse control, 
appetite and aggression. Since 5-HTT is a functional protein that regulates the amount 
of 5-HT in a synaptic gap, the agents that bind to 5-HTT, for example, serotonin 
reuptake inhibiting antidepressants, cocaine and ‘ecstasy’ will modify serotonergic 
transmission. These agents elevate mood in depressed or normal subjects. Therefore, 
5-HTT is one of the targets in the etiological study of psychiatric disorders including 
37 
mood and anxiety disorders 
There is a 44 bp pair insertion/deletion polymorphism in the promoter region of the 
human serotonin transporter gene (5-HTTLPR) containing 'long' (L) and 'short' (S) 
alleles (Heils et al., 1995). The L allele was shown to have higher transcriptional 
activity in vitro and in lymphoblastoid cells (Heils et al., 1996; Lesch et al., 1996). 
The 5-HTT gene (SLC6A4) is a candidate gene for smoking and predisposition to 
alcohol dependence because of its association with psychological traits relevant to 
smoking and alcohol dependence. For example, a Japanese study found that 
5-HTTLPR was associated with smoking (Ishikawa et al., 1999) and smokers with 
coronary heart disease (Arinami et al., 1999). 
1.4.3.5 Opioid receptor genes 
The human mu-opioid receptor (hMOR) plays a crucial role in the response to opioids 
and to both endogenous opioid peptides for the regulation of normal physiology of 
what and synthetic exogenous ligands (Kreek, 1996). Herz (1997) showed that reward 
behaviour was activated by /3 -endorphin, an endogenous opioid peptide that activates 
the )a-opioid receptor, the primary action site for heroin and endogenous P-endorphin. 
Mu-opioid agonists are important clinically in the management of pain and short 
acting opiates like heroin (Dole et al., 1996; Kreek, 1996). The hMOR A118G 
polymorphism has also been shown to be associated with heroin dependence in the 
Hong Kong Chinese population (Szeto et aL, 2001) and associated with heroin and 
alcohol-dependence in the German population (Franke et al., 2001) and in the Indian 
population in Singapore (Tan et al, 2003). 
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The delta-opioid receptor (OPRDl) T921C polymorphism has been shown to be 
associated with heroin dependence in the German population (Mayer et al., 1997) and 
we have also an association in the Hong Kong Chinese population (unpublished data) 
although not in mainland Chinese population (Xu et al., 2002). 
1.4.4 Linkage studies of drug abuse 
Linkage studies use multiple affected families to examine traits that are inherited 
together. It is based on the fact that genes that are located close to one another will be 
more likely to be inherited together from one parent than two genes located further 
apart. When there is a greater chance of genes being inherited together, the genes are 
therefore said to be linked. Comings et al. (1997) showed that a linkage was found 
between loci on chromosome 5q and the locus for the DA D1 receptor that has been 
always associated with smoking. A significant sib pair linkage in southwestern 
American Indian to chromosome 6 was found to be associated with antisocial 
alcoholism (Lappalainen et al , 1998). The strongest linkage with loci for alcohol 
dependence are on chromosomes 1, 2 and 7 (Reich et al., 1998). 
1.5 Genetic factor and personality trait 
Majority of genetic researches on personality traits include self-report questionnaires 
administered to adolescents and adults are based on the definition that personality is 
the vigor, temper or persistence of behaviour or to the emotional expression that 
accompanies it like fearfulness, exuberance, aggressiveness or self-restraint (Loehlin, 
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1992). Numerous self-report questionnaires like revised NEO Personality Inventory 
(NEO-PI-R) (McCrae and Costa, 1997); Eysenck's Personality Inventory (Eysenck, 
1952); Zuckerman's Sensation Seeking Scale (SSS) (Zuckerman, 1994); Cloninger's 
Tridimensional Personality Questionnaire (TPQ) (Cloninger, 1987a) and 
Temperament Character Index (TCI) (Cloninger et al., 1993) are in use and appear to 
reliably measure many of the same personality factors including novelty seeking 
(extraversion, conscientiousness, sensation seeking, psychoticism) and harm 
avoidance (neuroticism, anxiety-related traits). 
Cloninger and colleagues have proposed a biosocial model of personality based on 
four temperaments (novelty seeking, harm avoidance, reward dependence and 
persistence) (Cloninger et al , 1993). Novelty seeking is referred to the tendency to 
respond actively to novel stimuli or cues or potential rewards and escape from 
punishing (behaviour activation). Harm avoidance corresponds to the tendency toward 
an inhibitory response to signals of aversive stimuli that lead to avoidance of 
punishment and non-reward (behaviour inhibition). Reward dependence is the 
tendency for a positive response to signals of reward to maintain or resist behavioural 
extinction. Persistence is the perseverance despite frustration and fatigue (behaviour 
maintenance). According to this model, three of the four temperaments were 
associated with a specific central neurotransmitter. Novelty seeking is associated to 
dopaminergic activity; harm avoidance to serotonergic activity and reward 
dependence to noradrenergic activity. Thereby, it was suggested that genes 
corresponding to the neurotransmitter balance in the brain could change the 
personality traits including impulsive, compulsive and even addictive behaviours 
(Comings, 1996). 
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1.5.1 Twins study 
From the twin studies, it was shown that heritability of personality traits are in the 
30-50% range. Ebstein showed that extraversion is one of the most highly heritable 
categories (-50%) followed by neuroticism (-40%) (Ebstein et al , 2000). The within 
sex genetic correlations between neuroticism and major depression was 0.68 in men 
and 0.49 in women (Fanous and Kendler, 2004). The following are the studies in 
which an association of personality and genetic polymorphisms were found. 
Monozygotic twins of combat-related posttraumatic stress disorder (PTSD) probands 
had significantly more mood disorder symptoms than monozygotic controls and 
dizygotic PTSD probands (Koenen et al., 2003). One twin study illustrated that the 
phenotypic correlations between the control scale of the multidimensional personality 
questionnaire (MPQ, Tellegen, 1982) and the four subscales of the sensation seeking 
scale (SSS) with 55% attributed by genetic variance and the rest was specifically 
attributed to the control scale of the MPQ (Hur et al., 1997). 
1.5.2 Candidate gene studies 
Associations between specific genetic polymorphisms and specific personality traits 
have been reported (Benjamin et al , 1996; Ebstein et al., 1996), especially 
polymorphisms corresponding to the neurotransmitter receptor genes were largely 
investigated. 
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1.5.3.1 Dopamine (DA) 
Association of personality trait and the 48 base pair variable number of tandem 
repeats (VNTR) polymorphism in exon 3 of the DRD4 gene was reported. The long 
allele of the DRD4 was associated with higher novelty seeking (Noble et al., 1998; 
Kuhn et al., 1999; Strobel et al., 1999; Tomitaka et al., 1999) while some studies did 
not show the association (Vandenbergh et al., 1997; Bau et al., 1999). Recently, the 
DRD4 48bp VNTR polymorphism at exon 3 has been shown to be putatively 
associated with novelty seeking and other personality traits. DRD4 receptor knock-out 
mice exhibited reduced exploration of novel stimuli (Dulawa et al., 1999) whereas in 
humans, the DA D4.7 receptor variants have shown to be associated with novelty 
seeking behaviour (Benjamin et al., 1996; Ebstein et al., 1996). In a meta-analytical 
review of 20 studies (n = 3907), 13 reports suggested that the presence of longer 
alleles was associated with higher novelty seeking scores and seven showed the 
opposite results (Kluger et al., 2002). 
However, the relevancy of DRD4 to personality trait cannot be overlooked. Another 
functional polymorphism was found in the 5' region of DRD4 gene, this -521C/T 
polymorphism is located in the region that regulates cell-type specific gene expression 
in which the -52IT mutation showed significantly less transcriptional activity 
(Kamakura et al., 1997). An approximately 40% decrease in transcription efficiency if 
human retinoblastoma cells which transiently expressed -52IT (Okuyama Y. et al., 
2000). The -521C/T polymorphism was also shown to be associated with novelty 
seeking in the same study. Further, allele C had been shown to be associated with 
ADHD (Jonathan M. et al., 2003). Okuyama et al. (2001) showed a relevancy of the 
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promoter region of the DRD4 gene to novelty seeking; they showed that a promoter 
region polymorphism of the DRD4 gene with a functionally significant T variant of 
the -C521T polymorphism reduces transcriptional efficiency (Okuyama et al , 2001). 
In a meta-analysis, this -C521T polymorphism was found to be associated with 
novelty seeking (Schinka et al., 2002). An interesting finding was found that only the 
presence of the 48-bp VNTR and the -C521T polymorphism were associated with 
higher novelty seeking and lower harm avoidance scores (Lee et al., 2003). It shows 
the interaction between genotypes. 
The TaqI polymorphism in DRD2 gene characteristically presents two alleles named 
Al and A2. Human who carry the Al allele showed low relative glucose metabolic 
rates in brain regions that are rich in DA receptors and participate in a variety of 
complex cognitive and motivational processes (Noble et al., 1997). The presence of 
DRD2 TaqI Al allele has been associated to higher novelty seeking (Noble et al., 
1998), higher decrease in anxiety and craving following the use of a DA receptor 
agonist (Lawford et al., 1995), and stress (Berman and Nobel, 1997). 
1.5.3.2 COMT 
A G/A transition found in codon 108/158 results in a valine-to-methionine substitution, 
Met (108/158) is coded by the low-activity (A allele), whereas Val (108/158) is coded 
by the high-activity variant (G allele). The A allele in COMT val-met polymorphism 
has been associated with schizophrenia (Kotler et al., 1999) and A allele carriers 
expressed their anger more outwardly, whereas G allele carriers expressed it more 
inwardly and reported more stage anger (Rujescu et al , 2004). The A allele in COMT 
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gene in is believed to relating mood disorders, schizophrenia and obsessive 
compulsive disorder (Lachman et al., 1996). Moreover, this functional polymorphism 
also participated in anxiety (Enoch et al., 2003) and panic disorder (Woo et al., 2004) 
in women. 
1.5.3.3 MAO-A 
MAO-A acts as a catalyst in the degradation of neurotransmitters like DA, serotonin, 
and noradrenaline. In animal studies, chemical inhibition and deletion of targeted 
gene for MAO-A leads to an accumulation of serotonin and norepinephrine but not 
DA in brain (Cases et al., 1995). Low platelet MAO activity has been associated with 
personality characteristics such as sensation seeking and impulsiveness (Oreland, 
1993). The use of MAO-A inhibitors as antidepressants are well known (Dolle et al., 
2004). A silent RFLP have been identified, Fnu4HI T— G substitution in exon 8 on X 
chromosome, with the G allele associating with higher MAO-A activity (Hotamisligil 
and Breakefield, 1991). This G allele was associated with obsessive-compulsive 
disorder, particular in males with comorbid major depression (Karayiorgou et al., 
1999) while the lower level of MAO-A activity allele has been found more common 
in probands with bipolar disorder (Preisig et al., 2000), particular in males with 
comorbid major depression (Karayiorgou et aL, 1999), and the G allele was also 
associated with type II alcoholics (Parsin, 1999), while the T allele of MAO A G941T 
polymorphism was associated with generalized anxiety disorder (Tadic et al , 2003). 
1.5.3.4 Serotonin (5-HT) 
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There are two predominant alleles in the polymorphic promoter region in 5-HTT gene 
(SLC6A4), (5-HT transporter gene-linked polymorphic region, 5-HTTLPR) of this 
gene: a long and a short allele with 16 and 14 repeat units, respectively. This 44bp 
deletion in the 5-HTTLPR was found in affecting transcription of the gene (Heils et 
al., 1996) and the short allele has lower activity and is associated with several 
psychiatric disorders and personality traits. For example, it was associated with harm 
avoidance personality traits (Lesch et al., 1996). Schizophrenic patients with the 
homozygous short alleles (deletion variant) in 5-HTTLPR scored significantly higher 
on "guilt feelings" and "depression" items of the Positive and Negative Syndrome 
Scale (PANSS), and self-rated inventories (EPI, MMPI, STAI) scores (Golimbet et al., 
2004). A current study examines both association and linkage of the gene to two 
major anxiety-related personality measures, the harm avoidance scale on the TPQ and 
the neuroticism scale of the NEO-PI-R, in a sample of 148 Israeli subjects comprising 
74 same-sex sibling pairs. The short allele was consistently present in higher scores 
on the TPQ harm avoidance scale (P = 0.03) and also in the same direction of 
NEO-PI-R neuroticism subscales of anxiety (P = 0.03) and depression (P = 0.04) 
(Osher et al., 2000). Another study showed that a novel allele with 13 repeat units, 23 
base pairs shorter than the common short allele in the 5-HTTLPR was detected in a 
schizophrenic patient of Jewish Libyan origin who exhibited extreme aggressive 
behaviour and committed suicide after several attempts (Frisch et al., 2000). The 
results, however, have been inconsistent reported that there was no association in 
5-HTTLPR and personality traits of Japanese population (Kumakiri et al., 1999) and 
this no association also happened in DRD4 VNTR exon III in novelty seeking 
(Ebstein et al., 1997). 
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It may be due to multi-gene interaction since there was an association found between 
5-HTTLPR and DRD4: a significant DRD4 VNTR and 5-HTTLPR interaction was 
observed for harm avoidance, the subgroup with homozygous short 5-HTTLPR, 
7-repeat DRD4 genotype showed a higher mean harm avoidance score (Szekely et al., 
2004). 
Moreover, in a study, Studies demonstrated that 5-HTlB autoreceptors plays a role in 
the pathology of depression, anxiety, and obsessive-compulsive disorder (Moret and 
Briley, 2000) and it was shown that chronic administration of tricyclic antidepressants 
or selective reuptake inhibitors desensitizes the presynaptic 5-HTlB autoreceptors. 
(Briley and Moret, 1993). Finnish antisocial alcoholics were found to have a higher 
frequency of one specific SNP (a G-to-C substitution at the nucleotide position 861) 
and more 86IC alleles than Finnish control (Lappalainen et al., 1998). 
1.5.3.5 Opioid receptor 
An A118G nucleotide exchange in exon 1 of the OPRMl gene causes an Asn40Asp 
substitution polymorphism in the receptor's extracellular domain. 39 healthy men 
were genotyped (A vs G) and then underwent opioid receptor blockade with Naloxone. 
Subjects carried the variant polymorphism had lower scores on the conscientiousness 
factor and associated subscales of NEO-PI-R compared to subjects expressing the 
common receptor (Wand et al., 2002). The main finding of this paper is that the 
Cortisol response after naloxone challenge is different in A118G people. 
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1.5.4 Interaction between genes 
It has been shown that gene polymorphisms in the serotonergic, dopaminergic and 
opioid systems have been shown to be associated with association with certain 
personality traits like novelty seeking, impulsivity and anxiety. However, the 
inconsistency observed may due to the interaction between genes. Benjamin et al. 
(2000) showed an association in modulation of novelty seeking by the significant 
interaction between DRD4 exon III and 5-HTTLPR, and between COMT val/met and 
5-HTTLPR (Benjamin et al , 2000). Similarly another study showed that three-way 
univariate analysis of variance with the three polymorphisms as independent variables 
and with novelty seeking as dependent variable. The presence of the long 5-HTTLPR 
allele, in the presence of the COMT homozygous G allele genotype and carriers of the 
DRD4 exon III 7-repeat showed higher novelty seeking scores (Strobel et al., 2003). 
1.6 Aim of study 
There is an increasingly popular use of "club drugs" like ketamine, ‘ecstasy’， 
‘marijuana’，‘ice’，and marijuana in rave parties and discos among Chinese 
adolescents in Hong Kong these past few years. The first objective of this study is to 
obtain demographic and qualitative data such as pattern, frequency and reason of drug 
use amongst the young "club drug" users in Hong Kong. The time of first drug use, 
their knowledge about drugs of abuse, as well as physical, behavioural symptoms and 
potential for developing tolerance and dependence were also ascertained. 
Since it was shown that an association exists between personality traits and substance 
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abuse, the second objective of this study is to ascertain whether there is a difference in 
personality traits between "club drug" users and those from the control population. 
Genetic factors have been shown to influence personality traits like impulsive 
behaviour by affecting the imbalanced release of neurotransmitters in brain, thus 
implicating its role in addictive behaviours like smoking, gambling and drinking. The 
third objective of this study is to determine whether certain gene mutations may be 
associated with "club drug" use. The fourth objective is to examine whether these 
mutations may subsequently interact with personality traits thus may predispose 
certain individuals to “club drug" use. 
Chinese "club drug" users satisfying the inclusion criteria of having tried ketamine, 
marijuana, 'ecstasy' or ‘ice’ at least once during their lifetime with no history of 
heroin use and no history of psychiatric illness, head trauma, unconsciousness and 
seizures were recruited for this study and the following parameters were examined: 1) 
A structure-interview using a questionnaire of 72 questions to establish demographic 
information, pattern, frequency, reasons and knowledge of drug use. Physical and 
behavioural symptoms as well as potential to develop tolerance and dependence were 
also ascertained. 2) With the use of the Chinese version of the SSS-V (Zuckerman, 
1994) and the BIS/BAS scale (Carver and White, 1994), personality traits of the 
subjects and controls were ascertained and differences in personality traits between 
these two groups were compared. 3) Gene variants of the dopaminergic, serotonergic, 
and opioid receptors or transporter systems were examined amongst the "club drug" 
users and controls. 4) To establish whether a correlation exists between gene variants 
and personality traits. It is hoped that the results from this study can provide further 
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qualitative data regarding "club drug" use in Hong Kong. Furthermore, it is hoped 
that an interaction can be observed between gene variants and personality traits 
associated with "club drug" use. 
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CHAPTER TWO MATERIALS AND METHODS 
2.1 Recruitment of Subjects 
2.1.1. Club drug users 
366 unrelated Chinese “club drugs" users (268 male, 98 female) were recruited for 
this study. The patients were derived from two sources: the Substance Abuse 
Assessment Clinic at the Kwai Chung hospital (n=83) and snowball recruitment from 
the six social services agencies, namely: Hong Kong Children and Youth Services, 
Chinese YMCA, the Hong Kong Federation of Young Groups, Hong Kong 
Playground Association, Caritas-HK, The Boys' and Girls' Clubs Association of Hong 
Kong (n-283). 
Inclusion criteria for the selection of subjects being"club drug" users have to have 
ever used ketamine, 'ecstasy' (MDMA), marijuana or 'ice' (METH) at least once 
during their lifetime. Exclusion criteria being no history of heroin use, psychiatric 
disorders, head trauma, unconsciousness or seizures. 
2.1.2. Controls 
303 unrelated Chinese youngsters (193 male and 110 female) who are free of major 
medical and psychiatric problems were recruited. All subjects were required to fill in a 
questionnaire to ascertain their history of addiction behaviour. Only subjects with no 
history of alcohol, tobacco, or illicit drug use were included in this study. 
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The present study protocol has been approved by the Human Ethics Committee of 
The Chinese University of Hong Kong. All participants signed an informed written 
consent and those who were under 18, parents' written consent were obtained. 
2.2 Phenotype assessment 
A community-base structured-interview was conducted amongst the "club drugs" 
users that were recruited. Participants were asked to complete a questionnaire and 2 
personality trait assessments (see 2.2.2). A remuneration of HKDSlOO was paid to 
each participants who completed the 2-hour interview. For those who are willing to 
participate in the genotyping part of the project, a further remuneration of HKD$100 
were given. 
2.2.1 Questionnaire (Appendix la — Chinese version used; lb - English 
translated version for reference only) 
A total of 72 questions were constructed in the questionnaire. The information 
obtained on the drug users include: demographics, pattern of drug use, experiences of 
first time drug use, current drug use, effects of drug use, potential 
dependence/withdrawal and knowledge about drugs of abuse. 
2.2.1.1 Demographics 
It includes personal and family information: gender, age, educational background, 
occupation, housing and parent's marital status and ethnicity of parents. 
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2.2.1.2 Pattern of drug use 
All data from this section was obtained for drug use in both Hong Kong and across 
the border from Hong Kong, it includes information like pattern of rave parties/ disco 
attendance; the types, quantity and frequency of drug use plus the amount spent on 
drugs. For cross-border use, the region/town that the users most frequent was 
ascertained. 
2.2.1.3 First time drug use 
Age, source and reason of first time drug use and frequency of continuous drug use 
were recorded. 
2.2.1.4 Reason of drug use 
To investigate the perceived function for the drugs used. This is classified into 5 
domains according to Boys A. et al. (2001). This included 'changing mood，，‘physical 
effects', 'social purposes', 'facilitate activity' and 'manage effects from other 
substances'. 
2.2.1.5 Effects of drug use 
Physical and behavioural effects of drug use were recorded. Questions are adapted 
from the Substance Abuse Assessment Questionnaires (SAAQ) by Ghodse H. ASAU/ 
CUHK, 10/15/97, ver 1.1. 
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2.2.1.6 Potential dependence/ withdrawal 
Questions were about the potential dependence/ withdrawal and physical symptoms of 
stopping, cutting down on, or quitting drug use. Questions are adapted from the 
Substance Abuse Assessment Questionnaires (SAAQ) by Ghodse H. ASAU/ CUHK, 
10/15/97, ver 1.1. 
2.2.1.7 Knowledge about drug of abuse and psychological well-being. 
Subjects were asked about the knowledge of drugs used and about the current 
psychological well-being of the subjects. 
2.2.2 Personality assessments (Appendix 2a - Chinese version of SSS-V scale; 
2b -Chinese version of BIS/BAS scale) 
During the interview, apart from answering the questions of the questionnaire, 
subjects were also requested to complete the Chinese version of the SSS-V 
(Zuckerman, 1994) and the BIS/BAS tests (Carver and White, 1994). BIS/BAS was 
translated into Chinese and verified for this study. A total of 360 club drugs users and 
303 controls of a similar age group and socio-economic background completed this 
section. 
2.3 DNA extraction 
At the time of interview, subjects who gave consent to the genotyping part of the 
study had 6 ml of blood drawn from the peripheral vein by a doctor or a registered 
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laboratory technician. Blood samples were collected into EDTA blood collecting tubes 
and stored at -70°C before DNA extraction. DNA was extracted from peripheral blood 
samples with the QIAamp DNA mini kit (QIAamp catalog no. 51106). First of all, 
20\i\ of 20mg/jLil proteinase K was transferred into the bottom of a 1.5ml 
microcentrifuge tube. 200|al whole blood was added to the proteinase K and mixed 
immediately by vortexing for 15 seconds (sec). 200|LI1 buffer AL was added to the 
mixture and vortexed for 15 sec. Afterwards, the mixture was incubated at 56°C for 
10 minutes (min) to lyse the cells and inactive proteinase K. 200|li1 absolute ethanol 
was added to the mixture and mixed by vortexing. All the mixture then was applied to 
the 2ml QIAamp spin column (collection tube) without wetting the rim and 
centrifuged at 6000 x g for 1 min. After centrifugation, the collection tube was place 
in a clean 2ml collection tube; the tube containing the filtrate was discarded. 500)^1 
buffer AWl was added to the column and centrifuged at 6000 x g for 1 min. The 
column was placed to a clean 2ml collection tube and the tube containing the filtrate 
was discarded. 500jil buffer AW2 was added to the column and centrifuged at 20000 x 
g for 3 min. The column was placed to a clean 2ml collection tube and the tube 
containing the filtrate was discarded. 200jul buffer AE was added to the column and 
incubated at room temperature for 1 min. DNA was eluted with 200|il by 
centrifugation at 6000 x g for 1 min. 
2.4 Genotyping 
The number of subjects and controls for each gene variant is different, this is largely 
due to the failure in some of the DNA extraction procedures. 
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2.4.1 G1947A, Val^ ^^ ^^ ^^  Met polymorphism in the catechol-O-methyltransferase 
(COMT) gene 
Genotyping for this variant was performed on 303 controls and 277 “club drugs" 
users. 50ng purified DNA was diluted into the PGR reaction mix consisting of PGR 
buffer (lOOmM Tris-HCl, pH 8.8 at 25�C; 500ml KCl; 0.8% Nonidet P40 and 15mM 
MgCl), 1.5 mM MgCl2, 0.25 mM of each dNTP (dATP, dCTP, dGTP, dTTP), 25 pmol 
of each forward and reverse primer and lU Taq polymerase (Invitrogen, Life 
Technologies, USA) in a total volume of 2 5 j L i L The Nla III polymorphism was 
detected by RFLP analysis using a forward primer: 5'- ACT GTG GCT ACT CAG 
CTG TG -3，, and a reverse primer: 5'- CCT TTT TCC AGG TCT GAC AA -3' to 
amplify a 130bp PGR fragment. PCR was carried out in a thermal cycler (Perkin 
Elmer, PCR 9600, USA). The amplification steps were: i) denaturation at 94°C for 5 
min, ii) 35 cycles of denaturation at 95°C for 45 sec, iii) annealing at 56°C for 45 sec, 
iv) synthesis at 72°C for 1 min and v) final elongation at 72°C for 10 min. lOjul of the 
130 bp PCR product was digested with 5U Nla III (MBI Fermentas, USA, NY) 
restriction enzyme for at least 8 hours (hrs) at 37°C. The restriction-digested products 
were resolved on a 4% agarose gel stained with ethidium bromide. The fragment 
length of the G allele was 114bp, while the fragment length of the PCR product 
remained as 96bp when the A allele was present. Heterozygotes GA were indicated by 
the presence of both the 96bp and 114bp bands (Fig. 23). 
2.4.2 T941G polymorphism in the monoamine oxidase A (MAO-A) gene 
Genotyping for this variant was performed on 303 controls and 277 club drugs users, 
genders are analyzed separately since MAO-A gene is X-linked. 50ng purified DNA 
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was diluted into the PGR reaction mix consisting of PGR buffer (lOOmM Tris-HCl, 
pH 8.8 at 25°C; 500ml KCl; 0.8% Nonidet P40 and 15mM MgCl), 1.5 mM MgCls, 
0.25 mM of each dNTP (dATP, dCTP, dGTP, dTTP), 25 pmol of each forward and 
reverse primer and lU Taq polymerase (Invitrogen, Life Technologies, USA) in a total 
volume of 25|LIL The SatI polymorphism was detected by RFLP analysis using a 
forward primer: 5'- GAC CTT GAC TGC CAA GAT -3', and a reverse primer: 5'-
CTT CTT CTT CCA GAA GGC C -3 ' to amplify a 130bp PGR fragment. PGR was 
carried out in a thermal cycler (Perkin Elmer, PCR 9600, USA). The amplification 
steps were: i) denaturation at 94°C for 5 min, ii) 35 cycles of denaturation at 95°C for 
45 sec, iii) annealing at 56°C for 45 sec, iv) synthesis at 72°C for 1 min and v) final 
elongation at 72°C for 10 min. 10|LI1 of the 130 bp PCR product was digested with 5U 
SatI (MBI Fermentas, USA, NY) restriction enzyme for at least 8 hours (hrs) at 37�C. 
The restriction-digested products were resolved on a 4% agarose gel stained with 
ethidium bromide. The fragment length of the T allele was 130bp, while the fragment 
length of the PCR product remained as 65bp when the G allele was present. 
Heterozygotes TG were indicated by the presence of both the 65bp, 130bp bands (Fig. 
24). 
2.4.3 TaqI A Polymorphism of the DRD2 Gene 
Genotyping for this variant was performed on 296 controls and 277 club drugs users. 
50ng purified DNA was diluted into the PCR reaction mix consisting of PCR buffer 
(lOOmM Tris-HCl, pH 8.8 at 25°C; 500ml KCl; 0.8% Nonidet P40 and 15mM MgCl), 
1.5 mM MgCl2, 0.25 mM of each dNTP (dATP, dCTP, dGTP, dTTP), 25 pmol of each 
forward and reverse primer and lU Taq polymerase (Invitrogen, Life Technologies, 
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USA) in a total volume of 25|LIL The TaqI A polymorphism was detected by RFLP 
analysis using a forward primer: 5，-GCT CTA TCT CCA ACT CTC ACA-3，，and a 
reverse primer: 5,-AAG TCT ACT CAC CTC CAG GTA-3, to amplify a 310bp PGR 
fragment. PGR was carried out in a thermal cycler (Perkin Elmer, PGR 9600, USA). 
The amplification steps were: i) denaturation at 94°C for 5 min, ii) 30 cycles of 
denaturation at 95°C for 30 sec, iii) annealing at 56°C for 30 sec, iv) synthesis at 72°C 
for 1 min and v) final elongation at I T C for 10 min. 10|LI1 of the 310 bp PCR product 
was digested with 5U TaqI (MBI Fermentas, USA, NY) restriction enzyme for at least 
8 hours (hrs) at 65°C. The restriction-digested products were resolved on a 2% 
agarose gel stained with ethidium bromide. The fragment lengths of the A2 allele 
were 180 and 130bp, when the Al allele was present, the fragment length of the PCR 
product remained as 310 bp. Heterozygous A1A2 allele was indicated by the presence 
of the 130 bp, 180bp and 310 bp (Fig 27). 
2.4.4 7-repeat allele of a 48 bp repeat polymorphism (DRD4-7) in exon 3 of the 
dopamine D4 receptor gene (DRD4) 
Genotyping this repeat was performed on 187 controls and 239 club drug users. 50ng 
purified DNA was diluted into the PCR reaction mix consisting of PCR buffer 
(lOOmM Tris-HCl, pH 8.8 at 25�C; 500ml KCl; 0.8% Nonidet P40 and 15mM MgCl), 
1.5 mM MgCl2, 0.25 mM of each dNTP (dATP, dCTP, dGTP, dTTP), 25 pmol of each 
forward and reverse primer and lU Taq polymerase (Invitrogen, Life Technologies, 
USA) in a total volume of 25jjl 7-repeat allele of a 48 bp repeat polymorphism 
(DRD4-7) in exon 3 of the DRD4 gene was detected by using a forward primer: 5'-
GCT GCT GCT CTA CTG GGC -3 and a reverse primer: 5'- GTG CAC CAC GAA 
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GAA GGG-3'. PGR was carried out in a thermal cycler (Perkin Elmer, PGR 9600， 
USA). The amplification steps were: i) denaturation at 94°C for 5 min, ii) 35 cycles of 
denaturation at 95�C for 45 sec, iii) annealing at 61�C for 45 sec, iv) synthesis at 72°C 
for 1 min and v) final elongation at 72°C for 10 min. The size of PGR products for 
2-repeat allele is 475bp, 3-repeat allele is 523bp, 4-repeat allele is 571bp, 5-repeat 
allele is 619bp, and 6-repeat allele is 667 (Fig 30) and these fragments were resolved 
on a 4% agarose gel stained with ethidium bromide. 
2.4.5 -521C/T single nucleotide polymorphism (SNP) I the promoter region of 
the dopamine D4 receptor gene (DRD4) 
Genotyping for this variant was performed on 231 controls and 277 club drugs users. 
50ng purified DNA was diluted into the PCR reaction mix consisting of PGR buffer 
(lOOmM Tris-HCl, pH 8.8 at 25�C; 500ml KCl; 0.8% Nonidet P40 and 15mM MgCl), 
1.5 mM MgCl2, 0.25 mM of each dNTP (dATP, dCTP, dGTP, dTTP), 25 pmol of each 
forward and reverse primer and lU Taq polymerase (Invitrogen, Life Technologies, 
USA) in a total volume of 25|LIL The Nsbl polymorphism was detected by RFLP 
analysis using a forward primer: 5'- TCA ACT GTG CAA CGG GTG-3,, and a 
reverse primer: 5，-GAG AAA CCG ACA AGG ATG GA-3' to amplify a 380bp PCR 
fragment. PCR was carried out in a thermal cycler (Perkin Elmer, PCR 9600, USA). 
The amplification steps were: i) denaturation at 94°C for 5 min, ii) 35 cycles of 
denaturation at 95°C for 45 sec, iii) annealing at 60°C for 45 sec, iv) synthesis at 72°C 
for 1 min and v) final elongation at 72°C for 10 min. lOj^ il of the 380 bp PCR product 
was digested with 5U Nsbl (MBI Fermentas, USA, NY) restriction enzyme for at 
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least 8 hours (hrs) at 37�C. The restriction-digested products were resolved on a 4% 
agarose gel stained with ethidium bromide. The fragment length of the C allele was 
380bp, while the fragment length of the PGR product remained as 228bp and 152bp 
when the T allele was present. Heterozygotes CT were indicated by the presence of all 
the 380bp, 228bp, and 152bp bands (Fig. 31). 
2.4.6 G861C polymorphism in the serotonin receptor IB (5-HTlB) gene 
Genotyping for this variant was performed on 297 controls and 271 club drugs users. 
50ng purified DNA was diluted into the PCR reaction mix consisting of PGR buffer 
(lOOmM Tris-HCl, pH 8.8 at 25�C; 500ml KCl; 0.8% Nonidet P40 and 15mM MgCl), 
1.5 mM MgCl2, 0.25 mM of each dNTP (dATP, dCTP, dGTP, dTTP), 25 pmol of each 
forward and reverse primer and lU Taq polymerase (Invitrogen, Life Technologies, 
USA) in a total volume of 2 5 j L i L The Hindi polymorphism was detected by RFLP 
analysis using a forward primer: 5'- GAA ACA GAC GCC CAA CAG GAC -3', and 
a reverse primer: 5'- CCA GAA ACC GCG AAA GAA GAT -3' to amplify a 548bp 
PCR fragment. PCR was carried out in a thermal cycler (Perkin Elmer, PCR 9600, 
USA). The amplification steps were: i) denaturation at 94°C for 5 min, ii) 35 cycles of 
denaturation at 95�C for 45 sec, iii) annealing at 56�C for 45 sec, iv) synthesis at 72�C 
for 1 min and v) final elongation at 72�C for 10 min. lOjal of the 548 bp PCR product 
was digested with 5U Hindi (MBI Fermentas, USA, NY) restriction enzyme for at 
least 8 hours (hrs) at 37�C. The restriction-digested products were resolved on a 2% 
agarose gel stained with ethidium bromide. The fragment length of the G allele PCR 
products was 96bp and 452bp, while the fragment lengths of the PCR products were 
96bp, 142bp and 310bp when the C allele was present. Heterozygotes GC were 
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indicated by the presence of the 96bp, 142bp, 310bp and 452bp bands (Fig. 26). 
2.4.7 The 44 bp insertion/deletion polymorphism in the promoter region of the 
serotonin transporter gene (SLC6A4) 
Genotyping this variant was performed on 300 controls and 271 club drug users. 50ng 
purified DNA was diluted into the PGR reaction mix consisting of PGR buffer 
(lOOmM Tris-HCl, pH 8.8 at 25�C; 500ml KCl; 0.8% Nonidet P40 and 15mM MgCl), 
1.5 mM MgCl2, 0.25 mM of each dNTP (dATP, dCTP, dGTP, dTTP), 25 pmol of each 
forward and reverse primer and lU Taq polymerase (Invitrogen, Life Technologies, 
USA) in a total volume of 25|LI1. The 44 bp insertion/deletion polymorphism in the 
promoter region of the SLC6A4 gene was detected by using a forward primer: 
5'-GAG GGA CTG AGC TGG ACA ACC AC-3and a reverse primer: 5'-GAG GGA 
CTG AGC TGG ACA ACC AC -3. PGR was carried out in a thermal cycler (Perkin 
Elmer, PGR 9600, USA). The amplification steps were: i) denaturation at 94°C for 5 
min, ii) 35 cycles of denaturation at 95�C for 45 sec, iii) annealing at 61�C for 45 sec, 
iv) synthesis at 72°C for 1 min and v) final elongation at I T C for 10 min. The size of 
PCR products for the long allele is 528bp and the short allele is 484bp (Fig. 29); and 
these fragments were resolved on a 4% agarose gel stained with ethidium bromide. 
2.4.8 T921C Polymorphism in Exon 3 of the Human DOR (hDOR) Gene 
Genotyping for this variant was performed on 277 controls and 303 club drugs users. 
20ng purified DNA was diluted into the PCR reaction mix consisting of PCR buffer 
(lOOmM Tris-HCl, pH 8.8 at 25�C; 500ml KCl; 0.8% Nonidet P40 and 15mM MgCl), 
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1.5 mM MgCl2, 0.2 mM of each dNTP (dATP, dCTP, dGTP, dTTP), 25 pmol of each 
forward and reverse primer and lU Taq polymerase (Invitrogen, Life Technologies, 
USA) in a total volume of 25|li1. The T921C polymorphism was detected by an 
artificial BstEII RFLP analysis. Using a forward primer: 5,-TTC GTC ATC GTC 
TGG ACG CT-3' and a modified reverse primer: 5,-GGT TGA GGC TGC TAT TGG 
GGT A-3' in which nucleotide 1158 (underlined) was changed from a C to a G, 
thereby an artificial BstEII restriction site was generated. These two primers were 
combined to amplify a 106bp PGR fragment. PGR was carried out in a thermal cycler 
(Perkin Elmer, Model no. PGR 9600, USA). The amplification steps were: i) 
denaturation at 94�C for 5 min, ii) 35 cycles of denaturation at 94�C for 45 sec, iii) 
annealing at 62°C for 45 sec, iv) synthesis at 72°C for 45 sec and v) final elongation at 
72°C for 7 min. 8|LI1 of the 106 bp PGR product was digested with 5U BstEII (MBI 
Fermentas, USA, NY) restriction enzyme overnight at 37�C. The restriction digest 
products were resolved on a 5% agarose gel stained with ethidium bromide. The 
fragment length of the T allele was 89 bp, while the fragment length of the PGR 
product remained as 106 bp when the C allele was present. Heterozygotes TC were 
indicated by the presence of both the 89 and 106 bp bands (Fig. 25). 
2.4.9 A118G polymorphism in Exon 1 of the Human MOR (hMOR) Gene 
Genotyping for this variant was performed on 298 controls and 267 club drugs users. 
20ng purified DNA was diluted into the PGR reaction mix consisting of PGR buffer 
(lOOmM Tris-HCl, pH 8.8 at 25°C; 500ml KCl; 0.8% Nonidet P40 and 15mM MgCl), 
1.5 mM MgCl2, 0.2 mM of each dNTP (dATP, dCTP, dGTP, dTTP), 25 pmol of each 
forward and reverse primer and lU Taq polymerase (Invitrogen, Life Technologies, 
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USA) in a total volume of 25|LXL The Al 18G polymorphism was detected by an 
artificial Bsp681 RFLP analysis. Using a forward primer: 5'- TCA ACT TGT CCC 
ACT TAG ATC G -3' and a modified reverse primer: 5'- ACG CAC ACG ATG GAG 
TAG AG -3’ in which nucleotide 353 (underlined) was changed from a G to a C, 
thereby an artificial Nml restriction site was generated. These two primers were 
combined to amplify a 151bp PGR fragment. PGR was carried out in a thermal cycler 
(Perkin Elmer, PGR 9600, USA). The amplification steps were: i) denaturation at 
94°C for 5 min, ii) 35 cycles of denaturation at 94°C for 45 sec, iii) annealing at 62°C 
for 30 sec, iv) synthesis at 72°C for 45 sec and v) final elongation at i T C for 7 min. 
8|LI1 of the 151 bp PGR product was digested with 5U Nml (MBI Fermentas, USA, 
NY) restriction enzyme overnight at 37°C. The restriction digest products were 
resolved on a 5% agarose gel stained with ethidium bromide. The fragment length of 
the A allele was 151bp, while the fragment length of the PGR product remained as 
22bp and 129bp when the G allele was present. Heterozygotes AG were indicated by 
the presence of the 22bp, 129bp and 151bp bands (Fig. 28). 
2.5 DNA sequencing 
DNA sequencing was employed to ensure the accuracy of the genotype obtained. The 
PCR Clean Up system (NucleoSpin® Extract kit, Macherey-nagel, Catalog no. 
740590.250, Germany) was used. The 25 fiX PCR product was pipetted to a 1.5ml 
tube and 100//I of buffer NT2 was added. After mixing well, the mixture was 
transferred to the NucleoSpin® Extract column into a 2 ml collecting tube and then 
centrifuged for 1 min at ll,000g. The flow-through was discarded and the column 
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was placed back into the 2ml collecting tube. 600 ！11 buffer NT3 was added into the 
column and then centrifUged for 1 min at ll,000g. The filtrate again was discarded 
and the column and then placed back into the 2ml collecting tube. Further 200 [i 1 
buffer NT3 was added and then centrifUged for 2 min at ll,000g to remove buffer 
NT3 quantitatively. Finally, the column as placed into a new 1.5ml tube and then 50 [i 
1 elution buffer NE was added to the center of the column. The tube was left to stand 
at room temperature for 1 min and DNA was eluted by centrifUgation for 1 min at 
ll,000g. 5 / / I of purified PCR product was mixed with 1 j i l 3.2 pmol///1 forward 
primer, 8 ！11 terminator ready reaction mix (ABI PRISM® BigDyeTM Terminators V 
3.1 Kit, Perkin Elmer Applied Biosystems, USA), and 6 {i\ deionized water were 
mixed into a 20/ / I mixture. The sequencing reaction was carried out at 96°C for 10 
sec, then 25 cycles for 96°C for 10 sec, 50°C for 5 sec, 60°C for 4 min and finally 4°C 
for 7 in. Prior to DNA sequencing, an AutoSeq™G-50 column (Amersham Pharmacia 
Biotech Inc, USA) was used to remove the excess dRhodamine Terminator from the 
completed DNA sequencing reaction. DNA sequencing was then performed in an 
automated ABI P R I S M � 3700 DNA Analyzer (Perkin Elmer Applied Biosystems, 
USA). 
2.6 Statistical Analysis 
Data will be analysed using SPSS (version 11) for Windows. Descriptive statistics like 
mean (SD) and percentages will be used to summarize the information like 
demographic, patterns and extent of drug use. 
For the personality trait tests, Chronbach's alpha coefficient was used to initially 
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determine the internal reliability of the personality trait subscales. The mean scores of 
SSS-V and BIS/BAS subscales between subjects and controls were compared using 
the Student's t-test. 
• 2 2-tailed Yates chi-square (x ) analysis was applied to compare the difference in allele 
and genotype frequencies between (1) the club drug users and the controls, (2) 
prevalence of club drug by gender. P< 0.05 was considered statistically significant. 
Multivariate analysis with Bonferroni correction was used to study the interaction of 
personality traits subscales scores and each genotype. Comparisons between all three 
genotype groups of each candidate gene variant with mean scores of SSS-V and 
BIS/BAS subscales were carried by one-way ANOVA. The mean scores of SSS-V and 
BIS/BAS subscales were compared between subsamples defined by the presence or 
absence of alleles of each candidate gene variant by using Student's t-test. 
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CHAPTER THREE RESULTS 
3.1 Results from questionnaire 
3.1.1 Demographics of club drug users 
3.1.1.1 Gender and age 
Of the 336 club drugs users who were interviewed, 73.2% were male and 26.8% were 
female (Fig. 1). The age range of the respondents is 13 to 29 with a mean age of 18.12 
土2.48 years. The subjects mainly fall in the age range of 15 to 20 years (Fig. 2). 
3.1.1.2 District of residence 
87.8% club drugs users lived in the New Territories, 11.4% lived in Kowloon, and 
0.8% lived on Hong Kong Island in this study. The 5 most commonly districts of 
residence being Shatin (23.4%), Tsuen Wan (18.5%), Tai Po (16.9%), Kwai Tsing 
(15.2%) and North District (8.6%) (Table 1). 
3.1.1.3 Type of living quarters and cohabitation 
Among 336 club drugs users, 73.2% lived in public housing and 16.9% in private 
housing, and the remaining in other types of housing such as rented private house and 
home ownership estates (Fig. 3). 68.8% lived with their parents whilst 23.3% lived 
with their single parent 23.2%; the remainder live with relatives, friends or they live 
alone (Fig. 4). 
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3.1.1.4 Educational attainment and employment status 
On the educational background of the club drugs users, 58.7% has lower secondary 
education and 37.2% had upper secondary education. Most of the subjects had Form 3 
level (34.7%) followed by Form 5 level (21.9%) of education (Fig. 5). Information on 
their employment status showed that 42.1% subjects were unemployed, 30.9% were 
still employed (either part-time or full-time), and 21% were students (Fig. 6). 
3.1.1.5 Parents' details 
The parent's marital status was usually normal (61.9%) among the club drug users 
with only 38.1% were separated, divorced, re-married or with either of the parent 
deceased (Fig. 7). Most of the respondent's father had full time jobs (59%) and only 
13.9% were unemployed while 39.5% of the respondent's mothers have flill time job 
(with 38.6% of them being housewives (Fig. 8). The educational background of the 
subject's parents was mainly primary school and secondary school level (Fig. 9). 
More mothers had primary school educational background than those in fathers' 
(42.7% vs 34.7%) while more fathers had secondary school educational background 
than those in mothers' (35.2% vs 30.4%) (Fig. 9). More than half of the subjects' 
fathers had addictive habits like smoking (54.9%), drinking (36.1%), gambling 
(33.6%) and taking drugs (2.7%) (Fig. 10) while less than 10% of these addictive 
behaviours were shown in the mothers (Fig. 11). 
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Fig. 1) Demographics - Cohabitation of 366 club drugs users. 
Table. 1) Demographics - District of residence of 366 club drug users. 
Fig. 1 Gender of club drugs users 
Sex (N=366) 
W B W m i Male i ^ W 
Table 1. District of residence 
(N 二366) o/o 
Hong Kong Island 0.8 
Central & Western 0 




Yau Tsim Mong 2.1 
Sham Shui Po 3.3 
Kowloon City 0.3 
Wong Tai Sin 3.8 
Kwun Tong 1.9 
New Territories & Island 87.8 
Kwai Tsing 15.2 
Tsuen Wan 18.5 
Tuen Mun 2.5 
Yuen Long 0.8 
North District 8.6 
Tai Po 16.9 
Sha Tin 23.4 
Sai Kung 1.4 
Islands 0.5 
Fig. 2) Demographics - Stem-and-Leaf Plot of age of 366 club drugs users. 
Fig. 3) Demographics - Type of living quarters of 366 club drug users. 
Fig. 2 Stem-and-Leaf Plot of age in club drugs users 
Frequency Stem & Leaf “ 
1.00 13 . 0 
9.00 14 . 0000 
29.00 15 . 00000000000000 
54.00 16 . 000000000000000000000000000 
79.00 1 7 . 000000000000000000000000000000000000000 
63.00 18 . 0000000000000000000000000000000 
44.00 19 . 0000000000000000000000 
34.00 20 . 00000000000000000 
14.00 21 . 0000000 
21.00 22 . 0000000000 
6.00 23 . 000 
12.00 Extremes (>=24.0) 
Stem width: 1 
Each leaf: 2 case(s) & denotes fractional leaves. 
Fig. 3 Type of living quarters 
housing 73 2 % 
b 
Rented private house • 4.40/0 — L 
Private housing 16 .9% 
• S Others 1 .1% CO p O K 
I 1 1 1 
0 2 0 4 0 6 0 8 0 
0/0 
Fig. 4) Demographics - Cohabitation of 366 club drugs users. 
Fig. 5) Demographics - Educational attainment of 366 club drugs users. 
Fig. 4 Cohabitation of club drugs users 
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Fig. 5 Educational attainment of club drugs users 
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Fig. 6) Demographics - Cohabitation of 366 club drugs users. 
Fig. 7) Demographics _ Parental marriage status of 366 club drugs users. 
Fig. 6 Occupation of club drugs users 
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Fig. 7 Parental marriage status 
No change i | i • 
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Fig. 8) Demographics - Parental working status of 366 club drugs users. 
Fig. 9) Demographics - Parental educational level of 366 club drugs users. 
Fig. 8 Parental working status “ 
70「 
[ • Father 
. 0 丨 5 9 I 
⑷ I • j _ Mother 丨 
1 瞧 - t i... I FC 
Full-time Part-time Unempolyed Retired House wife others Work status 
Fig. 9 Parental educational level 
45 I 42.7 "Father 
； J L J I 
Not educated Primary school Secondary school University Others 
Education level 
Fig. 10) Demographics - Father's habits including smoking, gambling, drinking and 
drug use. " 
Fig. 11) Demographics - Mother's habits including smoking, gambling, drinking and 
drug use. 
Fig. 10 Father's habits 
• • • • • • • • • 54.9% 
Smokmg ^ ^ ^ ^ 42.10/0 
1 3.0% 
• • • • • 36.1% 
Dnnkmg ^ ^ ^ ^ ^ 45 3o/o 
^ ^ ^ 18.6% 
^ • • • • l 33.6% 
Gambling ^ ^ ^ ^ ^ ^ 40 2 % Frequency 
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_ I ^ ^ ^ ^ ^ ^ ^ ^ 
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Fig. 11 Mother's habits 
m g 10.4% 
Smokmg ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ 86 6% 
匪 3o/o 
8.5% 
Dnnkmg ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ 0 3 
^ B 11.2% 
• m 10.7% 
Gambling ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ 70.4% Frequency 
f^e磁 18.9% 
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3.1.2 First time drug use 
The mean age of initial drug use is 14.8±2.2 years old (range: 10-20 years). 
Subsequent to their initial drug use, 34% of club drug users took drugs 1 to 3 times 
per month, 24% took drugs 1 to 6 times per week and 24.3% took drugs occasionally 
without a specific drug use pattern (Fig. 12). 
When they tried drugs for the first time, their main source of drugs came from friends 
(79.40/0) followed by friends in triad society (36%) and drugs dealers in discos or rave 
parties (28.6%) (Fig. 13). 
The reasons for the first time drug use are 'peer pressure' (62.6%), 'curiosity' (58%), 
‘to seek excitement and fUn，(55.2%) and 'to relieve boredom' (40.1%) (Fig. 14). 
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Fig. 12) First time drug use _ Frequency of drugs taking subsequent to initial drug use 
of 366 club drugs users. 
Fig. 13) First time drug use - Source of drugs during first time drug use of 366 club 
drugs users. 
Fig. 12 Frequency of drugs taking subsequent to initial drug use 
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Fig. 14) First time drug use - Reasons of first time drug use of 366 club drugs users. 
Fig 14. Reasons of first time drug use 
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3.1.3 Prevalence of drug use 
The types of drugs used were similar for the periods: past 30 days (current use), past 
12 months or lifetime use in the order from the most prevalent (excluding alcohol and 
cigarette). They are ketamine, marijuana, 'ecstasy' and 'ice' (Table 2). The 
commonest type of drugs that club drugs users have ever tired was ketamine (88.5%) 
followed by marijuana (83.6%), 'ecstasy' (79.8%), ice (30.1%), benzodiazepines 
(24.0%), cough mixture (21.6%) and solvents (10.1%). The prevalence of club drugs 
used within the past year is: ketamine (81.1%), followed by marijuana (78.4%), 
‘ecstasy, (69.9%), benzodiazepines (24.0%), cough mixture (21.6%), ‘ice，(18.6%), 
and solvents (10.1%). The prevalence of current drugs use is: ketamine (54.4%), 
followed by marijuana (44.4%), 'ecstasy' (39.1%), cough mixture (9.3%), 'ice' (8.2%), 
benzodiazepines (4.1%) and solvents (2.2%). 
Of all club drug users interviewed in this study, 85.2% and 83.6% have smoked or 
consumed alcohol in their lifetime respectively. In the past year, 83.1% and 80.9% of 
them have smoked or drank alcohol respectively and in the current drug users, 71.2% 
and 65.2% of them still smoked or drank alcohol respectively. 
When male and female club drug users were examined separately, it is evident that the 
prevalence of marijuana and 'ice' used was significantly different (Table 2). Males 
showed a significantly higher prevalence of lifetime (OR二 1.91, p-0.04) and last 12 
months (OR=1.97, p=0.017) use of marijuana. However, females showed a 
significantly higher prevalence of lifetime (OR=2.21, p=0.002) and last 12 months 
(OR-2.28, p=0.005) use of 'ice'. 
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3.1.4 Frequency and quantity of drug used 
It can seen that the mean no. of days (土 S.D.) of drugs used in the last 30 days for 
each club drug used was shown in Table 3 with cigarette (21.6士8.35) and alcohol 
(7.5±1.1) being the most frequently used followed by marijuana (3.9士3.7), ketamine 
(3.2±2.9), ‘ecstasy, (3.1 士2.8) and cough mixture (3.2士0.37). 
The average quantity of each club drug used at any one occasion was shown in Table 
3. 70 to 100% of the users had 2 units of ketamine, ‘ecstasy, or marijuana; 1 unit of 
‘ice,, cigarette or cough mixture; 8 units of alcohol or benzodiazepines; only 0.5 unit 
for solvents at any one occasion. 
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Table. 2) Prevalence of club drug use among 366 club drug users during the periods of 
lifetime, the last 12 months, and the last 30 days in Hong Kong. 
Table 2. Prevalence of drug use in Hong Kong 
Group Lifetime (%) Last 12 Months (%) Last 30 Days (%) Ketamine Total 88.5 81.1 54.4 
Male 87.7 80.2 53:0 
Female 90.8 83.7 58 2 
Ecstasy Total 79.8 69.9 39.1 
Male 77.6 67.2 35:8 
Female 85.7 77.6 48.0 
Marijuana Total 83.6 78.4 44.4 
Male 86.2* 81.7* 46.1 
Female 76.5 69.4 39 g 
Ice Total 30.1 18.6 8.2 
Male 25.4 14.9 7.1 
Female 42.9* 28.6* 11 2 
Alcohol Total 83.6 80.9 65:2 
Male 85.8 82.8 67.4 
广 Female 77.6 75.5 58.2 
Cigarette Total 85.2 83.1 71.2 
Male 87.3 84.7 73.0 
Female 79.6 78.6 66.3 
Benzodiazepines Total 24.0 14.2 4.1 
Male 24.3 13.1 4.9 
Female 23.5 17.3 2 0 
Cough Mixture Total 21.6 15.6 9:3 
Male 24.3 18.4 11.2 
Female 14.3 8.2 4.1 
Solvents Total 10.1 3.3 2:2 
Male 10.1 3.0 1.5 
Female ^ ^ 
* Significant difference by gender in a specific period of drug use. (Yate's x^ analysis) 
Table. 3) Frequency and quantity 
Results showed i) the no. of club drugs users who have ever tried a specific club drug; ii) 
the no. of days per months (last 30 days) in which a specific club drug was consumed 
(mean 士 S.D); iii) the quantity of drug use as 么nit (as specify with each drug used) and 
the percentage of users using this quantity shown in brackets. 
Table 3. Frequency and quantity of drugs used 
N Frequency, days on ^ 0. 01 users tor drugs in the last month Quantity Type of drug each drug (mean士SD) <Unit, (%) 
Ketamine 199 3.2士2.9 2/pack, (89.4) 
Ecstasy 143 3.1 士2.8 2/tablet, (95.5) 
Marijuana 163 3.9土3.7 2/joint, (86.2) 
“Ice，， 30 1.7士0.1 1/row, (78.5) 
Alcohol 239 7.5士 1.1 8/can, (79.2) 
Cigarette 304 21.6士8.35 1/pack, (85.5) 
Benzodiazepines 52 1.2土0.02 8/tablet, (71.8) 
Cough Mixture 57 3.2士0.37 1/bottle, (100) 
Solvents 12 2.5士0.54 0.5/bottle, (73.1) 
3.1.6 Pattern of poly drug use 
The most frequent types of drug used amongst the subjects were ketamine (55.6%), 
‘ecstasy, (21.5%), marijuana (14.6%) and ‘ice’ (3.6%) (Fig. 15). 285 (77.9%) club 
drug users with 201 males (75% of total male subjects) and 84 females (85.7% of total 
female subjects) being polydmg users in which 165 (45.1%) drug users took 3 types 
of drugs at any one occasion whereas 120 (32.8%) of them took 2 types of drugs at 
any one time. Ketamine, ‘ecstasy, and marijuana were the most popular drugs used 
together with 126 (44.2%) of them using these 3 drugs together at any one occasion. 
Second to this, ketamine and ‘ecstasy, were the most popular choice in the 2 types of 
drugs used together with 85 (29.8%) of them using these 2 drugs at any one occasion. 
Only 81 (22%) club drug users have never tried polydmg use at any one occasion of 
which 49 (13.4%) were ketamine users followed by 19 (5.2%) 'ecstasy' users (Table 
4). 
3.1.7 Drug spending 
90.3% club drug users spent HK$2000 (US$253) or less per month on drugs with 
71.30/0 of these drug users having an income of HK$4000 (US$506) or less. Financial 
source are from salary (32%), family (28.6%), and ‘free, (24.1%) for males (Fig. 16). 
However, for females, 41.8% of them obtain their drug for free (significantly different 
to males with OR=2.25, 1 . 3 4 � C I � 3 . 7 7 , p=0.001) usually at rave parties or discos. 
Their other financial sources come from family in the form of pocket money (30.6%) 
and salary (16.3%) (Fig. 16). 
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Fig. 15) Common types of drug used among 366 club drugs users. 
Table. 4) Pattern of poly drug use including the pattern of non-mixing drug use and the 
combination of 2 types or 3 types of drug uses. 
Fig. 15 Common types of drug used 
Commonest drug use 
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Table 4. Pattern of polydrug use 
Drugs N % 
Ketamine 49 13.4% 
'Ecstasy’ 19 5.2% 
1 Type of drug Marijuana 8 2.2% 
Cough Medicine 3 0.8% 
‘Ice’ 1 0.3% 
Solvents 1 0.3% 
2 Types of drug ^ f amine + ‘Ecstasy, 85 23.2% 
s Others 35 9.6% 
3 Types of drug Ketamine + ‘Ecstasy, + Marijuana 126 34.4% 
^ Others 39 10.6% 
Total ^ 100% 
Fig. 16) Financial sources in obtaining the drugs by gender. 
Fig. 16 Financial sources in obtaining the drugs 
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3.1.8 Pattern of drug use in and outside Hong Kong 
In Hong Kong, 311 (85%) club drugs users attended rave parties or discos in Hong 
Kong of which 239 (76.8%) have been to rave parties or disco within the last six 
months. 91.7% of those who had attended rave parties or discos have ever tried drugs 
(other than alcohol and cigarettes). 
212 (57.9%) have been to rave parties or discos outside of Hong Kong with 147 
(40.2%) went there within the last six months. Shenzhen (199, 54.4%) was the most 
popular place that club drug users usually have rave parties or discos outside of Hong 
Kong of which all the club drug users showed that they have ever tried drugs (other 
than alcohol and cigarettes) whilst attending rave parties and discos in Shenzhen (Fig. 
17). 
When the drug use pattern of the club drug users were examined, they were further 
classified into two major subgroups, i) those who are cross-border drug users and ii) 
those who are non cross-border users. (Since approximately 85% of the cross-border 
dub drug users go to Shenzhen, only those figures of drug use in Shenzhen are 
reported here). The pattern of drug use of the cross-border users was further classified 
into a) drug use in Hong Kong and b) drug use in Shenzhen. This is to ascertain 1) 
whether there is a difference in the pattern of drug use across the border to that in 
Hong Kong, and 2) whether there is a difference in drug use pattern between the 
cross-border drug users and the non cross-border drug users. The pattern of drug use 
was further classified into the period of lifetime use, drug use in the last 12 months 
and in the last 30 days (current use) of (Table 5). 
71 
Results from the present study showed that there are 154 (42.1%) non cross-border 
drug users and 199 (57.9%) cross-border drug users. When cross-border (Hong Kong) 
and non cross-border (Hong Kong) drug using pattern was compared, cross-border 
drug users in Hong Kong use a similar or higher amount of all types of drugs when 
compared to non cross-border drug users in Hong Kong (Table 5). This prevalence is 
significantly higher for lifetime marijuana (OR=2.18, p=0.001) and benzodiazepines 
use (OR=2.58, p=<0.001). For drug use in the last 12 months, a significantly higher 
prevalence of 'ecstasy' (OR-1.91, p=0.037) and benzodiazepines use (OR=2.28, 
p=0.018) was found between the cross-border drugs users and the non cross-border 
drug users in Hong Kong. 
When cross-border users who use drugs in Hong Kong and Shenzhen were compared, 
it can be observed that there is a slightly higher prevalence of lifetime use and the last 
12 months use for club drugs like ketamine and 'ecstasy' in Shenzhen than in Hong 
Kong. In general, cross-border club drug users had higher lifetime drug use in 
prevalence of all kind of drugs listed in Table 4 except for the drugs ketamine and 
‘ecstasy’ in Hong Kong than that in Shenzhen. This prevalence is significantly higher 
for lifetime marijuana (OR=L95, p=0.015), 'ice' (OR=4.39, pO.OOOl), 
benzodiazepines (OR-2.45, p-0.0002), cough mixture (OR=3.20, p<0.0001) and 
solvent use (OR=7.71, p=<0.0001). For drug use in the last 12 months, a significantly 
higher prevalence of marijuana (OR=2.12, p=0.0016) and 'ice' use (OR=2.21, 
p=0.009) was found between the cross-border drugs users in Hong Kong and the 
cross-border drug users in Shenzhen. However, for current cross-border drug users, 
the prevalence of ketamine (OR=1.88, p=0.002), marijuana (OR=2.43, pO.OOOl), 
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alcohol (OR=3.28, pO.OOOl) and cigarette (OR=3.05, pO.OOOl) use in Hong Kong 
were significantly higher than that of Shenzhen (Table. 5). 
216 (59%) and 135 (37%) club drugs users interviewed recount their having attended 
rave parties or discos five times or less per month during the last six months in Hong 
Kong and in Shenzhen respectively. Approximately 70% of the club drug users were 
accompanied by their friends to rave parties or discos in both Hong Kong and 
Shenzhen. Approximately 30% of them were accompanied by boy/girlfriends and 
around 20% by classmates for both places (Fig. 18). 
Figure 19 shows the reasons for attending rave parties or discos were mostly ‘to have 
uninhibited fun', ‘to relax', 'to seek new exciting experiences' and ‘to find new 
boy/girlfriend' for both Hong Kong and Shenzhen. However, a marked difference was 
shown for the reason 'to buy cheaper drugs' between individuals who go to Hong 
Kong and those who go to Shenzhen. It was shown that 41.2% of club drug users gave 
this reason for going to Shenzhen as oppose to 15% given by users going to rave 
parties or discos in Hong Kong (Fig. 19). 
The source in which the club drugs were obtained in Hong Kong or in Shenzhen were 
mainly from friends (83.6% for HK and 78.9% for Shenzhen) followed by triad 
societies (45.5% for HK and 35.2% for Shenzhen) and drugs dealers at discos or rave 
parties (49.2% for HK and 57.3% for Shenzhen) (Fig. 20) 
Apart from rave parties or discos, friend's house (54.1%), park (48.6%), ‘at home' 
(35.8%) and street comer (33.3%) were the venues in which club drugs were usually 
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taken in Hong Kong. In Shenzhen, parks (27.6%) followed by friend's house (24.1%) 
were the places where club drugs users usually take their drugs (Fig. 21). 
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Table 5. Prevalence of drug uses in cross-border and non cross-border drug 
users in Hong Kong and Shenzhen 
Prevalence of each club drug use in Hong Kong in the periods of lifetime 
drug use, drug use in the last 12 months and drug use in the last 30 days. 
Pattern of drug use between the cross-border and non cross-border drug users 
were compared. The cross-border drug users were further divided into i) 
pattern of drug use in Hong Kong and ii) pattern of drug use in Shenzhen. 
Significant difference was calculated using Yate's x^ analysis between 
cross-border drug users and non cross-border drug users in a specific period 
of drug use in Hong Kong as well as between the Hong Kong and Shenzhen 























































































































































































































































































































































































































































































































































































































Fig. 17) Places outside of Hong Kong in which club drugs were used among 366 club 
drugs users. 
Fig. 18) The kinds of people that accompany the club drug users to the raves parties or 
discos in Hong Kong/ in Shenzhen during the last 6 months. 
Fig. 17 Places outside of Hong Kong in which club drugs were used. 
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Fig. 18 The kinds of people that accompany the club drug users to the raves 
parties or discos in Hong Kong/ in Shenzhen during the last 6 months 
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Fig. 19) Reasons for attending rave parties or discos in Hong Kong/ in Shenzhen. 
Fig. 20) Source of drugs used in Hong Kong/ in Shenzhen. 
Fig. 19 Reasons for attending rave parties or discos 
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3.1.9 Cause of drug use 
Table 6 summarizes the most popular functions according to each club drug use with 
the top five percentages marked. Moreover, the age and gender of the club drug users 
in each club drug use were also reported. The functions were classified according to 
Boys A. et al. (2001) to reflect the effects of club drug use in the past year. 
Ketamine use (n = 201) 
The mean age of 'the most frequent use of ketamine' users were 17.9±2.5 (range in 
13-29) with 67.8% males and 32.2 % females. Overall the most popular functions for 
ketamine use were to “ENJOY COMPANY" (80.1%), “ELATED/EUPHORIC” 
(68.3%), "RELAX" (67.3%), "KEEP GOING" (60.9%) and “FEEL BETTER" 
(54.0%). Seven of the 18 function items were endorsed by over half of those who had 
used ketamine on more than one occasion in the past year. By looking at the results 
we can predict that ketamine use mainly interferes with the two domains, they were 
"changing mood" and "social purpose". 
'Ecstasy' use (n = 78) 
The mean age of ‘the most frequent use of 'ecstasy" users were 18.7±2.3 (range in 
14-24) with 73.1% males and 26.9% females. Overall the most popular functions for 
‘ecstasy, use were to "ENJOY COMPANY" (83.3%), "ELATED/ EUPHORIC" 
(75.6%), ‘‘KEEP GOING" (71.8%), ‘‘FEEL BETTER" (54.0%) and “STOP 
WORRYING" (43.6%). Seven of the 18 function items were endorsed by over half of 
those who had used ‘ecstasy，on more than one occasion in the past year. By looking 
at the results we can predict that 'ecstasy' use mainly interferes with the two domains, 
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they were "changing mood" and “social purpose". 
Marijuana use (n = 53) 
The mean age of 'the most frequent use of marijuana' users were 17.7±2.7 (range in 
14-27) with 86.8% males and 13.2 % females. Overall the most popular functions for 
marijuana use were to “ENJOY COMPANY" (71.7%), “ELATED/ EUPHORIC" 
(69.8%), ‘‘RELAX,，(60.4%), "KEEP GOING" (50.9%) and "SLEEP" (43.4%). Four 
of the 18 function items were endorsed by over half of those who had used marijuana 
on more than one occasion in the past year. By looking at the results we can predict 
that marijuana use mainly interferes with the three domains including "changing 
mood", "physical effects" and "social purpose". 
'Ice' use (n = 13) 
The mean age of ‘the most frequent use of 'ice" users were 19.0+2.1 (range in 17-23) 
with 69.2% males and 30.8 % females. Overall the most popular functions for 
marijuana use were to "STAY AWAKE" (84.6%), "WORK" (76.9%), "ENJOY 
COMPANY" (69.2%), "INCREASE CONFIDENCE" (61.5%) and "KEEP GOING" 
(61.5%). Six of the 18 function items were endorsed by over half of those who had 
used ‘ice, on more than one occasion in the past year. By looking at the results we can 
predict that 'ice' use mainly interferes with the two domains including "physical 
effects" and "social purpose". 
In general, “social purpose" domain was the common function of substance use found 
in all the above club drugs. Other domains like "changing mood" and "physical 
effects" have also shown to be related to club drug use. In general, the prevalence of 
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‘the most frequent drug use, by age in the order from the youngest to the oldest, they 
were marijuana, ketamine, ‘ecstasy, and 'ice'; the prevalence of 'the most frequent 
drug use' by gender were in the order from the most prevalence for males to be 
marijuana, 'ecstasy', ketamine, and ‘ice，. 
3.1.10 The negative effects of drug use 
The negative effects of physical and behavioural symptoms shown within 24 hours 
after taking drugs were investigated base on the specific club drug that the club drug 
users most frequently used. The results were categorized by the most popular drug 
used out of 4 most popular drugs reported to be used, namely, ketamine, ‘ecstasy’， 
marijuana and 'ice' (Table 7). 
202 ketamine users reported to have physical symptoms like 'decrease in appetite' 
(71.3%), 'poor physical coordination' (55.0%) and 'extreme hyperactivity, e.g. 
dancing' (51.5%) (Table 7). Behavioural symptoms reported include 'feeling 
depressed or uninterested in things more than 24 hours' (58.7%), 'hallucination' 
(54%), and 'amnesia' (51.5%) (Table 8). 
78 'ecstasy' users reported physical symptoms like ‘loss of appetite' (71.8%), 
'inability to sleep, (69.2%) and 'poor physical coordination' (66.2%) within 24 hours 
after taking ‘ecstasy，(Table 7). Behavioural symptoms reported include 
'hallucination' (61.5%), 'negatively affected their job or school performance' (59%) 
and ‘amnesia, (47.4%) (Table 8). 
53 marijuana users reported to have physical symptoms like 'decrease in appetite' 
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(56.60/0), ‘dizzy; headache' (49.1%), and ‘irregular heartbeat' (34%) (Table 7). Other 
behavioural symptoms like 'hallucination' (43.4%), 'amnesia' (39.6%) and 
'negatively affected their job or school performance' (59%) were also found (Table 8). 
13 'ice' users had the physical symptoms like ‘decrease in appetite', (76.9%), 
‘inability to sleep' and ‘sweaty palm; shaking hands' (Table 7). 84.6% frequent ‘ice, 
users had ‘ hallucinations', 76.9% had 'feeling suspicious or paranoid of people for 
more than 24 hours' and 'jumpy or nervousness for more than 24 hours' (Table 8). 
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Table. 6) Proportion (%) of those who have used [substance] more than once, who 
endorsed each functional statement for their use in the past year. 
Roman numerals have been used to indicate the functions with the top five average 
scores noted by 'i to v，with shown the highest score. It also shows means for the 
total number of different items endorsed by individual users and the internal reliability 







































































































































































































































































































































































































































































































































































































































Table. 7) Physical symptoms shown within 24 hours after taking club drugs including 
ketamine, 'ecstasy', marijuana, and 'ice'. 
Table. 8) Behavioral symptoms shown within 24 hours after taking club drugs 
including ketamine, 'ecstasy', marijuana, and 'ice'. 
Table. 7 Physical symptoms shown within 24 hours after taking drugs 
% of the club drug users 
Physical symptoms Ketamine (202) Ecstasy (78) Marijuana (53) Ice (13) 
Decrease in appetite 71.3 71.8 56.6 100.0 
Poor physical coordination 55.0 66.2 24.5 61.5 
Inability to sleep 43.1 69.2 35.8 76.9 
Sweaty palms; shaking hands 47.5 52.6 26.4 76.9 
Dizzy; headache 45.0 42.3 49.1 53.8 
Irregular heartbeat 38.1 38.5 37.0 69.2 
Nausea, vomiting 50.5 46.2 32.7 69.2 
Extreme hyperactivity, 
(e.g. dancing) ^ ^ 69.2 
Table. 8 Behavioral symptoms shown within 24 hours after taking drugs 
% of the 'club drug'users 
Behavioural symptoms Ketamine(202) Ecstasy (78) Marijuana (53) Ice (13) 
Amnesia 51.5 47.4 39.6 53.8 
Hallucination 54.0 61.5 43.4 84.6 
Feeling depressed or uninterested in 
things for more than 24 hours 58.7 34.6 18.9 61.5 
Feeling suspicious or paranoid of 
people for more than 24 hours 23,0 23.1 32.1 76.9 
Negatively affected your family 
relationships and friendships 22.8 21.8 25.0 69.2 
Negatively affected your job or 
school performance 45.5 59.0 34.0 69.2 
Jumpy or nervous for more than 24 
hours 22.9 24.4 17.0 76.9 
Twitch 0.5 1.3 5.7 0 
Become violent 23.3 19.2 20.8 46.2 
Suicide attempt ^ ^ 9A 23.1 
3.1.11. Potential tolerance/ dependence 
After having stopped, cut down or quit taking drugs, 38.7% of club drug users found 
an 'increase in appetite', 33.1% ‘feel tired or sleepy,, 30.6% developed 'yawning' 
symptoms, 28.4% 'have trouble sleeping' and 23.7% have 'watery eyes or runny nose' 
(Fig. 22). 
27.2% club drugs users spent a great deal of time in those activities necessary to 
obtain the drugs or use the drugs, e.g. in a period of a month or more. 72.8% subjects 
have ever wanted to or tried to cut down on drugs and 27.7% subjects found they 
could not stop or cut down using drugs. 78% claimed that they needed to increase the 
quantity of drugs by 50% or more and 48.5% needed markedly increased amounts of 
drugs to get an effect or found that they could no longer get high on the amount they 
used to use. 40.7% have used drugs for more days or in larger amounts than before. 
38% club drug users have given up or greatly reduced important activities with friends 
or relatives or at work in order to use drugs. 52.9% subjects have received objections 
from family, friends, boss or people at work or school because of drug use of which 
74.2% continue to use drugs after they realized it was causing a problem. 26.9% club 
drug users have been under the effects of drug in a situation where it increased their 
chances of getting hurt, for instance, when driving, using knives or machinery, 
crossing against traffic, climbing or swimming (Fig. 22). 
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Fig. 22) Problems caused after having stopped, cut down or quit taking drugs among 
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3.1.12 Knowledge about drugs of abuse 
Seven questions regarding knowledge of drug abuse were asked and the summary of 
the respondents listed in Table 8. Generally the knowledge of the club drug users was 
quite good. Four out of 7 questions about harmfulness from taking club drugs were 
answered correctly by over 70% of the club drugs users on questions like ‘can harm 
to your body,, ‘may be contaminated with other drugs', 'can cause permanent 
damage to your body' and ‘using of needles to inject club drugs can cause AIDS'. 
20.9% and 31.3% club drugs users did not believe that club drugs could cause mental 
problems and that they are addictive and may lead to dependence respectively (Table 
9). 
3.1.13 Psychological well-being 
91.2% club drugs users felt stressful in their daily life of which 17% felt extremely 
pressurized. Only 8.8% of them felt no pressure at all. 52.1 % subjects were satisfied 
with their life while 29.5% were not happy about their life. 13.7% were even not sure 
whether they were happy about their present life style or not. 
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Table. 9) Knowledge about drugs of abuse among 366 club drugs uses. 
Table 9 Knowledge about drugs of abuse ^ ~~ % 
Questions of knowledge about drugs of abuse Yes No I don, � know Do you think that the 'club drugs' can cause harm to your body? 
83.8 6.0 10.2 
Do you think that the 'club drugs' can cause mental problems? . ^ 1 1 � 
67.3 20.9 11.8 
Do you think that the 'club drugs' are addictive and may lead to dependence? ^ 313 10 4 
Do you think some of the drugs that you take may be contaminated with other drugs? 们^ ^ ^ ^^ ^ 
Do you think that the 'club drugs' can cause permanent damage to your body? 1 n q ig q 
Do you think that the taking of the 'club drugs' can result in death? 64 8 17 3 17 9 
Do you think the using of needles to inject 'club drugs' can cause AIDS? ，。o c � 1: /o.o j.z 1 J.9 
3.2 Personality trait assessments 
3.2.1 Personality traits between club drugs users and controls 
When 360 club drug users were compared to 303 controls in the personality traits 
studied, in general club drugs users had higher scores for the SSS-V scale. For the 
BIS/BAS scales, club drug users also score higher for ‘BAS Reward responsiveness', 
'BAS fun seeking' and 'BAS drive'. However, a lower score for the 'BIS' in BIS/BAS 
scale in the club drug users were also observed when compared to controls (Table 10). 
Except for ‘BAS Reward responsiveness' in BIS/BAS scale, a significant difference 
was shown in the score of ‘boredom susceptibility, (pO.OOOl, | 0.68< CI<L23 |), 
'disinhibition' (pO.OOOl, 13.39< CI < 4.041), 'experience seeking' (pO.OOOl, 
1.69< CI < 2.25 I), 'thrill and adventure seeking' (p=0.008, |0.15< CI < 0.99 |) of 
the SSS-V scale; ‘BIS, (p<0.0001, |-l .56< CI < -0.581), ‘BAS fun seeking' 
(pO.OOOl, |0.98< CI < 1.59 I ) , and ‘BAS drive' (pcO.OOOl, | 0.52< CI < U 6 |) in 
BIS/BAS scale between club drugs users and controls (Table 10). 
3.2.2 Personality trait by gender 
By comparing 263 male club drug users to 193 male controls in personality traits, 
male club drug users had significantly higher scores for 'boredom susceptibility' 
(pO.OOOl, 10.62< CI<0.1.33|) 'disinhibition' (pO.OOOl, |3.20< CI < 4.061), 
'experience seeking' (p<0.0001, | 1.55< CI < 2.29 |), 'thrill and adventure seeking' 
(p二0.005, I 0.27< CI < 1.30 |) in the SSS-V scale; 'BAS drive' (pO.OOOl, | 0.44< CI 
< 1.24 I), 'BAS fun seeking' (pO.OOOl, | 0.83< CI < 1.61 |) but lower scores for 
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‘BIS, (pO.OOOl, I -1.41< CI < -0.11 I) in the BIS/BAS scales (Table 11). Although 
drug users also scored higher in the 'BAS Reward responsiveness' in BIS/BAS scale, 
there is no significant difference between cases and controls. 
When 97 female club drug users were compared to 110 female controls in personality 
traits, female club drug users had significantly higher scores for ‘boredom 
susceptibility' (p=0.001, | 0.38< CI<1.42|) 'disinhibition' (p<0.0001,丨 3.12< CI < 
4.24 I ) , 'experience seeking' (pO.OOOl, | 1.52< CI < 2.51 |) in the SSS-V scale; 
‘BAS drive, (p-0.005, | 0.29< CI < 1.56 |), 'BAS fun seeking' (pO.OOOl, | 0.88< CI 
< 2.05 I) but lower scores for ‘BIS’（p<0.0001, | -2.01< CI < -0.25 |) in the BIS/BAS 
scales (Table 12). Females also scored higher in 'thrill and adventure seeking' in the 
SSS-V scales and 'BAS Reward responsiveness' in the BIS/BAS scale, there is 
however no significant difference between cases and controls. 
Significantly higher scores in ‘boredom susceptibility' (p=0.018, | 0.09< CI < 1.06 |), 
'disinhibition' (pO.OOOl, |3.12< CI < 4.241), 'thrill and adventure seeking' 
(pO.OOOl, |-3.12< CI < -4.24 I ) in the SSS-V scales and a lower score in ‘BIS, 
(p<0.025, I 3.12< CI < 4.24 |) in the BIS/BAS scales were found when 263 male club 
drug users were compared to 97 female club drug users. While significantly higher 
scores in 'boredom susceptibility' (p=0.014, 10.09< CI < 1.06 |), 'disinhibition' 
(p<0.0001, |0.60< CI < 1.62 I ) in the SSS-V scales and a lower score in ‘BIS, 
(p<0.0001, I -2.06< CI < -0.62 |) in the BIS/BAS scales were found when 193 male 
controls were compared to 110 female controls (Table 13). 
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3.2.3 Reliability 
The coefficient Cronbach's alpha (a) of each subscale was calculated to assess 
the reliability of each subscale. This is particularly pertinent for the BIS/BAS 
subscales since this it is the first Chinese translation of such this test. The 
Cronbach's a were shown to be: 0.43 for ‘boredom susceptibility，，0.77 for 
‘disinhibition’，0.48 for 'experience seeking' 0.77 for ‘thrill and adventure 
seeking' in the SSS-V scales. For the BIS/BAS scales Cronbach's a were shown 
to be: 0.71 for ‘BIS,, 0.62 for ‘BAS Reward responsiveness', 0.58 for ‘BAS flin 
seeking' and 0.66 for 'BAS drive'. (Table 10). 
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Table 10. ‘ 
Independent-samples t-test comparing the scores between 303 controls and 360 club 
drugs users in the subscales of SSS-V and BIS/BAS personality scales. Cronbach's 
a of the reliability of each subscale was shown. 
Table 11. 
Independent-samples t-test comparing the scores between 193 male control and 263 
male club drug users in the subscales of SSS-V and BIS/BAS personality scales. 
Table 10 “ 
(Mean score 土 SD) 
‘ Club drug r 
Controls users 
(II 二 303) (n=360) T g 
Boredom susceptibility 2.5 ±1.7 3.5 ±1.9 6.8** 0.43 
Disinhibition 2.8 土 2.2 6.5 ± 2.0 22.4** 0.77 
Experience seeking 3.4 土 1.9 5.3 土 1.8 13.9** 0.48 
Thrill and adventure “ … ， ， seeking 5.) 土 2.9 6.1 ±2.7 2.6* 0.77 
BIS 20.2 ±3.1 19.1 士 3.3 -4.3** 0.71 
BAS reward responsiveness 16.5 土 2.0 16.5 ±2.2 -0.071 0.62 
BAS fun seeking 11.4 ±2.2 12.7 土 2.0 8.4** 0.58 
BAS drive 11.9 ±2.2 12.8 ±2.2 5.2** 0.66 
*p<0.05,**p<0.0001 
Table 11 
(Mean score 土 SD) 
Male club 
Male controls drug users 
(n 二 193) (n 二263) T 
Boredom susceptibility 2.7 ±1.7 3.6 ±1.8 5.5** 
Disinhibition 3.2 土 2.4 6.8 ±1.9 17.4** 
Experience seeking 3.5 ±2.0 5.4 士 1.8 11.P* 
Thrill and adventure seeking 5.7 ±2.8 6.5 ± 2.5 3.4** 
BIS 19.7 ±3.0 18.9 ±3.4 -2.6** 
BAS reward 
responsiveness 16.5 ±2.2 0.3 
BAS fun seeking 11.5 士 2.0 12.7 ±2.0 6.7** 
BAS drive 12.1 ±2.0 12.9 ±2.1 4.2** *p<0.05, **p<0.0001 
Table 12. — 
Independent-samples t-test comparing the scores between 110 female controls and 97 
female club drug users in the subscales ofSSS-V and BIS/BAS personality scales. 
Table 13. 
Independent-samples t-test comparing the scores between males and females within 
groups (control and club drug users, respectively) in the subscales of SSS-V and 
BIS/BAS personality scales. 
Table 12 -
(Mean score 土 SD) 
Female Female club 
controls drug users 
(n-llQ) (n=97) T 
Boredom susceptibility 2.2 ±1.7 3,0 ±2.0 3.3* 
Disinhibition 2.1 ± 1.8 5.8 ±2.2 13.3** 
Experience seeking 3.2 土 1.8 5.1 土 1.8 8.0** 
Thrill and adventure 
seeking 5.2 ±3.1 4.9 土 2.8 -0.8 
BIS 21.0 ±3.3 19.7 ±3.0 -3.0* 
BAS reward 
responsiveness 16.7 ±2.0 16.6 ±2.3 -0.4 
BAS flin seeking 11.2 ±2.1 12.6 ±2.0 4.8** 
BAS drive 11.7 ±2.0 12.4 土 2.4 2.5* 
*p<0.05，**p<0.0001 
Table 13 
Control Club drugs 
(Mean score 土 SD)^ (Mean score ± SD)~ 
Male Female M a l e F e m a l e 
(n=193) (n-llQ) (n 二263) (n-97) 丁 
Boredom susceptibility 2.7±1.7 2.2±1.7 2.5' 3.6±1.8 3.0±2.0 2.7* 
Disinhibition 3.2±2.4 2.1 土 1.8 4.6- 6.8±1.9 5.8±2.2 3.9** 
Experience seeking 3.5±2.0 3.2士1.8 1.3 5.4±1.8 5.1±1.8 1.3 
Thrill and adventure seeking 5.7±2.8 5.2±3.1 1.3 6.5±2.5 4.9±2.8 5.3** 
飢 S 19.7±2.9 21.0±3.3 -3.6 甜 18.9±3.4 19.7±3.0 -2.1* BAS reward 
responsiveness 16.4±2.1 16.7±2.0 -1.3 16.5±2.2 16.6±2.3 -0.5 
BAS fun seeking 11.5±1.9 11.2±2.1 1.2 12.7±2,0 12.6±2.0 0.6 
BAS drive | 12.1±2.0 11.7±2.Q 1.7 12.9±2.1 12.4±2.4 1.6 
p<0.05, p<0.0001 一 significant difference between male and female controls 
* P<0.05, **p<0.0001 - significant difference between male and female club drua users 
3.3 Genotyping 
3.3.1 G1947A,Vall08/158 Met polymorphism in the catechol-O-methyl-
transferase (COMT) gene 
The 130bp PCR product showed that the homozygous GG for high activity COMT 
was represented as a single 114 bp band, while homozygous AA for low activity 
COMT was represented by the presence of a 96 bp band. Both the 96 bp and 114 bp 
bands were found in the heterozygotes AG (Fig.23). 
Table 14a shows the genotype distributions and allele frequencies of G and A of the 
G1947A, Vali�8zi58 Met polymorphism of the COMT gene in club drugs users and 
controls. It reveals that 154 controls (51%) carried the GG homozygous genotype, 15 
controls (5%) carried the AA homozygous genotype and 134 (44%) were carriers of 
the GA heterozygote genotype. In the club drugs users, it was found that there were 
177(64%) and 15(5%) with GG and AA homozygous genotype respectively. 85 
subjects (31%) were GA heterozygous. Yates analysis showed that xV) =11.419; 
p=0.003. The G allele was the most common allele in both controls (73%) and club 
drugs users (79%). The prevalence of the G allele in the club drugs users was 
significantly higher = 6.298; p=0.013.) than that of the control group, while a 
higher prevalence of the A allele was found in controls (27%) than in the club drugs 
users (21%). It can be noted that the higher frequency of G allele in the control group 
contributed to the major genotype homozygous GG (n二 154, 51%) and heterozygous 
GA (n=134, 44%). In the club drug users, the number of homozygous GG individuals 
was two fold that of GA heterozygotes (177 vs 85). The relatively high percentage of 
homozygous GG subjects in the club drug users when compared to the controls 
84 
contributed to the high G allele frequency (64% in club drug users vs 51% in controls). 
The percentage of heterozygous GA individuals in the club drug users was lower than 
that of controls (31% in club drug users vs 44% in controls). 
Table 14b represents the SSS-V and BIS/BAS scores for club drug users with the 
three different genotypes (AA, AG, GG). Significant association between COMT 
genotype and ‘BAS drive' in the BIS/BAS scale (p=0.03) was shown with the 
interaction between genotype AG and GG (p-0.027; |0 .06�CI�1.43 | ) when all three 
groups were compared (one-way ANOVA), subjects homozygous for the G allele 
displayed lower BAS drive scores. By comparing the grouping AG+AA vs GG, 
individuals with two copies of the G allele scored significantly lower than individuals 
with at least one of the A allele on the subscale ‘boredom susceptibility' (p=0.02, 
|0.069�CI�0.995|) in the SSS-V scale and BAS drive (p=0.01, |0.196�CI�1.251 | ) . 
When the genotypes were grouped together in AG + GG vs AA, to compare between 
subjects with a G allele versus those without a G allele, no significant associations 
between the COMT polymorphism and SSS-V as well as BIS/BAS scales were found. 
Table 14c represents the SSS-V and BIS/BAS scores for the control group with the 
three different genotypes (AA, AG, GG). No significant association between COMT 
genotype and the two personality trait scales when all three groups were compared 
(one-way ANOVA). When the genotypes were grouped together in AG + AA vs GG, 
to compare between subjects with an A allele versus those without an A allele. 
Individuals with at least one of the A allele scored significantly lower than individuals 
with two copies of the G allele on the subscale ‘BAS fun seeking' (p=0.02, 
-1.0�CI�-0.01|) . By comparing the grouping AG+GG vs AA, none of the significant 
85 
association was found. 
86 
Fig 23. The 130bp PCR product was subjected to Nla III digestion and the resulting 
fragments were resolved on a 4% agarose gel that was stained with ethidium bromide. 
A DNA marker (GeneRuler™ 50bp DNA Ladder) was loaded on the left. Homozygous 
GG is shown as a 114bp band, homozygous AA is shown as a 96 bp band, heterozygous 
is shown as 114bp and 96bp bands. 
Table 14a. Genotype distribution and allele frequencies of the G1947A, COMT 
Val續 158 Met polymorphism in club drugs users and controls. The absolute number of 
cases and the percentage of total (in brackets) are shown. Yates x ^ analysis showed 
that ；^ 2 二 11.419; df =2;p 二0.03 in the distribution of genotype frequency and = 
6.298; d f= 1; p=0.013 in the allelic frequencies between club drugs users and controls. 
Fig. 23 
DNA marker 
114 bp ^ ^ 96 bp 
Table 14a. 
Genotype distributions and allele frequencies of COMT 
Genotypes, n (fiequencies) Allele frequencies 
A/A A/G G/G (p)i A G (p) 
Club drugs users (277) 15(0.05) 85(0.31) 177(0.64) 115(0.21) 439(0.79) 
Normal control (303) 15(0.05) 134(0.44) 154(0.51) 0.003 164(0.27) 442(0.73) 0.013 
I , 
P-value of Yates x 二 analysis 
Table 14b “ 
Scores of subscales of SSS-V and BIS/BAS Scales in club drug users with respect to 
COMT genotypes amongst 277 club drug users. The SSS-V and BIS/BAS scores for 
club drug users with the three different genotypes (AA, AG, GG) were shown. 
Comparisons between all three genotype groups with mean scores of SSS-V and 
BIS/BAS subscales were carried by one-way ANOVA. The mean scores of SSS-V and 
BIS/BAS subscales were compared between subsamples defined by the presence or 





































































































































































































































































































































































































































































































































































Table 14c “ 
Scores of subscales of SSS-V and BIS/BAS Scales in club drug users with respect to 
COMT genotypes amongst 303 controls. The SSS-V and BIS/BAS scores for club drug 
users with the three different genotypes (AA, AG, GG) were shown. Comparisons 
between all three genotype groups with mean scores of SSS-V and BIS/BAS subscales 
were carried by one-way ANOVA. The mean scores of SSS-V and BIS/BAS subscales 
were compared between subsamples defined by the presence or absence of alleles 






















































































































































































































































































































































































































































































3.3.2 T941G polymorphism in the monoamine oxidase A (MAO-A) 
The 130bp PCR product showed that the homozygous TT was represented by the 
presence of a 130 bp single band, whereas genotype GG was represented by the 
presence of a 65 bp single band. Both the 65 bp and 130 bp bands were found in the 
heterozygote TG sample (Fig. 24) 
Table 15a shows the genotype distributions and allele frequencies of G and T of 
T941G polymorphism in the MAO-A gene in male club drugs users. It reveals that 
103 controls (54%) carried the GG homozygous genotype and 89 (46%) carried the 
TT homozygous genotype. Similarly, it was found that there were 103 (56%) and 81 
(44%) club drugs users with GG and TT homozygous genotype respectively. Yates 
analysis showed that x ]�=1.049 ; p=0.679 (NS). Allelic frequency distribution shows 
that the G allele was the most common allele in both controls (54%) and subjects 
(55%). However, there was no significant different in allele frequencies between the 
control and subject groups (p=0.56) in the male club drug users. 
Table 15b shows the genotype distributions and allele frequencies of G and T of 
T941G polymorphism in the MAO-A gene in female club drugs users. It reveals that 
46 controls (42%) carried the GG homozygous genotype and 47 (43%) carried the TG 
heterozygous genotype and 17 (15%) were carriers of the TT genotype. Similarly, it 
was found that there were 37 (43%) club drugs users with TG heterozygous genotype. 
However, the GG and TT homozygous genotype was 25 (29%) and 24 (28%) 
respectively. Yates analysis showed a marginal insignificant difference between 
controls and subjects =5.74; p=0.057). When the allelic frequencies were 
87 
examined, the T allele was observed in larger proportion of club drugs users than in 
controls (49% vs 37%). x^test yielded a significant difference (xV) =6.278; p=0.012) 
between the two groups. The higher proportion of T was shown to be due to an 
increase in the number of TT homozygotes (28% in club drugs users vs 15% in 
controls). Moreover, the increase in TT homozygotes was accompanied by a decrease 
in GG homozygotes with no difference in the proportion of heterozygotes between the 
subjects and the controls (43%). 
Table 15c shows the scores of the SSS-V and BIS/BAS subscales for the female club 
drug users when analyzed with the three genotypes (GG, TG, TT). Significant 
association between MAO-A genotype and BIS score in BIS/BAS scale (p=0.03) with 
an interaction between genotype GT and TT (p=0.041, |0 .06�CI�3.56 | ) was found 
when compared to all three groups (one-way ANOVA), with subjects homozygous for 
the T allele displaying lower BIS scores. Individuals with two copies of the T allele 
scored significantly lower than individuals with at least one of the G allele (to 
compare those with TG+GG and those without a G allele) on BIS (p=0.008, 
0.479�CI�3.078|). When the genotypes were grouped together in TG+TT vs GG to 
compare those with a T allele and those without a T allele, subjects homozygous for 
the G allele scored significantly higher than individuals with at least one of the T 
allele on BAS reward responsiveness (p=0.024, |-2.20�CI�-0.162|). 
Table 15d shows the scores of the SSS-V and BIS/BAS subscales for the female 
control group when analysed with the three genotypes (GG, TG, TT). No significant 
association between MAO-A genotype and the personality trait subscales when 
compared to all three groups (one-way ANOVA). No significant difference on 
88 
personality traits was found when the genotypes were grouped together in TG+TT vs 
GG to compare with those with a T allele and those without a T allele or when the 
genotype was grouped in TG+GG vs TT to compare those with a G allele and those 
without a G allele. 
89 
Fig 24 The 130bp PCR product was subjected to Sat I digestion and the resulting 
fragments were resolved on a 4% agarose gel that was stained with ethidium bromide. 
A DNA marker ( G e n e R u l e r ™ 50bp DNA Ladder) was loaded on the left. Homozygous 
TT is shown as a 130bp band, homozygous GG is shown as a 65 bp band, heterozygous 
TG is shown as both 65bp and 130bp bands. 
Table 15a. Genotype distributions and allele frequencies of the MAO-A T941G 
polymorphism in male club drugs users and controls. The absolute number of cases and 
the percentage of total (in brackets) are shown. Yates x ^ analysis showed that x ^ 
=1.049; df=l;p二0.679 in the distribution of genotype frequency and 义 2 = 0.413; df = 1; 
p=0.56 in the allelic frequencies between club drugs users and controls. 
Table 15b. Genotype distributions and allele frequencies of the MAO-A T941G 
polymorphism in female club drugs users and controls. The absolute number of cases 
and the percentage of total (in brackets) are shown. Yates 义 ^ analysis showed that x ^ 
=5.74; df=2; p=0.057 in the distribution of genotype frequency and x ^ = 6.278; df = 1; 




Table ISa.Genotype distributions and allele frequencies of MAO-A (Male) 
Genotypes, n (fiequencies) Allele frequencies 
G/G T/G T/T (jyf G T (p)— 
Polydmg users (184) 103(0.56) 0(0) 81(0.44) 206(0.56) 162(0.44) 
Normal control (192) 103(0.54) 0(0) 89(0.46�0.679 206(0.54) 178(0.46) 0.564 
^P-value of Yates x ^ analysis. 
Table 15b Genotype distributions and allele frequencies of MAO-A (Female) 
Genotypes, n (frequencies) Allele frequencies 
G/G T/G T/T (p)i G T (p) Polydrag users (86) 25(0.29) 37(0.43) 24(0.28) 87(0.51) 85(0.49) 
Normal control (110) 46(0.42) 47(0.43) 17(0.15) 0-057 ！聊助 81(037) 0.012 
1 2 ‘ 
F-value of Yates X analysis. 
Table 15c ‘ 
Scores of subscales of SSS-V and BIS/BAS Scales in club drug users with respect to 
MAO-A genotypes amongst 86 female club drug users. The SSS-V and BIS/BAS 
scores for club drug users with the three different genotypes (GG, TG, TT) were shown. 
Comparisons between all three genotype groups with mean scores of SSS-V and 
BIS/BAS subscales were carried by one-way ANOVA. The mean scores of SSS-V and 
BIS/BAS subscales were compared between subsamples defined by the presence or 








































































































































































































































































































































































































































































































































Table 15d — 
Scores of subscales of SSS-V and BIS/BAS Scales in club drug users with respect to 
MAO-A genotypes amongst 110 female controls. The SSS-V and BIS/BAS scores for 
club drug users with the three different genotypes (GG, TG, TT) were shown. 
Comparisons between all three genotype groups with mean scores of SSS-V and 
BIS/BAS subscales were carried by one-way ANOVA. The mean scores of SSS-V and 
BIS/BAS subscales were compared between subsamples defined by the presence or 






































































































































































































































































































































































































































































































































3.3.3 T921C Polymorphism in Exon 3 of the Human DOR (hDOR) Gene 
The PCR product of 106bp showed that the TT genotype was represented by the 
presence of a 89 bp single band, while genotype CC was represented by the presence 
of a 106 bp single band. Both the 89 bp and 106 bp bands were found in the 
heterozygote TC sample (Fig. 25). 
Table 16a shows the genotype distributions and allele frequencies of the hDOR 
T921C polymorphism in club drugs users and controls. It reveals that 193 controls 
(640/0) carried the TT homozygous genotype, 19 (6%) carried the CC homozygous 
genotype and 91(30%) were carries of the TC heterozygote genotype. In club drugs 
users, it was found that there were 150 (54%) and 19 subjects (6%) with TT and CC 
homozygous genotype respectively whilst 96 (35%) were TC heterozygotes. Yates { 
analysis showed that 义：⑵=7.253; p=0.027. Allelic frequency distribution shows that 
the T allele was the most common allele in both controls (79%) and club drug users 
(710/0). The prevalence of the T allele in the control group was significantly higher 
(X (i)=8.131;p=0.004) than that of the club drug users. It can be noted that the higher 
frequency of the T allele in the control group contributed to the major genotype, 
homozygous TT (64%) and heterozygous TC (30%) with the number of homozygote 
TT individuals being two-fold that of TC heterozygous (64% vs 30%). In club drug 
users, there is a relatively higher percentage of heterozygous TC and homozygous CC 
that contributed to the higher C allele frequency found (35% in club drug users vs 
30% 
in controls) and (11% in club drug users vs 6% in controls) respectively. 
Table 16b represents the scores of the SSS-V and BIS/BAS subscales for the club 
90 
drug users with the three genotypes (TT, TC, CC). No significant association between 
T921C hDOR genotype and the 8 subscales of personality traits was found when 
compared to all three genotype groups (one-way ANOVA). When genotypes were 
grouped together in TC+TT vs CC, to compare between subjects with a T allele versus 
those without a T allele, no significant associations between the T921C hDOR 
polymorphism and SSS-V as well as BIS/BAS scales were found. When genotypes 
were grouped together in TC+CC vs TT, to compare between subjects with a C allele 
versus those without a C allele, again no significant was found in between personality 
traits and groups. 
Table 16c represents the scores of the SSS-V and BIS/BAS subscales for the control 
group with the three genotypes (TT, TC, CC). Significant association between T921C 
polymorphism in hDOR gene and 'BAS fun seeking' (p=0.02) was found with an 
interaction between TT and TC (p=0.014, |0.11�CI�1.31 | ) when all three groups were 
compared (one-way ANOVA). When genotypes were grouped together in TC+TT vs 
CC, to compare between subjects with a T allele versus those without a T allele, no 
significant associations between the T921C hDOR polymorphism and SSS-V as well 
as BIS/BAS scales were found. When genotypes were grouped together in TC+CC vs 
TT, to compare between subjects with a C allele versus those without a C allele, 
individuals with two copies of T allele scored significantly higher in that individuals 
with at least one of the C allele on the subscales 'BAS reward responsiveness' (p=0.02， 
|0.09�CI�1.04 | ) and ‘BAS fiin seeking' (p=0.004, |0.22>CI>L38|). 
91 
3.3.4 G861C polymorphism in the serotonin receptor IB (5-HTlB) gene 
The 548 bp PCR product genotype GG was revealed by the presence of 2 bands (96bp 
and 452bp), while the fragment length of the PCR product was 96bp, 142bp and 
310bp when the C allele was present. Heterozygotes GC were indicated by the 
presence of the 96bp, 142bp, 310bp and 452bp bands (Fig. 26). 
Table 17a shows that 92 controls (31%) carried the GG homozygous genotype and 82 
controls (28%) carried the CC homozygous genotype and 123 carried (41%) the GC 
genotype. For club drug users, 58 (21%) and 72 (27%) carried the GG homozygous 
and CC homozygous genotype respectively whilst 141 (52%) were GC heterozygous 
carriers. Club drug users showed a slightly higher prevalence of the C allele when 
compared with the control group (53% vs 48%). The G allele was the most common 
allele in controls (52%) while the C allele was the most common allele in club drug 
users (53%). However, there was no significant difference in allele frequencies 
between the control and club drug users (p=0.151). However, a statistically significant 
difference between club drugs users and controls was observed in the genotype 
frequency (Yates analysis showed that 义:�=8.411; p=0.015). 
Table 17b presents the scores of the SSS-V and BIS/BAS subscales for the club drug 
users with the three genotypes (GG, GC, CC). No significant association between 
G861C 5-HTlB genotype and the 8 subscales of personality traits was found when 
comparing all three genotype groups (one-way ANOVA). No significant difference on 
personality traits was found when the genotypes were grouped together in GC+GG vs 
CC to compare with those with a G allele and those without a G allele or when the 
92 
genotypes were grouped in GC+CC vs GG to compare with those with a C allele and 
those without a C allele. 
Table 17c presents the scores of the SSS-V and BIS/BAS subscales for the control 
group with the three genotypes (GG, GC, CC). No significant association between 
G861C 5-HTlB genotype and the 8 subscales of personality traits was found when 
comparing all three genotype groups (one-way ANOVA). No significant difference on 
personality traits was found when the genotypes were grouped together in GC+GG vs 
CC to compare with those with a G allele and those without a G allele or when the 
genotypes were grouped in GC+CC vs GG to compare with those with a C allele and 
those without a C allele. 
93 
Fig 25. The PCR product of 106bp size was subjected to BstEll digestion and the 
resulting fragments were resolved on a 4% agarose gel that was stained with ethidium 
bromid. A DNA marker ( G e n e R u l e i ™ 50bp DNA Ladder) was loaded on the left. 
Homozygous TT is shown as a 89bp band, homozygous CC is shown as a 106 bp band, 
heterozygous is shown as 89bp and 106bp bands . 
Table 16a. Genotype distributions and allele frequencies of C and T of the T921C 
polymorphism in exon 3 of the human DOR (hDOR) gene in club drugs users and 
controls. The absolute number of cases and the percentage of total (in brackets) are 
shown. Yates x " analysis showed that -7.253; df 二2;p二0.027 in the distribution 
of genotype frequency 8.131; df 二 1; p二0.004 in the allelic frequencies 
between club drugs users and controls 
Fig. 25 
DNA marker 
Table 16a. Genotype distributions and allele frequencies of T921C 
Genotypes, n (frequencies) Allele frequencies 
C/C T/C T/T (p)i C T (p) 
Polydmg users (277) 31(0.11) 96(0.35) 150(0.54) 158(0.29) 396(0.71) 
Normal control (303) 19(0.06) 91(0.30) 193(0.64) 0.027 129(0.21) 477(0.79) 0.004 
2 — — P-value of Yates % analysis. 
Table 16b ‘ 
Scores of subscales of SSS-V and BIS/BAS Scales in club drug users with respect to 
hDOR genotypes amongst 277 club drug users. The SSS-V and BIS/BAS scores for 
club drug users with the three different genotypes (CC, TC, TT) were shown. 
Comparisons between all three genotype groups with mean scores of SSS-V and 
BIS/BAS subscales were carried by one-way ANOVA. The mean scores of SSS-V 
and BIS/BAS subscales were compared between subsamples defined by the presence 








































































































































































































































































































































































































































































































































Table 16c ' 
Scores of subscales of SSS-V and BIS/BAS Scales in club drug users with respect to 
hDOR genotypes amongst 303 controls. The SSS-V and BIS/BAS scores for club 
drug users with the three different genotypes (CC, TC, TT) were shown. Comparisons 
between all three genotype groups with mean scores of SSS-V and BIS/BAS 
subscales were carried by one-way ANOVA. The mean scores of SSS-V and 
BIS/BAS subscales were compared between subsamples defined by the presence or 




























































































































































































































































































































































































































































































































3.3.4 G861C polymorphism in the serotonin receptor IB (5-HTlB) gene 
The 548 bp PCR product genotype GG was revealed by the presence of 2 bands (96bp 
and 452bp), while the fragment length of the PCR product was 96bp, 142bp and 
310bp when the C allele was present. Heterozygotes GC were indicated by the 
presence of the 96bp，142bp, 310bp and 452bp bands (Fig. 26). 
Table 17a shows that 92 controls (31%) carried the GG homozygous genotype and 82 
controls (28%) carried the CC homozygous genotype and 123 carried (41%) the GC 
genotype. For club drug users, 58 (21%) and 72 (27%) carried the GG homozygous 
and CC homozygous genotype respectively whilst 141 (52%) were GC heterozygous 
carriers. Club drug users showed a slightly higher prevalence of the C allele when 
compared with the control group (53% vs 48%). The G allele was the most common 
allele in controls (52%) while the C allele was the most common allele in club drug 
users (53%). However, there was no significant difference in allele frequencies 
between the control and club drug users (p=0.151). However, a statistically significant 
difference between club drugs users and controls was observed in the genotype 
frequency (Yates x analysis showed that % (2) =8.411; p=0.015). 
Table 17b presents the scores of the SSS-V and BIS/BAS subscales for the club drug 
users with the three genotypes (GG, GC, CC). No significant association between 
G861C 5-HT IB genotype and the 8 subscales of personality traits was found when 
comparing all three genotype groups (one-way ANOVA). No significant difference on 
personality traits was found when the genotypes were grouped together in GC+GG vs 
CC to compare with those with a G allele and those without a G allele or when the 
92 
genotypes were grouped in GC+CC vs GG to compare with those with a C allele and 
those without a C allele. 
Table 17c presents the scores of the SSS-V and BIS/BAS subscales for the control 
group with the three genotypes (GG, GC, CC). No significant association between 
G861C 5-HT IB genotype and the 8 subscales of personality traits was found when 
comparing all three genotype groups (one-way ANOVA). No significant difference on 
personality traits was found when the genotypes were grouped together in GC+GG vs 
CC to compare with those with a G allele and those without a G allele or when the 
genotypes were grouped in GC+CC vs GG to compare with those with a C allele and 
those without a C allele. 
93 
Fig. 26. The PGR product of 548 bp size was subjected to Hindi digestion and the 
resulting fragments were resolved on a 5% agarose gel that was stained with ethidium 
bromide. A DNA marker (GeneRulerTM 50bp DNA Ladder) was loaded on the left. 
Homozygous GG is shown as 96bp and 452bp bands, homozygous CC is shown as 96 
bp, 142bp, and 310bp bands, heterozygous is shown as 96bp, 142bp, 310bp, and 
452bp bands. 
Table 17a. Genotype distributions and allele frequencies of G and C of the G861C 
polymorphism in the serotonin receptor IB (5-HTlB) gene in club drugs users and 
controls. The absolute number of cases and the percentage of total (in brackets) are 
shown. Yates ^ ‘ analysis showed that%'-8.411; df 二2;p=0.15 in the distribution 
of genotype frequency a n d ^ ' - 2.064; df = 1; p二0.151 in the allelic frequencies 
between club drugs users and controls. 
Fig. 26 
DNA marker 
^ — — 4 5 2 bp 
^ 310 bp 
142 bp 
m i i i j ^ 
Table 17a. 
Genotype distributions and allele frequencies of 5HT1B 
Genotypes, n (frequencies) Allele frequencies 
G/G G/C C/C (p)i G C (p) 
Polydrug users (271) 58(0.21) 141(0.52) 72(0.27) 257(0.47) 285(0.53) 
Normal control (297) 92(0.31) 123(0.41) 82(0.28) 0.015 307(0.52) 287(0.48) 0.151 
^P-value of Yates X ^ analysis. 
Table 17b — 
Scores of subscales of SSS-V and BIS/BAS Scales in club drug users with respect to 
5-HTlB genotypes amongst 271 club drug users. The SSS-V and BIS/BAS scores for 
club drug users with the three different genotypes (GG, GC, CC) were shown. 
Comparisons between all three genotype groups with mean scores of SSS-V and 
BIS/BAS subscales were carried by one-way ANOVA. The mean scores of SSS-V 
and BIS/BAS subscales were compared between subsamples defined by the presence 













































































































































































































































































































































































































































































































Table 17c ^ 
Scores of subscales of SSS-V and BIS/BAS Scales in club drug users with respect to 
5-HTIB genotypes amongst 297 controls. The SSS-V and BIS/BAS scores for club 
drug users with the three different genotypes (GG, GC, CC) were shown. 
Comparisons between all three genotype groups with mean scores of SSS-V and 
BIS/BAS subscales were carried by one-way ANOVA. The mean scores of SSS-V 
and BIS/BAS subscales were compared between subsamples defined by the presence 
















































































































































































































































































































































































































































































3.3.5 TaqI A Polymorphism of the DRD2 Gene 
The 310 PCR product was subjected to TaqI digestion and the resulting fragments 
were resolved on a 2% agarose gel that was stained with ethidium bromide. Genotype 
Al was revealed by the presence of a single 310bp band, whereas genotype A2 was 
represented by the presence of 180bp and 130bp bands. All the 130bp, 180bp and 310 
bp bands were found in the heterozygote A1A2 samples (Fig. 27). 
Table 18a showed that 72 controls (24%) carried the Al homozygous genotype and 
107 controls (36%) carried the A2 homozygous genotype and 107 (39%) were carriers 
of the A1A2 genotype. In club drug users, it was found that there were 42 (15%) and 
99 (36%) having Al homozygous and A2 homozygous genotypes respectively whilst 
136 (49%) were A1A2 heterozygous carriers. A significant difference in genotype 
distribution was shown between controls and club drug users (x^ (2)= 1.344; p=0.011). 
A2 allele is the most prevalent allele in both controls (56%) and club drugs users 
(60%), however, there is no significant difference in allelic frequency (p=0.134) 
between the two groups. 
Table 18b showed the scores of the SSS-V and BIS/BAS subscales for club drug users 
with the three genotypes (AlAl, A1A2, A2A2). Results showed a significant 
association between DRD2 genotype and BIS in BIS/BAS scale (p=0.001) with the 
interaction between the genotypes A1A2 and AlAl (p=0.01, |0.33>CI>3.13|) when 
compared to all three groups (one-way ANOVA) with subjects homozygous for the 
Al allele displaying lower BIS scores. When genotypes were grouped together in 
A1A2+A2A2 vs AlAl to compare between subjects with an A2 allele versus those 
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without an A2 allele, individuals with two copies of Al allele scored significantly 
lower than those individuals with at least one of the A2 allele on the subscale 'BIS' 
(p=0.01, |0.45>CI>2.63|). When genotypes were grouped together in A1A2+A1A1 vs 
A2A2 to compare between subjects with an Al allele versus those without an Al 
allele, no significant personality subscale scores difference was found between 
groups. 
Table 18c showed the scores of the SSS-V and BIS/BAS subscales for controls with 
the three genotypes (AlAl, A1A2, A2A2). No significant association between DRD2 
genotype and the 8 subscales of personality traits was found when comparing all three 
genotype groups (one-way ANOVA). No significant difference on personality traits 
was found when the genotypes were grouped together as A1A2 + AlAlvs A2A2 to 
compare with those with an Al allele and with those without an Al allele or when the 
genotypes were grouped as A1A2+A2A2 vs AlAl to compare with those with an A2 
allele and those without an A2 allele. 
95 
Fig 27. The 310 PGR product was subjected to Taql digestion and the resulting 
fragments were resolved on a 2% agarose gel that was stained with ethidium bromide. 
A DNA marker ( G e n e R u l e r ™ 50bp DNA Ladder) was loaded on the left. 
Homozygous Al Al is shown as a 310bp band, homozygous A2A2 is shown as 130bp 
and 180bp bands, and heterozygous is shown as 130bp, 180bp and, 310bp bands. 
Table 18a. Genotype distributions and allele frequencies of Al and A2 of Taql A 
polymorphism of the DRD2 gene in club drugs users and controls. The absolute 
number of cases and the percentage of total (in brackets) are shown. Yates x ^ 
analysis showed that x ^ 二9.012; df =2; p=0.011 in the distribution of genotype 
frequency and ^ ^ = 2.251; df == 1; p=0.134 in the allelic frequencies between club 




^ ^ 180 bp 
m H ^ — — 1 3 0 bp 
Table 18a. 
Genotype distributions and allele frequencies of TaqI A 
Genotypes, n (frequencies) Allele frequencies 
MAI A1A2 A2A2 (p)丨 Al A2 (p) 
Polydmg users (277) 42(0.15) 136(0.49)99(0.36) 220(0.40) 334(0.60) 
Normal control (296) 72(0.24) 117(0.39) 107(0.36) 0.011 261(0.44) 331(0.56) 0.134 
^P-value of Yates % ^ analysis. 
Table 18b “ 
Scores of subscales of SSS-V and BIS/BAS Scales in club drug users with respect to 
DRD2 genotypes amongst 277 club drug users. The SSS-V and BIS/BAS scores for 
club drug users with the three different genotypes (AlAl, A1A2, A2A2) were shown. 
Comparisons between all three genotype groups with mean scores of SSS-V and 
BIS/BAS subscales were carried by one-way ANOVA. The mean scores of SSS-V 
and BIS/BAS subscales were compared between subsamples defined by the presence 
































































































































































































































































































































































































































































































Table 18c “ 
Scores of subscales of SSS-V and BIS/BAS Scales in club drug users with respect to 
DRD2 genotypes amongst 296 controls. The SSS-V and BIS/BAS scores for club 
drug users with the three different genotypes (AlAl, A1A2, A2A2) were shown. 
Comparisons between all three genotype groups with mean scores of SSS-V and 
BIS/BAS subscales were carried by one-way ANOVA. The mean scores of SSS-V 
and BIS/BAS subscales were compared between subsamples defined by the presence 



























































































































































































































































































































































































































































































































3.3.6 The A118G polymorphism in exon 1 of the human MOR (hMOR) gene 
The 151 PCR product was subjected to Nml digestion and the resulting fragments 
were resolved on a 4% agarose gel that was stained with ethidium bromide. Genotype 
A A was revealed by the presence of a single 151bp band, whereas genotype GG was 
represented by the presence of a 129 bp band and the absence of 151 bp band. Both 
the 151 bp and 129 bp bands were founds in the heterozygote AG sample. The 22bp 
fragment was difficult to visualize because of its small size and co-migration with the 
similarly sized primer residue; however, detection of this fragment was not critical for 
genotype determination (Fig. 28). 
Table 19 shows that 141 controls (47%) carried the AA homozygous genotype and 39 
controls (13%) carried the GG homozygous genotype whilst 118 (40%) carried the 
AG genotype. In the club drug users, 117 (44%) and 34 (13%) were AA homozygous 
and GG homozygous respectively whilst 118 (40%) were AG heterozygous carriers. 
The A allele was the most common allele in both controls (67%) and club drugs users 
(66%). No significant difference was observed in the genotype frequency (p=0.64) 
between the controls and club drug users. When allelic frequency was examined, no 
significant difference between the control and club drugs users (p=0.577) was also 
found. Since no significant difference was found in the genotype and allelic frequency 
for the hMOR polymorphism, further correlation studies with personality trait 
subscales were not made. 
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Kio 2S. The 151 1)CR product was subjected lo Nru\ digestion and the resulting i ragmcnls 
wcM-c resolved on a 4 % agarose gel lhat was stained with ethidium bromide. A DNA marker 
(GencRulc r™ 5()bp DNA Ladder) was loaded on ihc left. Homozygous AA is shown as a 
15 1 bp band, homozygous GG is shown as 12%p，and 3 1 Obp bands, he te rozygous is shown 
as 129bp and 15 1 bp bands. 
Table 19. Gcnotvpc distributions and allele f requencies of A and G of the A118G 
polymorphism in exon 1 of Ihc human M O R ( h M O R ) gene in club drugs users and controls. 
The absolute number of cases and ihc percentage of total (in brackets) are shown. Yates 义 
2 analysis showed thai x ' - 0 . 8 9 4 ; df 二2;p=0.64 in the distribution of genotype frequency 




^ ~ 151 bp 
Table 19.Genotype distributions and allele frequencies of A118G 
Genotypes, n (frequencies) Allele frequencies 
A/A A/G G/G (p)i A G (p) 
Polydrug users (267)117(0.44) 116(0.43) 34(0.13) 350(0.66) 184(0.34) 
Normal control (298) 141(0.47) 118(0.40) 39(0.13) 0.64 400(0.67) 196(0.33) 0.577 
ip-value of Yates % ^ analysis. 
3.3.7 The 44 bp insertion/deletion polymorphism in the promoter region of the 
serotonin transporter gene (SLC6A4) 
The 44bp insertion/deletion polymorphism in the promoter region of the serotonin 
transporter gene (SLC6A4) was shown in Figure 29 with the short (S) allele being 
represented by the presence of a 484 bp single band, and the long (L) allele being 
represented by the presence of a 528 bp single band. Both the 484 bp and 528 bp 
bands were found in the heterozygote SL genotype. 
Table 20 shows that 155 controls (52%) carried the SS homozygous genotype and 31 
controls (10%) carried the LL homozygous genotype whilst 114 (38%) carried the SL 
genotype. In the club drug users, 127 (47%) and 32 (11%) carried the SS homozygous 
and LL homozygous genotype respectively whilst 112 (41%) were SL heterozygous 
carriers. The S allele was the most common allele in both controls (71%) and club 
drugs users (67%). No statistically significant differences were observed between club 
drug users and controls for genotype frequency (p=0.511) and allele frequency 
(p=0.251). 
Since no significant difference was found in the genotype and allelic frequency for the 
SLC6A4 polymorphism, further correlation studies with personality trait subscales 
were not made. 
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Fig. 29. Observed alleles range from 484 bp short allele (S) and 528 bp long allele (L) of 
the 44bp insertion/deletion polymorphism in the promoter region of the serotonin 
transporter gene (SLC6A4) in club drugs users and controls were shown. A DNA marker 
(GeneRuler™ 50bp DNA Ladder) was loaded on the left. Homozygous LL is shown as a 
528bp band, homozygous SS is shown as a 484bp band, heterozygous SL is shown as 
484bp and 528bp bands. 
Table 20. Genotype distributions and allele frequencies of short allele (S) and long allele 
(L) of the 44 bp insertion/deletion polymorphism in the promoter region of the serotonin 
transporter gene (SLC6A4) in club drugs users and controls. The absolute number of cases 
and the percentage of total (in brackets) are shown. Yates x ^ analysis showed that % ^ 
=1.344; df =2;p二0.511 in the distribution of genotype frequency and义之二 1.316; df = 1; 
p=0.251 in the allelic frequencies between club drugs users and controls. 
Fig. 29 
DNA marker 
Table 20.Genotype distributions and allele frequencies ofSHTTLPR 
Genotypes, n (frequencies) Allele frequencies 
S/S S/L L/L (p)i S L (p) 
Polydrug users (271) 127(0.47) 112(0.41) 32(0.11) 366(0.67) 176(0.33) 
Normal control (300) 155(0.52) 114(0.38) 31(0.10) 0.511 424(0.71) 176(0.29) 0.251 
ip-value of Yates % ^ analysis. 
3.3.8 48 bp repeat polymorphism (DRD4) in exon 3 of the dopamine D4 receptor 
gene (DRD4) 
The repeat allele of a 48 bp repeat polymorphism (DRD4) in exon 3 of the DRD4 
gene was shown in Figure 30 with mainly the 2-repeat (2) allele being represented by 
the presence of a 475 bp single band, and the 4-repeat (4) allele being represented by 
the presence of a 619 bp single band. Both the 475 bp and 619 bp bands were found in 
the heterozygote 2/4 genotype. 
Table 21 shows that genotype 2/2, 2/4, and 4/4 of the 48 bp repeat polymorphism in 
DRD4 gene were the most common repeats found in the Hong Kong Chinese 
populations with the relatively less proportion of genotypes 2/3, 3/4, 4/5, and 4/6 
repeats presented. When we just focus the common repeat genotypes (2/2, 2/4, and 
4/4), 8 controls (4%) carried the 2/2 homozygous genotype and 114 controls (61%) 
carried the 4/4 homozygous genotype whilst 55 (29%) carried the 2/4 genotype. In the 
club drug users, 10 (4%) and 157 (66%) carried the 2/2 homozygous and 4/4 
homozygous genotype respectively whilst 55 (32%) were 4/7 heterozygous carriers. 
The 4 allele was the most common allele in both controls (78%) and club drugs users 
(80%). No statistically significant differences were observed between club drug users 
and controls for allelic frequency of short repeat (2-4 repeat) as opposed to long 
repeat (5-6 repeat) was 1.63; df = 1; P-value of Yates analysis = 0.66. 
Since no significant difference was found in the genotype and allelic frequency by 
comparing the for the DRD4-48bp repeat polymorphism, further correlation studies 
with personality trait subscales were not made. 
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Fig. 30. Observed alleles range from 475 bp 2-repeat allele (2), 523bp 3-repeat allele (3), 
and 571bp 4-repeat allele (4), 619bp 5-repeat allele (5), and 667bp 6-repeat allele (6) of a 
48 bp repeat polymorphism in exon 3 of the dopamine D4 receptor gene (DRD4) in club 
drugs users and controls were shown. A DNA marker ( G e n e R u l e r ™ 50bp DNA Ladder) 
was loaded on the left. Genotype distributions were found mainly the homozygous 4/4, 
heterozygous 2/4 and homozygous 2/2 of which homozygous 4/4 is shown as a517bp band, 
homozygous 2/2 is shown as a 475bp band, heterozygous 2/4 is shown as 475bp and 517bp 
bands. Allelic frequency of short repeat (2-4 repeat) as oppose to long repeat (5-6 repeat) 
was;^2 二 1.63; df 二 value of Yatesx^ analysis = 0.66. 
Table 21. Genotype distributions and allele frequencies of 4-repeat (4) and 7-repeat (7) of 
7-repeat allele of a 48 bp repeat polymorphism (DRD4-7) in exon 3 of the dopamine D4 
receptor gene (DRD4) in club drugs users and controls. The absolute number of cases and 
the percentage of total (in brackets) are shown. Yates x ^ analysis showed that 
=2;p=0.975 in the distribution of genotype frequency and % ^ 二 1.53; df = 1; p=0.98 in the 
allelic frequencies between club drugs users and controls. 
Fig. 30 
D N A m a r k e i ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ 一 
'^Wm 
Table 21.Genotype distributions and allele frequencies of DRD4 gene 
Club drug users ( n = 2 3 9 ) Control ( n = 1 8 7 ) 
Genotype 
2 - 2 1 0 ( 0 . 0 4 ) 8 ( 0 . 0 4 ) 
2 - 3 1 ( 0 . 0 0 4 ) 0 
2 - 4 5 5 ( 0 . 2 3 ) 5 5 ( 0 . 2 9 ) 
3 - 4 3 ( 0 . 0 1 ) 2 ( 0 . 0 1 ) 
4 - 4 1 5 7 ( 0 . 6 6 ) 1 1 4 ( 0 . 6 1 ) 
4 - 5 7 ( 0 . 0 3 ) 4 ( 0 . 0 2 ) 
4 - 6 6 ( 0 . 0 3 ) 4 ( 0 . 0 2 ) 
Allele 
2 7 6 ( 0 . 1 6 ) 7 1 ( 0 . 1 9 ) 
3 4 ( 0 . 0 1 ) 2 ( 0 . 0 1 ) 
4 3 8 5 ( 0 . 8 0 ) 2 9 3 ( 0 . 7 8 ) 
5 7 ( 0 . 0 2 ) 4 ( 0 . 0 1 ) 
6 6 ( 0 . 0 1 ) 4 ( 0 . 0 1 ) 
3.3.9 -521C/T polymorphism in the promoter region of the dopamine D4 
receptor gene (DRD4) 
The 380 bp PCR product showed that the homozygous CC was represented by the 
presence of a 380 bp single band, whereas genotype TT was represented by the 
presence of the two bands, 152bp and 228bp. All the 152bp, 228bp and 380bp bands 
were found in the heterozygote CT sample (Fig. 31) 
Table 22 shows the genotype distributions and allele frequencies of C and T 
of -521C/T polymorphism in the promoter region of the DRD4 gene. It reveals that 
32 controls (14%) carried the CC homozygous genotype and 156 (67%) carried the 
TT homozygous genotype and 43 (19%) were carriers of the CT genotype. Similarly, 
it was found that there were 33 (12%) and 182(65%) club drugs users with CC and TT 
homozygous genotype respectively whilst 65(23%) were CT heterozygous carriers. 
Yates x^ analysis showed that x^(2)=1.81;p=0.404 (NS). Allelic frequency distribution 
shows that the T allele was the most common allele in both controls (77%) and 
subjects (77%). However, there was no significant different in allele frequencies 
between the control and subject groups (p=0.941) in the club drug users. 
Since no significant difference was found in the genotype and allelic frequency for 
the -521C/T polymorphism in the promoter region of the DRD4 gene, further 
correlation studies with personality trait subscales were not made. 
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Fig 31 The 380 bp PCR product was subjected to Nsbl digestion and the resulting 
fragments were resolved on a 4% agarose gel that was stained with ethidium bromide. 
A DNA marker ( G e n e R u l e r ™ 50bp DNA Ladder) was loaded on the left. Homozygous 
CC is shown as a 380bp band, homozygous TT is shown as 152bp and 228bp bands and 
heterozygous CT is shown as all 152bp, 228bp and 380bp bands. 
Table 22. Genotype distributions and allele frequencies of the allele frequencies of —521C/T 
polymorphism in DRD4 gene in the club drugs users and controls. The absolute number of 
cases and the percentage of total (in brackets) are shown. Yates % ^ analysis showed that 
；^ 2 =1.81; df =2; p=0.404 in the distribution of genotype frequency and 0.008; df 二 1; 





^ J J J ^ ~ 152bp 
Table 22.Genotype distributions and allele frequencies of-521C/T polymorphism in DRD4 gene 
Genotypes, n (frequencies) Allele frequencies 
CC CT TT (py C T W ~ 
Polydmg users (280) 33(0.12) 65(0.23) 182(0.65) 131(0.23) 429(0.77) 
Normal control (231) 32(0.14) 43(0.19) 156(0.67) 0.404 107(0.23) 355(0.77) 0.941 
ip-value of Yates x : analysis. 
Table 23. , � i ^ 
Hardy-Weinberg Equilibrium (HWE) ratio of variant genes from both controls and club 
drus users were shown, including MAO-A T941G (female), COMT - val met, DRD2 -
TaqI Al, DRD4 — VNTR, -C521T, 5-HTTLPR, 5-HTlB - G861C, mu-opioid receptors _ 
A118G, and delta-opioid receptors - T921C. 
Table 23. Hardy-Weinberg Equilibrium (HWE) ratio 
Control Club drug users Locus 
Polymorphism p-value p-value 
MAO-A T941G (female) 0.45 —0.29 Xp 11.23 
COMT - vali58met 0.01 0.37 22qll.2 
DRD2-TaqlAl 0.01 0.23 "llq23 
DRD4 - VNTR - —- llpl5.5 
DRD4 - -C521T Q.Ql 0.01 llpl5.5 
5-HTTLPR 0.25 0.45 17qll.l-2 
5-HTlB - G861C 而2 0.15 ~~6ql3 
Mu-opioid receptors-A118G 0.15 0.50 6q24-25 
Delta-opioid receptors - T921C |o.21 |o.Q7 |lp36.1-34.3 
CHAPTER FOUR DISCUSSION 
This community-based study provides the drug use profiles of the young "club drug" 
users in Hong Kong as well as to investigate the association between candidate gene 
variants and personality traits amongst these subjects. In summary, ketamine (88.5%) 
followed by marijuana (83.6%), 'ecstasy' (79.8%) and 'ice' (30.1%) were the most 
commonly lifetime use drugs in Hong Kong (Table 2). Ketamine and ‘ecstasy’ were 
usually used in combination, with the occasional use of marijuana together with other 
stimulant and hallucinogenic drugs. Near to 90% and 60% of the “club drug" users 
have ever tried drugs during rave parties or discos in Hong Kong and in Shenzhen 
respectively (across the border). 
4.1 Demographics and pattern of club drug use 
The present study showed that there is a distinctive pattern of drug use including the 
local cross-border drug users in Hong Kong. Most of the "club drug" users are males 
with a mean age of 18.12±2.475 (ranged from 13 to 29). The occupational 
demographics of our "club drug" users, in general, are unemployed or in lower 
secondary education and thus experience social and economic marginalization 
associated with drug use. Majority of the “club drug" users lived with both parents in 
public housing; their fathers (60%) are in full-time job while most mothers are 
housewives or in full-time job. The characteristics of the "club drug" users in Hong 
Kong, not surprisingly, are similar to those studies of 'ecstasy' users (Topp et al, 1999; 
von Sydow et al, 2002; Degenhardt, 2004) in which all of the drug users were living 
with their parents with lost cost housing. In the present study, the fathers of the 
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subjects are frequently found to be involved in several addictive behaviours including 
smoking (54.9%), drinking (36.1%) and gambling (33.6%) (Fig. 10). 
The initial age of "club drug" use was 14.8土2.2 years (ranged from 10 to 20 years) in 
our study, this result did not agree with the 'floor effect' mentioned in Riley et al. 
(2001) (Riley et al, 2001) that represented a population who are familiar with drugs by 
the time they reach the legal clubbing age of 18. According to Riley et al. (2001), 
'floor effect' means the people who reach the legal clubbing age of 18 are more 
susceptible to taking drugs since they can access drugs during clubbing. In our study, 
the first time drug use was found to be closely related to the education background of 
the "club drug" users: the educational level of ‘‘club drug" users were mainly Form 3 
of lower secondary level in which most of the students finished this level at around 
14-15 years old. In Hong Kong, government policy dictates that students have to 
receive 9 years of compulsory education (up to Form 3 level). From the present study, 
it seems that those youngsters who are unable to continue their study may be more 
susceptible to club drug use. According to the school survey study in Hong Kong, 
'The 2000 survey of Drug Use among Students' (Lau, 2000), students from Hong 
Kong Institute of Vocational Education (IVE) schools which provide job-related 
training and education for the students who dropped out of school after Form 3 to 
pursue vocational training, were amongst the ones with the highest drug use rate. 
Again it showed that young people who dropped out of school after Form 3 were 
susceptible to drug use. 
Although the 'floor effect' was not shown in our study, rave parties/ discos is the 
venue where the "club drug" users are most likely to take drugs with friends. Some 
101 
studies have also identified the prevalence of stimulant drugs at dance events (Forsyth, 
1996; Bean et al., 1997). The present study showed that 91.7% out of the 311 (85%) 
club attendees have ever taken drugs during rave parties or discos in Hong Kong and 
100% tried drugs when attending rave parties or discos in Shenzhen, China. Going to 
discos and taking club drugs in Shenzhen became a new trend amongst young people 
in Hong Kong over the recent years. The reasons of taking drugs in Shenzhen were 
similar to those reasons given for Hong Kong which are: 'to have uninhibited fun', 'to 
relax', and 'to seek new exciting experiences'. It was shown that "club drug" users 
could buy cheaper club drugs at the discos in Shenzhen when compared to Hong 
Kong (42% as opposed to 15% in Hong Kong, Fig 19). A significantly higher 
prevalence of 'ecstasy' (0R=L91, p=0.037) and benzodiazepines use (OR=2.28, 
p=0.018) were found in cross-border drugs users in Hong Kong in the last 12 months 
when compared to those non cross-border drugs users in Hong Kong. A significantly 
higher prevalence of marijuana (OR=1.95, p=0.015); (OR二2.21, p=0.0016) and 'ice' 
use (OR=4.39，pO.OOOl); (OR=2.21, p二0.009) were found in cross-border drugs 
users in Hong Kong in the last 12 months and lifetime use respectively when 
compared to the same group of cross-border drugs users taking drugs in Shenzhen. 
The reason for this could be marijuana and 'ice' is not the drugs usually taken during 
clubbing in Shenzhen, in other words, those drugs were not the common drug used 
among the cross-border drug users when they were taking drugs in Shenzhen, 
‘ecstasy’ use was shown consistently to be prevalent among cross-border drug users in 
Hong Kong and Shenzhen during the period of lifetime, the past 12 months, and 
current use. It was suggested that 'ecstasy' was the common drug use among the 
cross-border drug users in Shenzhen, the reason for this could be related to the lower 
price of club drugs sold in Shenzhen. Such a trend is of concern since this will 
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encourage more club drug use across the border. However, the purity of the drugs, like 
‘ecstasy，，esp. drugs from across the border, various ‘ecstasy, tablets ranged from 
having 10%-30% MDMA as the active ingredient (Cheng et al., 2003), whereas 
‘esctasy’ from across the border, the purity of MDMA ranged from 0.10 to 0.15 grams 
ofMDMA.HCl per tablet. 
Marijuana was the second most common "club drug" used among the "club drug" 
users, this is however different to that reported by the government's CRD A report 
in which marijuana was the third common club drugs among those drug users. The 
reasons for this discrepancy may due to the different sources of the “club drug" users 
between the present study and the 5”! CRD A report. In the CRD A report, 61.6% of 
newly reported cases were reported by law enforcement agencies, 23.9% by treatment 
and rehabilitation agencies, 19.7% by welfare agencies and 2.5% by hospitals and 
clinics while all club drugs users in our study were recruited from the community, in 
other words, the hidden population of "club drug" users were investigated in the 
present study. Our study also showed that marijuana followed by ‘ecstasy,, 'ice', 
cough mixture, benzodiazepines, and solvents were the next most common club drugs 
used. The present study showed a significant higher cumulative prevalence for 
marijuana use in males (OR=1.97, p=0.017). A similar result was also shown in a 
German study (Perkonigg A. et al, 1999). Warner et al., (1995) suggested that the 
significant gender difference observed was due mainly to the significantly higher risk 
for first use of marijuana among males. Moreover, it was shown in our study that the 
younger age group tends to be the most frequent users of marijuana suggesting that 
younger males may prefer using marijuana. 
103 
The most common drugs used amongst female "club drug" users were ketamine, 
‘ecstasy’ and ‘ice,. A significantly higher frequency of 'ice' use among females was 
reported in our present study (OR=2.28, p=0.017, Table 2), this is in agreement with 
that reported by Riley et al. (2001) in which Scottish females was also reported to use 
'ice' significantly more frequently than males (Riley et al, 2001). In Hong Kong, the 
higher prevalence of "club drug" use like ketamine and 'ecstasy' and 'ice' among 
females could be related to the higher incidence of free "club drugs" given by friends 
(41.8% in females as opposed to 24.1% in males, Fig 16). 
The present study showed a difference between polydrug use (more than one club 
drug being used at different occasions) and multiple drug use (more than one club 
drug used in combination at any one occasion) in our samples (92.9% having used 
more than one drug within the year and 77.9% of respondents having used more than 
one drug at any one time). Of all the participants recorded in this study, 77.8% who 
mixed drugs reported using between two and three drugs in their ‘usual mix' with the 
combination of ketamine and 'ecstasy' being used together (67.2%) being the most 
common. 50% of the polydrug users use a combination of ketamine, 'ecstasy' and 
marijuana together at any one time. This polydrug use pattern found in our study was 
not unique, some studies have also shown that 'ecstasy' users were more likely to use 
marijuana, as well as being engaged in drinking and smoking (Strote et al., 2002). It 
was also shown that 'ecstasy' was used by adolescents who used other legal and 
illegal substances in a polydmg-use pattern with stronger associations towards 
subcultural music preferences and house-party-going (Pedersen and Skrondal, 1999). 
An 18-item scale designed to measure perceived functions for substance use from 
104 
Boys et al. (2001) (Boys et al., 2001) was translated into Chinese for this study. Four 
of the most commonly used club drugs namely, ketamine, ‘ecstasy,, marijuana, and 
‘ice’ were used in reference to the questions on ‘perceived functions'. It was found 
that both ketamine and ‘ecstasy，users shared common functions with the top five 
items scoring highest being: 'to help to enjoy company，，'to help to feel elated/ 
euphoric', ‘to relax', 'to keep going on a night out with friends', and 'help to feel 
better when down or depressed'. Since common perceived functions for ketamine and 
'ecstasy' use were found, this may perhaps explain why ketamine and ‘ecstasy’ were 
used together at any one occasion among the Hong Kong "club drug" users. Further to 
this, ketamine with 'ecstasy' and marijuana was the next most common combination; 
the top five items with the highest scores were similar to that in perceived functions 
for ketamine and 'ecstasy' use with the exception of ‘to help to feel better when down 
or depressed' was replaced by 'help to sleep'. When the perceived function of ‘ice’ 
use was examined, results were quite different from the other three “club drugs" use 
because the main function is 'to help to stay awake' and 'help to concentrate to work 
or study'. The results from our study were similar to that reported by Boys et al. 
(2001)(Boys et al., 2001) in which the functions of "club drug" use, apart from 'ice' 
use, were mainly for changing mood and social purposes. 
The physical symptoms shown within 24 hrs after taking "club drugs" were mainly: 
decrease in appetite (68.8%), poor physical coordination (53.6%) and inability to 
sleep (49.2%). Behavioral symptoms include: hallucination (58.3%), amnesia (49.2%), 
and feeling depressed or uninterested in things for more than 24 hrs among the “club 
drug" users who used most frequently any one of the four “club drugs" including 
ketamine, marijuana, ‘ecstasy，，and 'ice'. The above symptoms, not surprising, were 
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due mainly to ketamine and 'ecstasy' use. It has been shown in humans that ketamine, 
at subanaesthetic doses, disrupted attentional function and explicit memory (Adler et 
al., 1998;Krystal et al., 1998;Newcomer et al., 1999). Furthermore, some studies 
reported that regular, frequent use of 'ecstasy' is associated with sleep disorders, 
depressed mood and elevated anxiety and trait impulsiveness (Morgan et al., 1998, 
2000; Parrott et al., 2000; Wareing et al , 2000). The symptoms mentioned in these 
studies of the frequent ketamine or ‘ecstasy’ users are similar to that described in our 
"club drugs" users, thus raising considerable alarm that these subjects are perhaps 
suffering from some of the long term cognitive deficits as well as psychiatric 
disorders reported in other studies. It seems that long term medical follow-up of these 
individuals is needed. 
The development of potential tolerance and dependence symptoms were also shown 
in the present study. 72.8% "club drug" users have ever wanted to or tried to cut down 
on drugs but 27.7% subjects found they could not stop or cut down using drugs 
suggesting that these individuals may be developing dependence towards "club drug" 
use. 78% claimed that they needed to increase the quantity of drugs by 50% or more 
and 48.5% needed markedly increased amounts of drugs to get an effect or found that 
they could no longer get high on the amount they used to use; 40.7% have used drugs 
more days or in larger amounts than the "club drug" users. This suggested they were 
developing tolerance to these drugs. Even though dependence on ketamine was 
sporadically described (Hurt and Ritchie, 1994) it was suspected to be not uncommon. 
The present study further provides evidence that the use of ketamine may result in 
drug dependence. It has been shown that ketamine induce place preference using the 
conditioned place preference method in mice suggesting the dependence potential of 
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this drug (Suzuki et al , 2000). It was suggested that ketamine could indirectly activate 
the mesolimbic dopaminergic system by blocking the NMDA receptors which was 
verified to modulate the mesolimbic dopamine neurons in the VTA and NAc 
(Pulvirenti et al., 1991), resulting in the production of the rewarding effect since a 
high dose of ketamine increased dopamine turnover in several brain regions (Irifune et 
al., 1997). It was also shown that long-term marijuana use can lead to addiction for 
some people and along with craving, withdrawal symptoms like difficulty sleeping, 
and anxiety can make it hard for chronic marijuana users to stop using the drug 
(Hanson, 2002). In line with the potential that "club drugs" like ketamine and 
marijuana can develop tolerance and dependence, this poses considerable medical 
concern for the community and that the government should provide more health 
check-up service for these club drug youths in which such problems could be 
identified earlier. 
When drug users were questioned on their knowledge on drugs, 20.9% and "club 
drugs" users did not believe that "club drugs" could cause mental problems whilst 
31.3% did not believe it may be addictive or could lead to dependence. Such poor 
knowledge on the negative effects of drugs could result in increased frequency of 
drug use of "club drugs" or enhanced risky behaviour like unprotected sex. It is 
therefore crucial to provide continual drug education especially for the youngsters 
who are still at school. 
The psychological status of "club drugs" users was that 91.2% of them felt stressful in 
their daily life of which 17% felt extremely pressurized. In our study, only 30.9% of 
our subjects are employed, the rest are unemployed or still at school, therefore most 
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of them were facing the problems of unemployment. Furthermore, 38.1% are from 
single homes, hence pressure come from single parent family was present among 
some of our “club drug" users. These factors could have an additive effect in the 
stresses in life that they encounter. It was shown that the initiation of smoking in 
adolescence is a means to cope with stressful events in life (Koval et al., 1999, 2000). 
Since most of our subjects are smokers, this could be related to the stressful elements 
in the life that they lead. 
4.2 Personality traits assessment 
In order to understand whether personality traits are related to the vulnerability of 
drug use, two personality trait scales, namely, SSS-V and BIS/BAS were used to study 
sensation seeking and harm avoidance behaviour respectively. Some personality traits 
like sensation seeking and aggressive antisocial behaviour have been shown to be 
predictors of drug taking, drinking or smoking (Zuckerman and Kuhlman, 2000). We 
therefore compared the personality traits of 360 club drug users to that of 303 controls 
to ascertain whether such a correlation exists for Chinese club drug users since no 
such information is currently available. Results showed that "club drugs" users had 
significantly higher sensation-seeking scores measured by both SSS-V and BIS/BAS 
subscales, they include: ‘boredom susceptibility', 'disinhibition', 'experience seeking', 
'thrill and adventure seeking' for SSS-V, and, ‘BAS fun seeking’，‘BAS drive' for 
BIS/BAS but not for ‘BAS reward responsiveness' in which there was no significant 
difference between "club drug" users and control. This could be due to the tendency 
of both adolescent "club drug" users and controls focusing on the positive response to 
reward. For the BIS subscale of BIS/BAS scale, "club drug" user scored lower than 
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the controls (Table 10), the lower scores observed in the "club drug" users may be 
attributable to their chronic drug use. In general, our study showed that higher 
sensation seeking and lower anxiety scores were found in "club drug" users, these 
results agreed to what Wagner et al. (2001) proposed in that high sensation seeking 
and low anxiety are predictors of substance use (Wagner, 2001). Another study also 
showed that ‘ecstasy，users tend to have higher sensation seeking scores (Bobes et al., 
2002) thus also agreeing with the present findings. It was shown that higher anxiety or 
harm avoidance was associated with alcohol dependence (Lynskey et al., 1999). Our 
study showed a significantly lower BIS (a trait indicated anxiety) scores in “club 
drug" users with alcohol use suggesting these subjects may be the type II alcohol 
users who drink for enjoyment and for the disinhibition produced by alcohol and are 
more likely to be engaged in fighting and other antisocial behaviours (Cloninger, 
1987b). 
The mean score of ‘disinhibition，in "club drug" users was more than double the score 
in controls; it could be explained by the presence of the 'drug-related statements' in 
the 10-statement 'disinhibition' subscale resulting in "club drug" users having a 
dramatically different score from controls. 
When gender was taken into consideration (Table 11 & 12), no significant difference 
was found in 'thrill and adventure seeking' between female “club drug" users and 
female controls, in other words, the higher score observed for the 'thrill and adventure 
seeking' subscale in all the "club drug" users was merely contributed by the males. 
Furthermore, male "club drug" users were shown to have significantly higher scores 
in sensation seeking including, ‘boredom susceptibility' (p=0.018), 'disinhibition' 
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(p<0.0001), and lower anxiety scores, BIS (p<0.025) (Table 13). It may explain why 
there are more male than female "club drug" users observed in the general population 
(Gov't 5ist CRDA report) as well as in our present study. Female "club drug" users in 
our study were shown to have significantly higher BIS scores (anxiety). A study 
illustrated that females showed a stronger response to ‘ecstasy, when compared to 
males was consistent with an increased susceptibility of women to the 5-HT-releasing 
effects (5-HT is known to play an important role in mood and anxiety disorders) 
(Liechti et al., 2001) thus may explain why females respond to the chronic "club 
drug" uses resulting in higher anxiety scores when compared to male “club drug" 
users, 
4.3 Gene polymorphisms 
The current hypothesis is to test whether there is an association in "club drug" use 
with gene variants of the reward and reinforcement pathway of the brain. The 
hypothesis is then extended to test whether these gene variants are further associated 
with certain personality traits like novelty seeking, impulsivity and anxiety thus 
making an individual more vulnerable to "club drug" use. COMT, MAO-A, hMOR, 
hDOR, DRD2, DRD4, 5HT1B, and 5HTTLPR gene variants in "club drug" users and 
controls were examined. Polymorphisms that were investigated included the G1947A 
Vaiio8/i58 Met polymorphism in the COMT gene, T941G polymorphism in the 
MAO-A gene, T921C polymorphism in exon 3 of the hDOR gene, A118G 
polymorphism in exon 1 of the hMOR gene, TaqI A polymorphism of the DRD2 gene, 
VNTR 48 bp repeat in exon 3 of the DRD4 gene, G861C polymorphism in the 
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5-HTlB gene, and the 44 bp insertion/deletion polymorphism in the 5-HTTLPR gene. 
Statistical significance was found between the "club drug" users and controls in the 
1 0 8 / 1 5 8 
COMT v a l • � � m e t polymorphism in both the genotype and the allelic frequency 
(Table 14a). For the MAO-A T941G polymorphism, a significant difference (Table 
15b) in allelic frequency in the female subjects was found. For the T921C 
polymorphism in exon 3 of the hDOR gene, significant differences were found in both 
the genotype and allelic frequency (Table 16a). Genotype frequencies of the G861C 
polymorphism in the 5-HT IB gene (Table 17a) and the TaqI A polymorphism of the 
DRD2 gene (Table 18a) were also found to be significantly different between subjects 
and controls. However, no statistical significance was found in the polymorphisms of 
the hMOR, DRD4, and 5-HTTLPR genes (Tables 19-22). 
When the interaction between personality traits and the gene variants were examined, 
It was showed that G1947A val^^^^^^Vet polymorphism in the COMT gene was 
associated with personality traits namely ‘BAS drive,, ‘BAS fun seeking' and 
'boredom susceptibility' (Table. 14b, 14c); T941G polymorphism in the MAO-A gene 
was associated with personality traits, ‘BIS，and ‘BAS reward responsiveness' (Table. 
15c, 15d); T921C polymorphism in exon 3 of the hDOR gene was associated with 
‘BAS reward responsiveness' and ‘BAS fun seeking' (Table. 16b, 16c); and TaqI A 
polymorphism of the DRD2 gene was associated with ‘BIS’ (Table. 16b, 16c). 
4.3.1 COMT G1947A, V a l ^ ^ Met polymorphism 
COMT is an obvious candidate gene for a number of neurologic disorder that involve 
noradrenergic or dopaminergic systems since the gene variant G1947A is a functional 
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mutation that affects enzyme activity. A predominance of H alleles (G allele, high 
COMT activity) had been shown to be associated with substance abuse (Vandenbergh 
et al., 1997; Lachman et al , 1997) increase risk for schizophrenia (Egan et al., 2001) 
as well as ADHD impulsive-hyperactive phenotype (Eisenberg et al., 1999). On the 
other hand, a predominance of L alleles (low COMT activity) was shown to be 
associated with late-onset alcoholics (Hallikainen et al., 1999b); higher frequency of 
social drinking in individuals (Kauhanen et al., 2000); and higher susceptibility to 
obsessive-compulsive disorder or depressive disorders (Karayiorgou et al., 1997, 
1999). In view of this, we have examined the Chinese "club drug" users for the 
COMT val/met polymorphism. The results in the present study showed that a 
significant association exists for the COMT val/met polymorphism in the Chinese 
"club drug" users. In the Hong Kong Chinese population, the H allele is more 
common than the L allele in both controls (73%) and "club drug" users (79%) with 
“club drug" users having a higher H allele frequency than the controls. The increase 
of H allele was due to the significant increase in HH genotype with a decrease in the 
number of HL genotype. The increase in H allele and in the “club drug" subjects 
suggested that these individuals, due to their higher COMT activity, might have an 
increase in dopamine catabolism resulting in lower dopamine availability in the 
prefrontal cortex. This in turn may generate a feedback mechanism whereby the 
intake of "club drugs" could help stimulate the release of dopamine in the mesolimbic 
pathway thus compensating for the depletion of dopamine in the prefrontal synaptic 
area. 
There is considerable ethnic differences in the distribution of the COMT*H allele 
frequencies. The H allele frequency ranged from: Chinese (range, 0.72-0.78) (Xie T. 
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et al, 1997; Chen et al, 1997), Han Chinese (0.82) (Hinney et al , 1997), Japanese 
(range 0.65-0.71) (Kunugi et al., 1997; Ohara et al., 19098), Spanish (0.57) (Gutierrez 
et a l , 1997), Caucasian (0.48) (Hoda et al., 1996), Finnish (0.42) (Syvanen et al , 
1997). Our subjects and controls fall in the Chinese range, namely (0.73-0.79), 
reported by other studies. This suggests that the Chinese population have global 
higher H allele frequency and could be more predisposed to "club drug" use. 
The personality trait study showed that the "club drug" users have higher sensation 
seeking and lower anxiety (BIS) scores when compared to the controls. When the 
interaction between the genotypes and that of the personality traits of the "club drug" 
users we studied (Table 14b), a significantly higher score in 'boredom susceptibility' 
(aversion to persistence of repetition) (p=0.02, |0.069�CI�0.995|) and 'BAS drive' 
(p=0.01, |0.196>CI>1.251|) in individuals with at least one L allele than in individuals 
with two copies of the H allele. When we examined the control group, there was no 
significant difference in ‘boredom susceptibility' and 'BAS drive' scores but there 
was a significant difference in ‘BAS fun seeking' according to the genotypes (Table 
14c). Individuals with two copies of the H allele scored significantly higher than 
individuals with at least one of the L allele on the subscale 'fun seeking' in controls 
(p=0.02, |-1.0>CI>-0.01|). Since a significantly higher H allele frequency was also 
shown in "club drug" users, this association could reflect a relatively higher 'fun 
seeking' score in individuals with two copies of the H alleles. The significant 
difference found between "club drug" users and control could therefore be related to 
the chronic drug use resulting in change in personality traits in "club drug" users. A 
longitudinal study of these same "club drug" users will further confirm this 
possibility. 
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Benjamin et al. (2000) showed that there was a significant interaction between COMT 
and 5-HTTLPR in which with the presence of both COMT homozygous HH or LL 
genotypes and the presence of the short 5-HTTLPR allele raised ‘persistence，score -
a subscale of the reward dependence trait in TPQ. Those with high persistence scores 
were characterized as industrious, hard working, ambitious, perfectionistic in the TPQ 
(Benjamin et al., 2000). Therefore the lower scores of boredom susceptibility found in 
both homozygote HH and LL genotypes but higher scores in heterozygote HL 
genotype found in the present study might be under the interference of other genes. 
However, "club drug" users carried heterozygote HL was found to have higher 
sensation seeking score together with lower BIS score when compared with those 
with homozygote HH or LL. It may due to the heterozygote HL genotypes with the 
midway enzyme activity between homozygote individuals did not have the problem 
of excess (in LL genotype) or depletion (in HH genotype) of dopamine in prefrontal 
cortex. 
4.3.2. MAO-A T941G polymorphism 
The present study revealed that a significant difference in MAO-A genotype and 
allelic frequency in female "club drug" users. It seemed that the T allele might play a 
role in the predisposition of "club drug" use in females since there is a significant 
increase in allelic frequency for the T allele in the female "club drug" users. The 
increase in T allele was mainly due to the increase in homozygous TT genotype with 
a significant decrease in homozygous GG genotype in female "club drug" users. The 
female "club drug" users also showed a lower BIS score of the BIS/BAS personality 
trait assessments. When the interaction between genotype and personality traits was 
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assessed, it was shown that females with homozygous TT genotype were significantly 
associated with lower BIS score (lower anxiety) than those with homozygous GG 
genotype. A relatively higher BIS score was found in individuals carrying TT 
genotype than individual carrying homozygous GG genotype even if no significant 
difference was found in the control group. TT genotype is shown to be associated 
with lower MAO-A activity, thus individuals should have more serotonin level in 
brain since MAO-A was shown to have a higher potency in degrading serotonin than 
dopamine (Cases et al., 1995). Serotonin is the key element in the role of the 
behavioural inhibition mechanism mediated by the serotonergic system that originates 
in the medial raphe nucleus and ascending to limbic and neocortical brain structures 
(Zuckerman and Kuhlman, 2000) therefore disturbed serotonin metabolism in the 
brain has been associated with depressive mood and anxiety (Staley et al., 1998). Our 
female subjects have homozygous TT allele (low MAO-A activity) associated with 
lower anxiety scores suggesting that anxiety traits and MAO-A may be a good 
predictor for "club drug" use in females. 
However Li et al. (2004) showed that women having higher anxiety levels may be 
due to the fact that estrogen inhibits COMT (Li et al., 2004). It was shown that there 
is an interaction between the homozygote HH COMT (high H) is also associated with 
lower BIS scores (Enoch et al., 2003). Therefore from our study, it was shown that 
there is a genetic association in anxiety traits in female "club drug" users. 
4.3.3. hDOR T921C polymorphism 
Mayer et al. (1997) showed that the C allele in the T921C silent polymorphism in 
exon 3 of the hDOR gene was significantly associated with heroin dependence 
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(Hinney et al., 1997). It has also been demonstrated that there is an upregulation of the 
DOR binding site accompanying the development of morphine tolerance and 
dependence in mice (Abdelhamid and Takemori, 1991). Results from our laboratory 
also showed an association exists with Chinese heroin-dependent subjects with 
heroin-dependent subjects having a higher frequency of the C allele when compared 
to the controls (unpublished data). Although none of our "club drug" users have ever 
tried opiates like heroin, the frequency of the C allele frequent was also shown to be 
significantly higher in the "club drug" users than in the controls. Significant 
difference in genotype frequency was also found in "club drug" users; there is a 
significantly higher number of homozygous CC and heterozygous TC individuals than 
controls. Since the C allele was significant different for both the heroin and "club 
drug" users in the Chinese population, the hDOR polymorphism may be associated 
with substance use in general. It may be speculated that individuals with at least one 
copy of C allele may be more predisposed to substance abuse. On the other hand, 
individuals with homozygous TT may be protected. 
When the interaction of personality traits and hDOR polymorphism was studied no 
association was found in “club drug" users. In controls, however, individuals with two 
copies of T allele scored significantly higher on the subscales ‘BAS fun seeking' 
(p=0.004, |0.22>CI>1.38|) than individuals with at least one of the C allele. Similar to 
that shown in COMT, the T921C polymorphism also showed a significantly higher T 
allele frequency in "club drug" users; this could be related to the relatively higher 
‘BAS fun seeking' in individual with two copies of the T alleles. Due to chronic drug 
use, the significant difference in 'fun seeking' score between genotypes in the T921C 
polymorphism was absent in "club drug" users. 
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Since this silent hDOR T921C polymorphism did not show any change in the receptor 
protein sequence (Hinney et al., 1997), a functional non-synonymous OPRDl 
substitution 80T>G [Phe27Cys] was found (Blomqvist et al., 2000) that may be 
associate with the T921C polymorphism. Unfortunately this 8 0 T � G polymorphism 
was not found in both Chinese subjects and controls (Xu et al., 2002). 
However, in the animal study delta-opioid receptor mediated morphine-induced 
CCK-LI release in the spinal cord (Gustafsson et al., 2001) and the chronic morphine 
treatment in rats is associated with marked reduction in phosphorylated CREB (the 
active form of this transcription factor) in cortex and/or striatum (23-26%) of mu- and 
delta-opioid receptor KO mice，but not in kappa-KO animals. These results suggest 
that the endogenous opioid tone acting on mu-/delta-receptors tonically stimulate 
CREB activation in the brain (Garcia-Sevilla et al., 2004) as well as the emotional 
responses, an interactions between mu- and delta- receptors was shown knock-out 
mice experiment (Filiol et al., 2000). In the future, other hDOR and hMOR functional 
polymorphisms should be investigated to further evaluate together for their 
contribution to substance abuse. 
4.3.4. hMORAllSG polymorphism 
It was shown that when the ligand binding ability of the hMOR A118G 
polymorphism was studied, A118G-transfected cells bind to P-endorphin 3 times 
more tightly and more potently (Bond et al., 1998.). The binding and signal 
transduction change in the receptor may influence normal physiology of the receptor, 
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thus rendering an individual's vulnerability to addiction. A118G have been shown to 
be associated with heroin-dependence in Chinese (Szeto et al., 2001) subjects. The 
allele frequency of the 118G for Chinese heroin-dependent subjects is 39.5% when 
compared to 29.4% and in controls. It seemed that the G allele might play a role in the 
predisposition of heroin dependence since there is a significant increase in allelic 
frequency for the G allele in the heroin-dependent subjects. These frequencies are 
comparatively higher when compared to the Caucasian (11.5%), Hispanic (14.2%) 
and African-American (1.6%) control population (Bond et al., 1998). 
In the present study, there was no significant difference in genotype or allelic 
frequency for the A118G polymorphism in the club drug users. However, the allele 
G frequency of our "club drug" users was 34%, falling in between that reported in the 
heroin-dependent and control population reported earlier. 
4.3.5 DRD2 TaqI A polymorphism 
The DRD2 TaqI polymorphism characteristically presents two alleles namely Al and 
A2 with Al allele carriers having lower DRD2 density and fewer binding sites in the 
striatum (Pohjalainen et al., 1998). These carriers also demonstrated lower glucose 
metabolic rates in brain regions that are rich in dopamine receptors, namely regions 
that participated mostly in cognitive and motivational processes (Noble et al., 1997). 
Moreover it was also shown that the Al allele of the DRD2 was associated with 
alcoholism (Bau et al., 2000; Blum et al, 1990; Ishiguro et al., 1998; Pato et al., 1993) 
and cocaine dependence (Noble et al., 1993), substance abuse in general (Comings et 
al., 1994; Goldman et al., 1997; Uhl et al., 1993), psychostimulant-preferring 
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polysubstance abusers (Persico et aL, 1996), smoking (Anokhin et al., 1999), 
compulsive-impulsive-addictive behaviour (Comings et al., 1993), schizophrenia and 
smoking (Comings et al., 1996) and high sensation-seeking behaviour together with 
alcoholism (Ratsma et al., 2001). 
In the present study, a significant difference in TaqlA genotype was found between 
"club drug" users and controls. Although there is no significant difference in allelic 
frequency of the Al allele between the "club drug" users (40%) and controls (44%), 
the "club drug" users however have more heterozygous A1A2 genotype and fewer 
homozygous AlAl genotypes when compared to the controls. As the Al allele of the 
DRD2 gene is associated with numerous disorders, fewer than half of the "club 
drugs" users were found to carry the Al allele, it cannot be with total conviction that 
one could state that the heterozygous composition is the cause of each disorder. It 
could be also explained by that TaqlA polymorphism may be in linkage 
disequilibrium with other functional mutations nearby. 
When the interaction of personality traits and genotype was performed, homozygous 
AlAl genotype was found to be significantly associated with lower BIS score (lower 
anxiety). Individual with two copies of the Al allele displayed lower BIS scores when 
compared to individuals at least one copy of the A2 allele (p=0.01, |0.33>CI>3.13|). 
However, this significant association was not found in control group, the lower BIS 
score associated with homozygous AlAl genotype in "club drug" users could be 
related to the chronic "club drug" use. Our results are in agreement with that reported 
by David et al. (2003) in which the A2/A2 genotype was significantly associated with 
higher anxiety levels (David et al., 2003). 
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4.3.6 DRD4 48bp VNTR polymorphism 
In the present study, there is no significant difference in genotype or allelic frequency 
between “club drug" users and controls. It is possible that the investigated 
polymorphism itself does not confer susceptibility to "club drug" uses, but is in 
linkage disequilibrium with another closely situated real susceptibility polymorphism 
in Chinese population. In the present study, allele 4 repeats (80%) followed by 2 
repeats (16%) with no 7 repeats polymorphism present in DRD4 gene is the most 
frequent in the Chinese population; Chinese heroin abuser carried mostly the allele 4 
repeats (71%), 2 repeats (22%), 7 repeats (0.4%) (Li et al., 2000); Japanese 
population also carried mostly allele 4 repeats (76.1%), 2 repeats (13.8%) but only a 
small proportion of 7 repeats (2.2%) (Tomitaka et al., 1999); Jews carried allele 4 
repeats (67.3%), allele 2 repeats (3.1%), and allele 7 repeats (24.5%) (Kotler et al., 
2000); European American carried allele 2 repeats (4.5%), 4 repeats (69.7%), and 7 
repeats (18.2%); African American carried allele 2 repeats (3.8%), 4 repeats (62.8%) 
and 7 repeats (21.8%). Recently DRD4*7R allele was found to be associated with 
higher novelty seeking, independent of ethnicity, sex, or age (Benjamin et al., 1996; 
Ebstein et al., 1996) but the findings could not be replicated in Finnish (Malhotra et 
al., 1996) and Swedish (Jonsson et al., 1997). Since DRD4*7R allele was seldom 
found in Chinese population, the effect of DRD4*7R allele might not contribute much 
in Chinese population. In other words, there might be other genes contribute the 
factor of novelty seeking in Chinese population. 
120 
4.3.7. DRD4 -C521T polymorphism 
The present study showed that there was no significant difference in -521C/T 
polymorphism for both genotype and allelic frequency "club drug" users (77% T 
allele and 23% C allele) and control (77% T allele and 23% C allele), however, the 
“club drug" users were shown to have higher T allele frequency than that in Chinese 
heroin abusers (55%) (Li et al., 2000). According to the allele database 'ALFRED' 
from Kidd (2003), the global allele frequency of T allele polymorphism of —C521T in 
DRD4 gene is various among different ethnicity: 65.2% in African; 65.2% in Irish; 
67.4% in Han Chinese; 53.2% in Japanese; 76.6% in Mexican. It was shown that the 
allele T frequency in Hong Kong Chinese population was relatively higher when 
comparing with different ethnic groups. Since an approximately 40% decrease in 
transcription efficiency if human retinoblastoma cells which transiently 
expressed -52IT (Okuyama et al., 2001), resulting in relatively lesser prefrontal 
synaptic dopamine being available and much more susceptible to Chinese population 
to abstain the "club drugs" to stimulate the release of dopamine in mesolimbic 
pathway resulting in compensating for the depletion of dopamine in the prefrontal 
synaptic area. 
4.3.8. 5-HTlB G861C polymorphism 
In the present study, although there is no significant difference in allele frequency of 
the 5-HTlB G861C polymorphism between "club drug" users with 53% C allele and 
controls with 48% C allele, a significant difference in genotype frequency was 
however found. The "club drug" users have a higher frequency of heterozygous GC 
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genotype and a lower frequency of homozygous GG genotype. It is suggested that 
carriers with at least one C allele may be more predisposed to "club drug" use. A 
Finnish study showed that antisocial alcoholics were found to have a higher 
frequency of the 86IC (62%) allele in the 5-HT IB polymorphism G861C than 
Finnish controls (Lappalainen et al , 1998). Ethnic variation in the 5-HTlB G861C 
polymorphism allele frequency was present; Taiwanese alcohol dependence with 
allele C (47%) and control with allele C (43%) (Sun et al., 2002); Japanese suicide 
victims with allele C (50.6%) and control (49.4%) (Nishiguchi et al., 2001). It seemed 
that our Chinese population was placed in the relatively high allele C frequent in the 
5-HT IB G861C polymorphism when comparing to the other Asian countries. It was 
suggesting that Chinese might be more susceptible to be alcoholic or commit suicide. 
However, in the present study, when the interaction of the genotypes to personality 
traits was studied, there was no significant difference found in both "club drug" users 
and controls. It might be suggesting the present of a linkage disequilibrium with other 
known or unknown polymorphisms that affect gene expression or function of gene 
product. 
4.3.9. 5-HTTLPR SLC6A4 44 bp insertion/deletion polymorphism 
The 44bp insertion/deletion polymorphism in 5-HTTLPR gene has been also found 
associated with affective illness and anxiety related traits (Collier et al., 1996; Lesch 
et al , 1996; Ogilvie et al., 1996; Neumeister et al., 2002). Gelemter et al. (1997) 
showed that there is a significant difference in the short (S) allele frequency amongst 
European American (40.4%), African American (25.4%), and Japanese (80.2%) 
samples in the 44bp insertion/deletion polymorphism in 5-HTTLPR gene. Individuals 
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(Finnish sample) with higher S alleles were shown to have a reduction in transcription 
efficiency and it was found higher S alleles is associated with type 2 alcoholics (53%) 
characterized by having antisocial-aggressive traits; and with individuals who have 
early onset and familial history of alcoholism as compared to type 1 alcoholics (40%) 
(Hallikainen et al., 1999a). Moreover, the S allele was also reported to be associated 
with high novelty seeking and low harm avoidance of the anti-social alcoholics 
(Hallikainen et al., 1999) and is also higher in heroin-dependent subjects (west 
European Caucasians with S allele 51.5%) (Gerra et al., 2004). 
In the present study, there was no significant difference between the genotype and 
allelic frequency between the "club drug" users and controls. At present, the "club 
drug" users and controls were shown to have 67% S alleles and 37% L allele in 
5-HTTLPR. However, it was shown that Chinese population carries relatively higher 
frequency of S allele when comparing with those populations in western country. It 
implicate that Chinese might be more susceptible to be alcoholic, heroin abuse and 
antisocial (S allele-related traits). 
Although no significant genotype distribution and allele frequency difference found in 
the present study, there might be other genes interact with 5-HTTLPR, for example, a 
significant interaction between 5-HTTLPR polymorphism and DRD4 VNTR was also 
found, with individuals bearing homozygous for the 7-repeat of the DRD4 genotype 
together with homozygous SS 5-HTTLPR genotype having higher mean scores for 
harm avoidance behaviour in TPQ questionnaire (Szekely et al.，2004). However, in 
the present study, no 7 repeat allele in DRD4 found in the “club drug" users, therefore 
some other genes might be taken part in affecting the expression of 5-HTTLPR. 
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In the present study, it can be concluded that the H allele in COMT G1947A, 
vali08"58met polymorphism and C allele of T921C polymorphism of hDOR gene are 
both associated with "club drug" use. Moreover, significant association was found 
between T allele in T941G polymorphism in MAOA-gene in female "club drug" 
users. A significant difference in genotype distribution of TaqI A polymorphism in 
DRD2 gene and G861C polymorphism in 5-HT IB gene were also found. It has been 
shown that T941G polymorphism in MAO-A gene and TaqI A polymorphism in 
DRD2 gene were associate with the personality trait ‘BIS’ (anxiety trait) in the "club 
drug" users whereas COMT G1947A, val^^^^^^Wt polymorphism and TaqI A 
polymorphism in DRD2 gene were associate with the personality trait 'fun seeking' in 
control groups. It is therefore concluded from the present study that both gene 
variants and personality traits were associated with "club drug" use. It might also 
suggest that multi-gene was contributes to a certain extent and the cumulative effects 
of their functional change might generate a more robust influence. Other potential 
candidate genes nearby the associated polymorphism genes found in the present study 
are worth to be investigated for the linkage disequilibrium. However, bias is always 
found in the genetic association studies as shown in a meta-analysis study of a subset 
of 25 associations with approximately 12 potential replication studies per association 
(Lohmueller et al., 2003). It was shown that false positive associations are abundant 
in the literature and the genetic effect in an association study will be biased upward 
with the original reported associations being false positive reports, conditional on that 
study being the first to reach statistical significance and be published. Even if there 
was ethnic and population stratification among the false positives association, small 
sample sizes could be the issue of a lack power to reliably detect the genetic effects. 
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Another study revealed that gene-based approach (genes are highly consistent across 
diverse human populations) in genetic association studies could avoid population 
differences usually found in the SNP-based, haplotype, and functional variant studies 
(Neale and Sham, 2004). In order to improve the present genetic association study, 
more explicit phenotype criteria, precise localization of the polymorphisms of interest, 
low genotyping error rate, larger sample size will be needed. 
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訪問員•• 訪問曰期•• 問卷編號： 
個 人 鉢 颜 























3) • 待 業 
4) •學生 
5) • 輕 學 
6) •其他(請註明）： 
7.個人習慣： 、ht 
‘ 有 間 中 開 始 年 齢 沒有 
吸煙 • • ^ 
飲酒 • • L 



















有 沒有 間中 
吸煙 • • • 
飲酒 • • • 
賭搏 • • C 
毒 品 口 • ~ 
1 8 . a你家中成員有行是濫用藥物？ 
1) •有(請註明關係）: 










2) • 廣 東 省 
3) • ¥國其他省份(請註明）： 
4 ) •其他國家(請註明）： 
5 ) • 否 第 2 1 題 ） 
2 0 .根據 1 9題所選的地方中，你最常使用藥物的地方是？ 
1) •深圳 
2) •廣東省 






21. 你有有曾經去過的士高或R a v e Party? 
1)過去6個月內曾經去過 • • 
2 ) 6個月前曾經去過 • C 
3 )否 




忘日己了 • _ 
23. •過去半年，你大約去過多少次的士高或Rave Party? 
(如答0次，％第26題） •••次 •••次 
1) 一 日 來 回 • • 次 
2 )過一夜 ••次；通常星期•返上去 ^^  
3)若逗留超過一晚，你(過去半年)平均去過多少次 
24.過去半年,你通常與甚麼人一齊去的士高或Rave Party?(可選多項） 
1)同學 • 匸 
2 )朋友 0 口 
3)男/女朋友 0 匸 
4)同事 O f 
5)父母 • 口 
6)兄弟姊妹 0 匸 
7)其他親戚 0 口 
8 )自己 • • 
在香港 在20題所選的地方 
25.過去半年,你通常每次會與多少人一齊前往的士高或Rave Party? • • • 人 ••口人 
(如自己上塡0人） 
2 6 .你去的士高或R a v e Party的原因是（可選多項） 
1)可以尋找新剌激 • • 
2)可以結識女朋友/男朋友 • • 
3)個人可以毫無拘束地玩樂 • • 
4)可以較便宜地買到藥物 • • 
5 )可以徹底放鬆 • • 
6)其他(請註明） ： • • 
2 7 a .你有否在的士高或R a v e Par ty使用過以下藥物？ 有 第 2 7 c 題 ） 否 • 
27b.你有否使用過以下藥物？ 有 第 2 7 c 題 ） 否 第 3 2 題 ） 
27c 
曾經服食過 I過去一年曾服食過 通 最 常 用 的 每 次 平 均 
服用方式 總服用量 
V 二是/ V = 是 / (過去三十天內）（如：服食/注射/ (如：粒/包/樽 
“X” = 否 / “X” = 否 / 鼻吸等） 等） 
“?” _ 口吾知） “?” 二 口吾矢口 
口在2 0題在香港題所在香港 I 在2 0題在香港 I 在2 0題在香港 I 在2 0題 
所選的地 選的地方 所選的地 所選的地 所選的地 
互 ^ ^ 方 
K 仔 一 “ 
搖頭九 ^ 
冰 一 一 
大麻 
M ： ： 
S ： ： 
安定 — 
藍精靈 — — 
十字架 -
咳水 ~ ~ “ 
天拿水 _ -
其他 I I I I I I I I I I — 
在香港 在20題所選的地方 
28.你通常每次花多少錢買這些藥物？ $ $ 
免費，其他人請• • 
29.你從哪裏獲得上述藥物？（可選多項） 
1 )朋友 • • 
2)黑社會兄弟 • • 
3 ) 同學 • • 
4 )藥房門市 • C 
5 )網B a r內之拆家 • C 
6)的士高或Rave P a r t y之拆家 • C 
7)自己由香港買上深圳 • • 
8 )家人 • • 
9)其他(請註明） ： • • 
30.在哪裏服用？（可選多項） 
1 )自己屋企 • [ 
2 )朋友屋企 • • 
3 )街角 • • 
4 )遊戲機中心 • • 
5 )卡拉 0 K • C 
6) 公廁 • [ 
7 ) 公園 • • 
8 )其他地方(請註明） : • • 
31.你有有曾經試過因服用藥物而感不適並被送往醫院？ 
1 )曾經試過 • [ 
2 )未曾試過 • • 
第一次濫用藥物;ZI5驗 
32.你有否曾經使用過最少一次上述藥物（Q 27c,除了煙，酒之外） 
1) • 有 
2) • 否 第 6 1 題 ） 






5 ) •網Bar內之柝家 








4 ) • 自 第 一 次 後 從 不 服 用 第 3 7 題 ） 
3 6 .多久會服用一次？ 
1) • 一 日 1 次 
2) •一星期1 - 6次 
3 ) •—個月1 - 3次 













3 8 .你最常服用哪一種藥物 ? 
3 9 .你有否試過同時服用超過一種藥物？ 
1) •有——•試過同時服用哪幾種？（並依照服用次數列出，最多次數先寫） 
U J 
1 . 2 ) 
1.3) 
2) • 否 
40.你最近服用藥物係幾時？ 
年 月 
4 1 . a )你購買藥物的主要經濟來源是： 
1) •主要是靠工作入息 
2) •主要是向家人借 
3 ) • 主要是向朋友借 
4 ) • 主要是靠非法途徑 
5 ) •主要是靠工作入息和向別人借 
6) •主要是靠工作入息和從事非法途徑 
7 ) •主要是向別人借和從事非法途徑 
8 ) • 免 費 ， 其 他 人 請 第 4 3 題 ） 
9 ) • 主要是靠零用錢 
10) •其他原因（請註明）:___ 
4 1 . b )每月大槪有多少元零用及收入:$ 
4 2 •你估計每月花多少錢在購買藥物？ 
4) 
4 3 .你最常服用的這種藥物(第3 8題)會否令你產生以下效果？（可選多項） 
1) •當我情緒低落或沮喪時，會令我感到舒服一點 
2) •使我感到不需擔心問題 
3 ) • 幫我鬆弛自己 
4 ) •使我感到情緒高昂或興奮 
5 ) •令我爛醉如泥或興奮得不能自製 
6) •性交時加倍興奮 
7 ) • 使我毫無睡意 
8) •幫我減肥 
9 ) • 幫 我 入 睡 
1 0 ) n使我能夠與朋友一起享樂 
11) •使我更有信心或有能力去與人交談 
12) •使我不再顧忌 
1 3 ) •使我整晚與朋友外出玩樂 
1 4 ) • 幫我專心工作或讀書 
1 5 ) •提高活動(包括音樂感或跳舞)的表現 
16) •令我做事時減少沈閲的感覺 








4 ) •手心出汗或手震 
5 ) • 頭暈，頭痛 
6) •不規則心跳 




2 ) •幻覺 2 . 1 )•聽幻覺 2 . 2 )•視幻覺 2 . 3 )•觸幻覺 2 . 4 )•嗅幻覺 
3 ) •對事物沮喪或不感興趣超過一天 
4 ) •對別人猜疑或妄想超過一天 
5 ) •影響與家人或朋友的關係 
6) •影響工作或上學表現 
7 ) •神經過敏或容易緊張超過一天 
8) • 痙 攣 




45.你有有在一個月或以上的時間內每天用很多時間去購買、 • • 
服用藥物或從藥物的作用中恢復過來？ 
46.你有有希望或嘗試停止服用藥物？ • • 
47.你有冇發現自己不能停止服用藥物？ • • 
48a你有有需要增加服用藥物的份量，否則就不會出現預期效果9 • • 
(•^第 49 題）^^  
48b有有比平常服用份量多出一半或以上？ • • 
49.你有有因服用藥物而經常減少出席與家人或朋友的重要聚會及工作？ • • 
50.你有有經常服用多於之前擬定的藥物份量或服用日數？ • 口 
有 有 
51.停止服用藥物後，有有出現以下問題(可選多項） 
1) 沮喪 • • 
2 )緊張或不安 • • 
3 )疲勞或倦意 • • 
4 ) 失眠 • • 
5 ) 食慾增加或減少 • • 
6 )打顫或痙攣 • • 
7 )流汗或發燒 • • 
8) n惡心D區吐 • C 
9 )肚寫或胃痛 • • 
1 0 )流眼水或鼻水 • C 
11)打呵欠 • c 
12)心跳加速 • • 
52.停止服用藥物後，有有同時出現兩個或以上在第51題的癥狀？ • • 
53.你有有因減低或消除斷癮癥狀而服在第38題的藥？ • • 
54a除了斷癮癥狀外，有有因服用藥物後的其他健康問題？ 口 P 
請註明： ^^  
第 55a 題 
54b當發現這些健康問題後，你有冇繼續服用藥物？ • • 
5 5 a •你的家庭、朋友、上司、同事或同學有有曾經對你服用藥物反映不滿？ • • 
第56穎 
55b.當知道因服用藥物後所帶來的問題後，你有有繼續服用藥物？ • • 
56.你有有因服食藥物後，產生興奮感覺或其他效果而影響在上學，上 • • 
班或做家務時的表現？ 
5 7 a . 服食藥物時，你有有發現任何心理問題，如沮喪、猜疑、胡思亂想、聽• 
幻覺、嗅幻覺、觸幻覺、視幻覺或神經質？（請列明癥狀） 
n 1 ^ 
s! 第 58 題 
57b.當你發現這些徵狀時，你有有停止服食藥物？ • • 
58.你有有因受服食藥物的影響而增加受傷的機會，如在駕験時、 




1.1) •是 1.2) •不是 
60.你有有任何刑事記錄？ • 
你的刑事記錄是否與藥物有關？ 















會 不 會 不 知 道 
63.你認爲以上所提及的藥物會否對身體造成傷害？ • • 口 
64.你認爲以上所提及的藥物會否令到精神有毛病？ • • 口 
65.你認爲以上所提及的藥物會否令人上癮及產生依賴性？ • • • 
66.你認爲部份你所服用的藥物會否含有雜質？ • • • 
67.你認爲以上所提及的藥物會否造成身體永久性破壞？ • • • 
68.你認爲以上所提及的藥物會否導致死亡？ • • • 
’ 69.你認爲以針筒注射以上所提及的藥物會否感染愛滋病？ • • • 



















Appendix lb (English translated version for Hong Kong only) 
Interviewer : Date : / / Questionnaire No.: 
Hello! I am a researcher of XXX organization. We are currently conducting a study in collaboration with 
the Chinese University of Hong Kong on psychostimulant use among the youths in Hong Kong. I sincerely 
hope that you can help us complete this questionnaire in order we can have a better understanding of the 
current trend of psychostimulant use. The information you provide will be kept in the strictest confidence 
and will only be used for the purpose of this study. Thank you for your cooperation! 
Personal information 
1. Sex: l ) n M 2) O F 
2. Age: 
3. District of residence: 
4. Type of housing: 
1) • Temporary housing/squatter 5) • Home Ownership Scheme 
2) • Rented bed 6) • Self-owned private housing 
3) • Public housing 7) • Others; please specify: 
4) 口 Rented private housing 
5. Education level: 
1) • Primary school 5) • Form 4 
2) • Form 1 6) • Form 5 
3) • F o r m 2 7) • Form 6/7 
4) n Form 3 8) • Others; please specify: 
6. Work status: 
1) • Full time work 4) • Student 
2) • Part time work 5) • Drop out of school 
3) • Unemployed 6) • Others; please specify: 
7. Personal habits: 
Yes Never Occasionally 
Smoking • • L 
Drinking • U L 
Gambling • U L 
Substance Use • 口 [ 
8. At present, who do you live with? 
i 1) • Parents 5) • On one's own 
i 2) • Single parent OFather • Mother) 6) • Don't have a fixed address 
I 3) • Relatives 7) • Others; please specify 
I 4) • Friends 
! 
i 
9. Parents' marital status? 
1) • Married 4) • Remarried 
2) • Separated 5) • Father and/or mother deceased 
3) 口 Divorced 
10. Name the province of origin of your father's family: • I don't know 
11. Father's work status: 
1) • Full time work 4) 口 Retired 
2) • Part time work 5) • Others; please specify: 
3) • Unemployed 
12. Father's education level: 
1) • Never received any education 4) •Univers i ty 
2) 口 Primary school 5) 口 Others; please specify: 
3) • Secondary school 
13. Father's personal habits: 
Yes Never Occasionally 
Smoking • • [ 
Drinking • • [ 
Gambling • • [ 
Substance Use • 口 [ 
14. Name the province of origin of your mother's family: • I don't know 
15. Mother's work status : 
1) • Full time work 4) • Housewife 
2) • Part time work 5) • Retired 
3) • Unemployed 6) • Others; please specify: 
16. Mother's education level: 
1) • Never received any education 4) • University 
2) • Primary school 5) • Others; please specify: 
3) • Secondary school 
17. Mother's personal habit: 
Yes Never Occasionally 
Smoking • • L 
Drinking • • L 
Gambling • U L 
Substance Use • U L 
18a. Does any member of your family have a history of substance abuse? 
1) • Yes (Relationship): 
I 2) • No 
I 3) • I don't know 
I 18b. Does any member of your family (including yourself) have a history of mental illness? 
I 1) • Yes (Relationship and name of illness): 
I 2) • No 
I 3) • I don't know 
Pattern of drug use 
19. Have you ever taken drugs outside of Hong Kong? (For example, Shenzhen, other places in Mainland 
China, or some foreign countries) (You can check more than one box) 
1) • Shenzhen 
2) • Guangdong province 
3) • Other provinces in China; please state : 
4) • Other countries; please specify : 
5) • Never (Go to Q21) 
20. Please specify the place where you most often take drugs among the places you specified in Q19. 
1) • Shenzhen 
2) • Guangdong province 
3) • Other provinces in China; please specify : 
4) • Other countries; please specify : 
(If you have answered Q20, please filled in both columns from Q21 to Q31) 
(If you have taken drugs only in Hong Kong please just fill in the left column) 
Column 1 Column 2 
(In Hong Kong) (Place specified in Q20) 
21. Have you ever been to any disco or rave party? 
1) Within the past 6 months 口 [ 
2) More than 6 months ago 口 [ 
3) Never (Go to Q27b) • C 
22. When was the first time you went to a discos or rave parties? 
(Yr) (Yr) 
(Mth) (Mth) 
] F o r g o t n Forgot 
23. During the last 6 months, approximately how many times did you go to the discos or rave parties? 
(If never, go to Q26) • • • times • • • times 
1) Day trip •口 times 
2) Stay overnight • • times; which day of the week do you 
usually go there? ^ 
3) Stay more than one night times 
Column 1 Column 2 
(In Hong Kong) (place specified in Q20) 
24. During the last 6 months, who did you go to the discos and rave parties with? 
(You can check more than one box) 
1) Classmates U L 
2) Friends D L 
3) Boy/Girlfriend • • 
4) Colleagues U L 
5) Parents _ L 
6) Brothers/Sisters • L 
7) Other relatives • L 
8) Alone LJ L 
25. During the last 6 months, how many people on average each time did you go to the 门门门 p 
discos and rave parties with? (If you go alone, please fill in “0，,） U U L J People 
Column 1 Column 2 
(In Hong Kong) (place specified in Q20) 
26. What is/are the reason(s) for going to discos or rave parties? 
(You can check more than one box) 
1) To seek new exciting experiences 口 [ 
2) To find new boy/girlfriend • [ 
3) To have uninhibited flin 口 [ 
4) To buy cheaper drugs 口 [ 
5) To relax 口 [ 
6) Others; please specify: • [ 
27a. Have you ever taken the following drugs listed in Q27c in the discos or rave parties? 
] Y e s • No 
(Go to Q27c) 
27b. Have you ever taken the following drugs listed in Q27c? 
] Y e s • No 
(Go to Q27c) (Go to Q32) 
27c. 
Drug(s) ever Dmg(s) taken Frequency. Route of (/^tgcTc^^^lliL 
tried (Past 12 months) (Past 30 days) administration p^^kets ‘ bottles) 












Column 1 Column 2 
(In Hong Kong) (place specified in Q20) 
28. On each occasion, how much do you spend to buy drugs? $ $ 
• Free • L 
Column 1 Column 2 
(In Hong Kong) (place specified in Q20) 
29. Where did you obtain the drugs? (You can check more than one box) 
1) Friends 口 [ 
2) Friends in Triad societies 口 [ 
3) Classmates 口 [ 
4) Pharmacy 口 [ 
5) Dealers at cyber cafes 口 [ 
6) Dealers at discos or rave parties 口 [ 
7) Family 口 [ 
8) Others; please specify : 口 [ 
30. Apart from rave parties and discos, what other locations do you take drugs? 
(You can check more than one box) 
1) At home • [ 
2) Friend's house • [ 
3) Street comer 口 [ 
4) Cyber cafe 口 [ 
5) Park • C 
6) Public toilet • [ 
7) Hotel/Motel • 口 
8) Others; please specify : 口 [ 
31. Have you ever been sent to a hospital because of drug overdose? 
1) Yes • C 
2) Never • [ I 
First time drug use 
32. Have you ever tried at least one of the drugs listed in Q27c (excluding cigarette and alcohol)? 
1) • Yes. What was the first drug you tried? 
2) • No, (Go to Q61) 
3 3. How long ago did you first take this drug? (Yr) (Mth) ago 
34. Where did you obtain the drug? (You can check more than one box) 
1) 口 Friends 6) 口 Dealers in disco or rave party 
2) • Friends in Triad society 7) • I brought back from outside Hong Kong 
3) • Classmates 8) • Family 
4) • Pharmacy 9) • Others; please specify: .__ 
5) 口 Dealers in cyber cafes 
35. After you first-take this drug, what is the frequency of subsequent use? 
I 1) • Always 3) • S e l d o m 
2) • Often 4) • Never, go to Q37 
36. How frequent will you take this drug? 
1) • Once a day 4) • Less than once a month 
2) • 1 to 6 times a week 5) • No fix time 
3) • 1 to 3 times a month 
37. The reasons you take drugs for the first time: 
(You can check more than one box) 
1) • To feel more mature, and to show off to others 
2) n To seek excitement and flin 
3) 口 Peer pressure 
4) 口 To be trendy 
5) 口 To relieve boredom/depression 
6) 口 Curiosity 
7) • To avoid personal problems 
8) • To relax and relieve anxiety 
9) • To relieve fatigue and increase alertness 
10) 口 Others; please specify: 
The reasons of drug taking 
38. Which drug do you use most frequently? 
39. Have you ever taken more than one drug at a time? 




2) D N o 
40. When was the last time you take drug? (Yr) (Mth) 
41a. How did you finance your [Drug] use? 
1) • Mainly by income from employment. 
2) • Mainly by borrowing from family members. 
3) Q Mainly by borrowing from friends. 
4) 口 Mainly by committing crimes. 
5) O A combination of income and borrowing. 
6) • A combination of income and committing crimes. 
7) • A combination of borrowing and committing crimes. 
8) O Others; please specify: 
41b. What is your average monthly income? $ 
42. What is your monthly expenditure in [drugs] use? $ 
43. Please state whether the dnig(s) in Q38 that you use most frequently create the following effects after 
you take them? (You can check more than one box) 
1) • Make yourself feel better when down or depressed 
2) 口 Help you stop worrying about a problem 
3) • Help you to relax 
4) • Help you feel elated or euphoric 
5) • Just get really stoned or intoxicated 
6) • Enhance feelings when having sex 
7) • Help you to stay awake 
8) • Help you lose weight 
9) • Help you to sleep 
10) • Help you enjoy the company of your friends 
11) • Help you feel more confident or more able to talk to people in a social situation 
12) • Help you lose your inhibitions 
13) • Help you keep going on a night out with friends 
14) • Help you to concentrate or to work or study 
15) • Enhance an activity such as listening to music or playing a game or sport 
16) • Help make something you were doing less boring 
17) • Improve the effects of other substances 
18) • Help ease the after effects of other substances 
The negative effects of drug use 
(After taking the drugs in Q38, have you found any following symptoms with 24 hours?) 
44a. Physical signs 
1) • Increase or decrease in appetite 
2) • Staggering walk; poor physical coordination 
3) • Inability to sleep 
4) 口 Sweaty palms; shaking hands 
5) • Dizzy; headache 
6) 口 Irregular heartbeat 
7) 口 Nausea, vomiting 
8) • Extreme hyperactivity, e.g. Dancing 
44b. Behavioral signs 
1) • A m n e s i a 
2) • Hallucinogens 2.1) • h e a r i n g 2.2) • seeing 2.3) • smelling 
3) • Feeling depressed or uninterested in things more than 24 hours 
4) • Feeling suspicious or paranoid of people more than 24 hours 
5) • Negatively affected your family relationships and friendships 
6) • Negatively affected your job or school performance 
7) 口 Jumpy or nervous more than 24 hours 
8) • Twitch 
9) • Become violent 
10) 口 Suicide attempt 
Potential tolerance/ dependence 
45. Have you spent a great deal of time in those activities necessary to obtain the • Yes G No 
drugs or use the drugs, e.g. in a period of a month or above? 
46. Have you often wanted to or tried to cut down on drugs? • Yes • No 
47. Did you ever find you could not stop or cut down using drugs? • Yes • No 
48a. Did you ever need markedly increased amounts of drugs to get an effect or find • Yes • No 
that you could no longer get high on the amount you used to use? 
48b. Would you say 50% more? • Yes • No 
49. Have you often given up or greatly reduced important activities with friends or • Yes • No 
relatives or at work in order to use Drugs? 
50. Have you often use drugs more days or in larger amounts than you intended to • Yes • No 
do? 
51. Has stopping, cutting down on, or quitting Drug ever caused you any of these problems? 
(You can check more than one box) 
Yes No 
1) Feel depressed • L_ 
2) Feel nervous or restless D L_ 
3) Feel tired or sleepy 口 L_ 
4) Have trouble sleeping D L_ 
5) Increase or decrease in appetite 口 L 
6) Tremble or twitching 口 L 
7) Sweating or fever D [ 
8) Nausea or vomiting • L 
9) Diarrhea or stomachaches • L 
10) Watery eyes or runny nose U L 
11) Yawning LI L 
12) Increase in heart rate • L 
52. Was there a time when two or more of these symptoms in Q44 occurred together • Yes 口 No 
because you were not using [Drug] in Q51? 
53. Have you often used Drugs in Q38 to make these withdrawal symptoms go away • Yes • No 
or to keep from having them? 
54a. Did using Drugs cause you to have any other physical health problems; other than withdrawal? 
1) • If yes; please specify: 
2) • No (Go to Q55a) 
54b. Did you continue to use Drugs after you knew it caused this problem? • Yes • No 
55a. Did you ever experience objections from family, friends, boss or people at work • Yes • No 
or school because of your Drug use? (Go to Q56) 
55b. Did you continue to use Drug after you realized it was causing a problem? • Yes • No 
56. Have you often been high on drugs or suffering its after-effects while in school 口 Yes 口 No 
working or taking care of household responsibilities? 
57a. While using [drugs], did you ever have any psychological problems start or get worse, such as feeling 
depressed feeling paranoid, trouble thinking clearly, hearing, smelling, or seeing things or feeling 
jumpy? 




2) D N o , got to Q58 
57b. Did you continue to use [drugs] after you knew it cause any of these problem? • Yes • No 
58. Have you often been under the effects of Drug in a situation where it increased • Yes • No 
your chances of getting hurt-for instance, when driving, using knives or 
machinery, crossing against traffic, climbing or swimming? 
59. Have you ever received any treatment for using drugs of abuse? 
1) • If yes, are you still receiving treatment? 
1.1) DYes 
1.2) D N o 
2) D N o 
60. Do you have any criminal records? 
1) • If yes, does the record relate to drug? 
1.1) n V e s 
1.2) D N o 
1.3) • Both have tried 
2) D N o 
Knowledge about drugs of abuse 
61. Please state 3 drugs you know best: 
1) 2) 3) 
62. Where did you get to know about these drugs? 
1) • TV/Radio/Movie 5) • Parents 
2) • Friends 6) • School 
3) • Social worker 7) 口 Others; please 
4) 口 Newspaper specify: 
63. Do you think that the aforementioned drugs can cause harm to your body? 口 Yes 口 No 
64. Do you think that the aforementioned drugs can cause mental problems? 口 Yes 口 No 
65. Do you think that the aforementioned drugs are addictive and may lead to O Yes • No 
dependence? 
66. Do you think some of the drugs that you take may be contaminated with other • Yes • No 
drugs? 
67. Do you think that the aforementioned drugs can cause permanent damage to • Yes • No 
your body? 
68. Do you think that the taking of the aforementioned drugs can result in death? • Yes • No 
69. Do you think the using of needles to inject aforementioned drugs can cause • Yes • No 
AIDS? 
Psychological well being 
70. How stressful is your daily life? 
1) • Very stressful 3) D A little stressful 
2) • Quite stressful 4) • Not stressful at all 
71. Do you feel that you have control over your own life? 
1) • In complete control 4) • Partly lost control 
2) • Partly in control 5) • Completely lost control 
3) 口 Undecided 
72 In general, are you satisfied with your life? 
1) • Very satisfied 4) •Dissat isf ied 
2) • Satisfied 5) • Very dissatisfied 
3) • Undecided 
The End, Thank you very much! 
rvjjjjcuuiA ^a ^iiiiiejje version oi scale 





















































































.vppeiiuiA in inese version ol scale 
訪問員： 訪問曰期： 問卷編號： 
請細閱此問卷中每一項，用1 ’ 2 ’ 3， 4代表你有多同意該項。所有項目必須回答。請獨立地考慮每項， 
毋需擔心不同項目之間答案不一致，只要準確及誠實地回答便可。（請在適當的方格上塡“V ”） 
1 二非常同意 2 =有點同意 3 =有點不同意 4二非常不同意 
1 2 3 4 
1家庭在一個人的人生中是最重要的。 " B E 5 • “ 
2 即使有壞的事情發生在我身上，我也很少感到恐懼或緊張。 E • ^ 
3 我會竭盡所能去得到我想要的東西。 • 5 ^ 
4 當我把事情做得好時，我會喜歡繼續去做它。 • • ^ 
5 我總是願意嘗試我覺得可能會是有趣的新事物。 • • • ^ 
6 我 注 重 個 人 的 衣 著 。 • • • ^ 
7 當我得到我想要的東西時，我便感到興奮及充滿活力。 • ^ “ ^ 
8 被批評或被責駡對我造成較嚴重的傷害。 • ^ E ^ 
9 我通常會盡全力去追求我渴望得到的東西。 • • ^ 
1 0我常常會去做某些事，只因爲它們有趣。 • • • 
11對於某些要做的事，例如剪頭髮，我感到難以抽空去做。 • • • ^ 
1 2當我知道有機會去得到我想要的東西時，我會立即採取行動。^ • • • ^ 
13當我認爲或知道有人生我的氣，我會感到非常擔憂及苦惱。 • • • ^ 
1 4當我遇到一個機會能得到我喜歡的東西時，我會立即興奮起來。^ • • ^ 
1 5我常因一時興奮就行動。 • • • ^ 
16若我覺得有不愉快的事情要發生，我通常會坐立不安。 ^ • • 
1 7我經常想知道爲何人們會有這樣的舉動。 • • ^ 
18當有如意的事彳青發生在我身上，我會受到強烈的影響。 • 5 • ^ 
1 9我會因爲弄垮了重要的事情而感到憂心。 • E ^ 
2 0我渴求獲得刺激及新感覺。 ^ • ^ 
21我會以“排除萬難”的態度去追求我渴望得到的東西。 • • ^ 
• 22相比我的朋友我很少有憂慮的情緒。 • • • ^ 
2 3當我贏得比賽時，我覺得很興奮。 • E • ^ 
2 4我擔心我犯錯。 • • 

• ETThTtiOD 
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